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Abstract 
Atherosclerosis and its possible consequences, infarction events in various arteries, are very 
common diseases in industrialized countries and the mechanisms of their pathogenesis are 
only poorly understood. It’s known that external (diet, exercise, stress) as well as internal (ge-
netic predispositions, physiological changes, sex) factors play a role, but the exact processes 
need to be investigated more intensively to develop novel therapy approaches.  
As an all-round talent in the mammalian body, the monoamine serotonin (5-HT) might be a 
promising candidate to play a crucial role in the pathogenesis of atherosclerosis. If and how 
this hormone affects atherosclerotic plaque formation, macrophage invasion, calcification and 
fibrotic changes in vessels and heart was the focus of this study. 
This study is the first of its kind using the novel approach of transgenic double knockout mice 
lacking the apolipoprotein E (ApoE, atherosclerosis model) and additionally either the key 
enzyme in peripheral 5-HT synthesis, tryptophan hydroxylase 1 (Tph1) or the major 5-HT 
transporter in cells, SERT. Physiology, metabolic parameters and atherogenic processes in 
ApoE/Tph1
-/- 
and ApoE/Sert
-/-
 animals were examined using a very broad spectrum of biologi-
cal, biochemical, molecular and histological methods and resulted in an extensive overview of 
how 5-HT might influence the pathogenesis of atherosclerosis. 
The most striking results of this study are the following: 
5-HT receptor distribution is altered in vessels of different mouse strains, such as C57Bl/6 
(B6) and FVB/N, and also in Tph1 deficient animals generated in these background strains. 
This phenomenon partly explains why atherosclerosis-related processes, such as vascular cal-
cification or blood pressure regulation are differently exhibited in mice of these strains. Fur-
ther, the examination of   ApoE/Tph1
-/- 
and ApoE/Sert
-/-
 mice elucidated that both double 
knockouts exhibit by far not the same phenotypes: While Tph1 deficiency resulted in signifi-
cantly decreased bodyweight, plasma cholesterol and liver damage parameter levels and sig-
nificantly increased relative liver weight, Sert deficiency caused significant increases in blood 
glucose, plasma cholesterol, atherosclerotic plaque size in aortas and collagen amounts in 
atherosclerotic plaques. Long term Western Diet applied to ApoE/Tph1
-/-
 and ApoE
-/-
 control 
animals (acute atherosclerosis induction) confirmed that Tph1 deficiency decreases body-
weight gain and has protective effects on lipid metabolism, but a clear effect on atherogenesis 
could not be reported. 
Concluding, this study highlights the complex relationship between many factors acting on 
atherosclerotic pathogenesis. 5-HT plays a role in many of those factors, but seems to have 
only minor but protective effects on atherogenesis itself. 
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Zusammenfassung 
Atherosklerose und als mögliche Folge auch diverse Infarktereignisse in verschiedenen Gefä-
ßen, sind in Industrieländern weit verbreitete Krankheiten, und die Mechanismen ihrer Patho-
genese sind nur unzureichend bekannt. Sehr wohl bekannt  ist jedoch, dass sowohl externe 
(Ernährung, Bewegung, Stress) als auch interne (genetische Veranlagung, physiologische 
Veränderungen, Geschlecht) Faktoren eine Rolle spielen. Die zugrunde liegenden Prozesse 
müssen jedoch genauer untersucht werden, um neue Therapieansätze zu entwickeln. 
Als Allroundtalent im Säugetierkörper könnte das Monoamin Serotonin (5-HT) ein vielver-
sprechender Kandidat sein, der eine entscheidende Rolle bei der atherosklerotischen Pathoge-
nese spielt. Ob und wie dieses Hormon die Bildung atherosklerotischer Plaques, die 
Makrophageninvasion in die Gefäßwände, die Verkalkung und die fibrotischen Veränderun-
gen in den Gefäßen und im Herzen beeinflusst, war Gegenstand dieser Studie. 
Die vorliegende Studie ist die erste ihrer Art, die den neuartigen Ansatz von transgenen Dop-
pel-Knockout-Mäusen verwendet, denen das Apolipoprotein E (ApoE, ein 
Atherosklerosemodell) fehlt und, die zusätzlich entweder das Schlüsselenzym für die periphe-
re 5-HT-Synthese, Tryptophanhydroxylase 1 (Tph1), oder den primären Transporter für 5-HT 
in Zellen (SERT) nicht bilden können. Physiologie, Stoffwechselparameter und atherogene 
Prozesse wurden in ApoE/Tph1
-/- 
und ApoE/Sert
-/-
 Tieren mithilfe eines sehr breiten Spekt-
rums an biologischen, biochemischen, molekularen und histologischen Methoden untersucht 
und resultierten in einem umfassenden Überblick über die möglichen Wirkungsweisen von   
5-HT auf die atherosklerotische Pathogenese. 
Die bedeutendsten Ergebnisse dieser Studie sind die folgenden: 
Die 5-HT-Rezeptorverteilung ist unterschiedlich in Gefäßen von verschiedenen Mauslinien, 
wie C57Bl/6 (B6) und FVB/N und ebenfalls in denen von Tieren mit Tph1-Defizienz, die in 
diesen Hintergrundstämmen erzeugt wurden. Dieses Phänomen erklärt zum Teil, warum 
atheroskleroseverwandte Prozesse wie Gefäßverkalkung oder Blutdruckregulation bei Mäusen 
dieser Stämme unterschiedlich ausgeprägt sind. Ferner ergab die Untersuchung von 
ApoE/Tph1
-/- 
und ApoE/Sert
-/-
 Mäusen, dass beide Doppel-Knockouts bei weitem nicht diesel-
ben Phänotypen aufweisen: Während die Tph1-Defizienz im Atherosklerosemodell zu einer 
signifikant verminderten Zunahme des Körpergewichts, niedrigeren Plasmacholesterinwerten 
und Leberschadensparametern und einem erhöhten relativen Lebergewicht führte, verursachte 
eine Sert-Defizienz signifikante Erhöhungen des Blutzuckers, des Plasmacholesterins und die 
Ausbildung größerer atherosklerotischer Plaques in der Aorta und eine vermehrte 
Kollagenakkumulation innerhalb dieser atherosklerotischen Plaques. Die Langzeitgabe einer 
sogenannten Western-Diät, die bei den getesteten ApoE/Tph1
-/-  
und ApoE
-/- 
Kontrolltieren zu 
akuter Atherogenese führte, bestätigte, dass eine Tph1-Defizienz die Zunahme von Körper-
gewicht vermindert und schützende Auswirkungen auf den Lipidstoffwechsel hat, ein klarer 
Effekt auf die Atherogenese konnte jedoch nicht ermittelt werden. 
Zusammenfassend hebt diese Studie die komplexen Beziehungen zwischen vielen Faktoren, 
die auf die atherosklerotische Pathogenese einwirken, hervor. 5-HT spielt bei vielen dieser 
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Faktoren eine Rolle, scheint jedoch nur eine schwache aber protektive Wirkung auf 
Atherogenese selbst zu haben. 
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1 Introduction 
1.1 Serotonin – The Story begins 
In the years around 1950 two independent research groups identified a molecular substance 
isolated from gastrointestinal enterochromaffin cells (EC) (Erspamer & Asero, 1952) and in 
bovine blood-serum (Rapport et al., 1948a, b, c). While one group found that the substance 
had the ability to induce smooth-muscle cell contraction the other showed that it caused vaso-
constriction after being released from blood platelets. Only in 1952, after some years of re-
search on the chemical structure of the pretended two matters it could be proven that they 
were identical and the substance finally got named after its major function: being located in 
the serum and influencing the vaso-tonus: “serotonin”. Since then it could be shown that ser-
otonin is present in many taxa throughout the whole animal kingdom from insects (e.g. Dro-
sophila melanogaster, Apis mellifera and Periplaneta americana) (Bishop & O’Shea, 1983; 
Schürmann & Klemm, 1984; Vallés & White, 1988) to mammals and it is located not just in 
several peripheral organs, but also in the central and peripheral nervous system (CNS and 
PNS) (Twarog & Page, 1953). 
1.2 The Structure of the Mammalian Serotonergic System 
1.2.1 Two households, both alike in dignity
1
As well as many other animal species mammals feature a barrier between the CNS and pe-
ripheral system, a thin layer of brain capillary endothelial cells connected to each other by 
complex tight-junctions (Ohtsuki, 2004), namely the blood brain barrier (BBB). Serotonin can 
be found on both sides of this barrier, unable to cross it (Hardebo & Owman, 1980) due to its 
hydrophilic structure (see Fig. 1). It was assumed for many years that the mammalian seroto-
nin system is located at two different sites but its synthesis and distribution processes are 
identically structured and controlled by the same mediators: Serotonin is synthesized by a 
two-step process (see Fig. 2) which is primarily mediated by the enzyme tryptophan hydrox-
ylase (TPH), determining the 
rate-limiting step, and the aro-
matic amino acid decarboxylase 
(AADC). 
However, this concept was chal-
lenged in 2003 when Walther 
and colleagues generated a clas-
sical knock-out mouse model for 
TPH, originally to investigate 
the role of serotonin in cardio-
vascular regulation (Walther & 
Bader, 2003; Walther et al., 
2003a). After confirming the 
loss of serotonin-production in 
several peripheral organs, the 
1
 From William Shakespeare’s ‘Romeo & Juliet’, Act 1, Prologue 
Fig. 1 – Structural Formula of 5-HT 
Chemical structural formula of the monoamine 5-HT. 5-HT 
is an indolamine with a hydroxylation of the fifth position 
(hydroxyl group) and a primary amine nitrogen which serves 
as a proton acceptor at physiological pH. This combination 
makes 5-HT a hydrophic substance. 
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authors surprisingly found unaltered levels of serotonin in the CNS. Following genetic screens 
indicated another tph-gene that codes a second TPH isoform in the CNS. Since then, the para-
digm changed to the idea that at least mammals have two separate serotonin systems based on 
two separate genes and enzymes. 
While the novel CNS-specific TPH isoform was named TPH2, the initially examined isoform 
in the peripheral system was renamed TPH1. The two TPH isoforms show a homology of 
71% (Walther & Bader, 2003) and of about 50% to other members of the aromatic amino acid 
hydroxylase family, such as the tyrosine hydroxylase (TH) and phenylalanine hydroxylase 
(PAH) (reviewed in Beis, 2014). As the major enzyme controlling serotonin synthesis in the 
periphery, TPH1 could be shown to be present in structures like EC, thymus, immune cells, 
heart and chromaffine cells of the suprarenal gland medulla and additionally in the pineal 
gland in the CNS (Ahern, 2011; Côté et al., 2003; Watts et al., 2012). Contrasting, TPH2 is 
the major enzyme isoform in the adult mammalian CNS and could be detected in the murine 
raphe nuclei (RN) and human pons, cortex, striatum, hippocampus and other brain regions 
(Côté et al., 2003; Gutknecht et al., 2009; Liu et al., 2008; Patel et al., 2004; Walther & Bader, 
2003; Yadav et al., 2009). TPH2 cannot be found in peripheral organs (Gutknecht et al., 2009; 
Patel et al., 2004; Walther et al., 2003a; Yadav et al., 2009; Zill et al., 2007), except in the gut 
enteric nervous system where it acts as a neuroprotector and activates neurogenesis (Gershon, 
2012).  
In conclusion, the major amount of serotonin in the mammalian body is stored in the gastroin-
testinal tract (70-90%). The here located serotonin comes from both synthesis systems       
(e.g. TPH1 in the EC and TPH2 in the myenteric plexus neurons) and helps controlling gut 
activity and, in case of disturbances or inflammations, correlates with “irritable bowel-
syndrome” (reviewed in Fujimiya & Inui, 2000; Gershon, 2012). 
1.2.2 Serotonin – Who are you, where do you come from and where do you go? 
Chemically, serotonin belongs to the family of tryptamines and, as mentioned above, it ap-
pears to have a hydrophilic structure. This trait is caused by the hydroxyl-group at fifth-
position within the heterocyclic indole-structure and the primary amine nitrogen which acts as 
a proton acceptor at physiological pH (see Fig. 1). Congruously, the chemically correct name 
of serotonin is 5-hydroxytryptamine (5-HT).  
The biochemical story of 5-HT starts with L-Tryptophan (Trp), an essential amino acid for 
humans that is encoded genetically by the codon UGG and can naturally be found in nutrients 
as milk and some seeds (e.g. sunflower). Commonly, the L-stereoisomer of Trp is used as 
biogenic amino acid for enzymes and structural proteins and is produced by plants and micro-
organisms (Radwanski & Last, 1995), in contrast the R-stereoisomer is only occasionally 
found in nature (Pallaghy et al., 1999). 
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The first step in 5-HT synthesis is the TPH mediated hydroxylation of Trp to 5-hydroxy-
tryptophan (5-HTP); however calculations estimate that only 5-10% of total bioavailable Trp 
is used for 5-HTP synthesis in humans (Salter et al., 1995; Stone & Darlington, 2002; Watts 
et al., 2012). Trp is mainly used for other biochemical pathways and for protein synthesis. 
There are even studies suggesting that about 99% of all ingested Trp is used for other path-
ways than 5-HT synthesis, such as metabolization by indoleamine dioxygenase 1 and 2    
(IDO 1 and 2) (Ball et al., 2009; Duleu et al., 2010; Kwidzinski & Bechmann, 2007; 
Kwidzinski et al., 2003; Stone & Darlington, 2002). 
This first anabolic step is mediated by either TPH1 or TPH2 in a rate-limiting manner and 
chemically identical. The reaction requires Fe
2+
-ions, oxygen (O2) and tetrabiopterin (BH4) as 
cofactors (Lovenberg et al., 1967) (see Fig. 2). The here generated 5-HTP gets decarboxylated 
by an aromatic amino acid decarboxylase (AADC) to 5-HT in the second step. AADC is 
broadly distributed throughout the whole mammalian body with highest activity levels in pin-
eal gland, liver, and adrenal glands (Rahman et al., 1981). It can also decarboxylate Trp di-
rectly to tryptamine. 
In the end, 5-HT is degraded by monoamine oxidases (MAO) to 5-hydroxyindole acetalde-
hyde (5-HIAL) (see Fig. 2). The flavoproteins MAO can be found throughout the mammalian 
body, are located at the outer mitochondria membrane of cells and arise in two isoforms, cod-
ed by two different genes: MAO-A and MAO-B. Both isoforms are able to metabolize nu-
merous biogenic amines in the body with different specificities (Shih & Chen, 2004). 5-HT, 
dopamine and norepinephrine are mainly degraded by MAO-A, while trace amines 
(tyramines, benzylamine, or beta-phenylethylamines) are degraded by MAO-B (Beis, 2014; 
Luo et al., 2003). Finally, 5-HIAL is degraded to 5-hydroxyindole acetic acid (5-HIAA) via 
aldehyde dehydrogenase (ALDH). 5-HIAA is the last catabolic substrate of this pathway and 
gets secreted in the urine (Brady et al., 2012). Elevated urinary levels of 5-HIAA can be found 
Fig. 2 – Synthesis and Degradation of 5-HT 
This figure shows the pathway of 5-HT synthesis and degradation with the key-enzymes and cofac-
tors. Highlighted in green are the sequential enzymes of the 5-HT metabolism, in purple the regen-
eration pathway of tetrahydrobiopterin (BH4) and in red the de novo synthesis pathway for BH4. 
AADC: aromatic amino acid decarboxylase; ALDH: aldehyde dehydrogenase; MAO-A/-B: mono-
amine oxidase A and B; GCH1: cyclohydrolase 1; PTPS: 6-pyruvoyl-5,6,7,8-tetrahydropterin; 
qBH2: quinoid dihydrobiopterin. 
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in patients with malignant carcinoid tumors, especially with liver metastases, which synthe-
size massive amounts of 5-HT. 
1.3 From Serotonin Transporters and Receptors and other Signaling Mechanisms 
The cytoplasmatically synthesized pool of 5-HT (e.g. in EC in the gut or RN in the brain) can 
be used for either serotonylation of some proteins (Paulmann et al., 2009; Walther et al., 
2003b) or needs to leave the cells to act as an ubiquitous hormone throughout the periphery or 
as a neurotransmitter in the CNS. For that 5-HT has to switch cellular compartments and 
needs a transporter. Consistently, released 5-HT needs molecular receivers on target cells that 
respond to signaling (reviewed in Beis, 2014). 
1.3.1 Large neutral amino acid transporter (LNAAT) 
Not directly a 5-HT transporter but still important to mention is the large neutral amino acid 
transporter (LNAAT) that is located (luminal and abluminal) in endothelial cells and translo-
cates Trp from the plasma into the brain tissue to supply the 5-HT synthesis via TPH2 here. 
This carrier is able to transport large neutral amino acids (LNAA
2
) like Trp through the BBB 
in a sodium-dependent manner (O’Kane et al., 2004). 
1.3.2 Vesicular monoamine transporter (VMAT) 
If the 5-HT content in the cytoplasm is not used for serotonylation of proteins via 
transglutaminases (TG) (Hummerich & Schloss, 2010; Paulmann et al., 2009), it must be 
transferred into vesicles for the further transport. For this purpose there is a transport system 
controlled by the vesicular monoamine transporters (VMAT). VMAT are integrated in the 
lipid bilayer of secretory vesicles for intracellular storage and release of biogenic amines. 
There are two isoforms of VMAT existing: VMAT1, that is expressed in the peripheral sys-
tem (e.g. in chromaffine cells and EC) but also in neuronal cells of the PNS, and VMAT2, 
that is mainly expressed in monoaminergic cells of the CNS, but also in some cells of the 
uterus and the oxyntic mucosa of the stomach (Bottalico et al., 2004; Erickson et al., 1996) 
and in the biggest storage site for peripheral 5-HT: the blood platelets (Cesura et al., 1990; 
Zucker et al., 2001). 
1.3.3 Serotonin transporter (SERT) 
After 5-HT has been released into the extracellular space or, in case of the CNS, into the syn-
aptic cleft, its activity is terminated by the re-uptake into the releasing cell or into another cell 
(e.g. blood platelets or glia cells) (Höltje et al., 2003; Rudnick, 2006a). This transport is medi-
ated by a serotonin transporter (SERT or 5-HTT), which is a 12-membrane spanning trans-
porter encoded by a single gene (Slc6a4) and it is expressed in many different cell types, as 
blood platelets, liver cells, cells of the intestine and 5-HT positive neurons in the CNS 
(Hensler, 2012; Lesch et al., 1993; Mercado & Kilic, 2010; Rudnick, 2006). As an anti-porter 
SERT exchanges extracellular 5-HT against intracellular K
+
 at physiological conditions 
(physiological gradient of Na
+
 and Cl
-
 is needed (Rudnick, 2006b)). 
                                                 
2
 Large neutral amino acids (LNAA) are: Leucine, isoleucine, valine, tryptophan, tyrosine, phenylalanine, methi-
onine, alanine, histidine, threonine and gycine. 
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1.3.4 Serotonin receptors (5-HT receptors) 
Generally, each neurotransmitter needs a proper recipient structure on a target cell to transmit 
a signal or activate cellular processes. According to the latest statement of the International 
Union of Basic and Clinical Pharmacology (IUPHAR) there are at least 14 different receptor 
types in the mammalian serotonergic system which are encoded by at least 18 different genes. 
These receptors can be classified into seven groups due to their pharmacological properties, 
molecular structure and downstream second messenger signaling. Most of the 5-HT receptors 
are G-protein coupled seven transmembrane receptors (GPCR). Only one group appears to be 
an unselective ligand gated ion channel (LGIC) namely 5-HT3 (5-HT receptor type 3 and sub-
types) that mediates post-synaptic depolarization and rapid desensitization (Niesler et al., 
2003; van Hooft & Yakel, 2003). 
Besides the numerous inter- and intracellular effects throughout the CNS which were subject 
of equally numerous studies (see for example Barnes & Sharp, 1999; Lesch & Waider, 2012; 
Millan et al., 2008; Nichols & Nichols, 2008) GPCR 5-HT receptors are broadly involved in 
activation and signaling in the mammalian peripheral system: 
In the gut the major 5-HT receptor is 5-HT4 which, activated by 5-HT, enhance the release of 
transmitters from submucosal intrinsic afferent neurons and hence controls peristaltic and 
secretory reflexes. Another receptor which is discussed to be involved in this area is the        
5-HT1P type (unofficial name) (Frazer & Hensler, 1999; Gershon, 2004). 
In liver it is known that 5-HT2A and 5-HT2B are the key players in tissue regeneration and cell 
proliferation as well as in controlling of the hepatic blood flow (Clavien, 2008; Ruddell, 
Mann, & Ramm, 2008; Ruddell et al., 2006). 
In kidney it could not clearly be shown which receptor type is dominantly active, but is was 
validated that 5-HT2A and 5-HT2B are expressed (Watts & Thompson, 2004) as well as          
5-HT1A (Raymond et al., 1993). What seems to be quite certain as well is that 5-HT receptors 
mediate the salt and water transport in the mammalian kidney and hence regulate blood vol-
ume and pressure. 
In the mammalian heart the story becomes even more complicated: It is well-known that      
5-HT4 is expressed in cardiomyocytes and at the heart valves and it is mainly involved in in-
creasing atrial function and arrhythmias as well as positive inotropic
3
, lusitropic
4
, and ar-
rhythmic effects in the ventricles (Kaumann & Levy, 2006). HT2B was shown to be crucial for 
normal heart development and function (Nebigil & Maroteaux, 2001). 5-HT can also act as a 
sympatholytic through activation of 5-HT1 receptors on sympathetic nerve terminals, inhibit-
ing norepinephrine release. Even though they are not GPCR 5-HT receptors, it needs to be 
mentioned here, that 5-HT3 receptors also play a critical role in the heart due to their distribu-
tion in the vagus nerve (nervus vagus, n. vagus) and their ability to activate the Bezold-
Jarisch
5
 reflex (Saxena & Villalón, 1990). Other 5-HT receptors can be found in the heart or 
                                                 
3
 Positive inotropic effect: Increase of the strength of muscular contraction. 
4
 Lusitropic effect: Rate of myocardial relaxation 
5
 Bezold-Jarisch reflex: Variety of cardiovascular and neurological processes which cause hypopnea (excessively 
shallow breathing or an abnormally low respiratory rate) and bradycardia (abnormally low resting heart rate). 
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related structures and all are handled as modulators for heart rate, blood pressure and cell pro-
liferation (Watts et al., 2012). 
The last peripheral organ that will be introduced here is, to be correct, an organ network, 
namely the blood vessels: As described above, 5-HT was discovered, in part, as a vasocon-
strictor and for this property 5-HT is known best in the cardiovascular and maybe even in the 
whole peripheral system. As reviewed in Watts et al., 2012 it can be summarized that ‘virtual-
ly every blood vessel, when mounted in a tissue bath, responds to 5-HT with contraction from 
baseline. By contrast, not all blood vessels can relax to 5-HT.’. To elucidate this general 
statement a bit, here are the major 5-HT receptor types and their function in the human and/or 
murine vasculature: Mouse aorta (contraction by 5-HT2B); human coronary artery, arteria 
coronaria (contraction by 5-HT2); human femoral artery, arteria femoralis (contraction by 
5-HT2); human saphenous vein, vena saphena magna (contraction by 5-HT1B, 5-HT2A); hu-
man cerebral artery, arteria cerebri (contraction by 5-HT1B, 5-HT2A; relaxation by unknown 
receptor type). There are several more 5-HT receptors acting on the vessels of different 
mammalian species (see Fig. 3) and the exact detailed structure and distribution of 5-HT re-
ceptors in the mammalian vasculature stays unclear. 
1.3.5 Serotonylation 
In addition to all above described modes of action, 5-HT has been shown to play the key role 
in another critical intracellular process: the serotonylation. Serotonylation is a receptor inde-
pendent signaling mechanism in which 5-HT is covalently bound to small GTPases by 
transglutaminase 2 (Walther et al., 2003b). It could be demonstrated that serotonylation of 
those small GTPases leads to α-granule release. α-granules are known to carry a broad variety 
of molecules, such as adhesion molecules, inflammatory molecules, pro- and anticoagulation 
factors, chemokines and membrane proteins (Barthels, 2012). Hence, 5-HT is able to trigger 
processes like platelet aggregation, cell proliferation and inflammation but also insulin secre-
tion (Hummerich & Schloss, 2010; Paulmann et al., 2009; Walther et al., 2003b). Further-
more, it could been shown that serotonylation of the small GTPase Ras homolog gene family, 
member A (RhoA) is involved in the development of pulmonary hypertension (PH) in mice 
(Guilluy et al., 2009) and that serotonylation of cell skeleton proteins can cause contraction of 
blood vessels (e.g. aorta) in rat (Watts, Priestley, & Thompson, 2009). Latest findings even 
identified a direct role of 5-HT, independent from its contributions to neurotransmission and 
cellular signaling, in the mediation of permissive gene expression (Farrelly et al., 2019). 
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Fig. 3 – Response of the Mammalian Vasculature to 5-HT 
A scheme of the mammalian vasculature, as depicted by using the rat vasculature as a model. Both 
constriction (C) and relaxation (R) may be listed for the same species if both responses were ob-
served. Species name is listed, and the subtype of the receptor mediating the response is listed se-
cond (1B, 2A). UK, unknown receptor mechanism.  Picture taken from Watts et al., 2012. 
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Tab. 1 - 5-HT Receptors Overview 
Overview of 5-HT receptors, their tissue distribution and a selection of possible agonists and antago-
nists. All specifications are reviewed from Watts et al., 2012, and currentness of data was confirmed 
by the ‘Guide to Pharmacology – 5-HT receptors’ 
(https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1). Some of the 
agonists and antagonists could not be confirmed by both of the mentioned authorities; in these cases 
the substances got labeled with either *(only from Watts et al., 2012), #(CP-809101: Strong et al., 
2009; CPBG: Kondaurova et al., 2012), °(receptor type not described in the ‘Guide to Pharmacolo-
gy’. SMC: Smooth muscle cells. 
5-HT Recep-
tor Name 
Location and Function (selection) Agonists (selection) Antagonists (selec-
tion) 
5-HT1A CNS; lower, raise blood pressure 
Kidney 
Coronary arteries (poorly expressed) 
8-OH-DPAT 
U92016A 
NLX-112 
WAY100635 
NAN 190 
Robalzotan 
5-HT1B SMC; contraction 
CNS + PNS; lower, raise blood pres-
sure 
Coronary arteries, Heart 
Eletriptan (partial) 
Sumatriptan (partial) 
8-OH-DPAT 
GR 127935 
GR-55562 
SB236057 (inverse) 
5-HT1D SMC; contraction 
Coronary artery, Heart (poorly ex-
pressed) 
PNU109291 
Alniditan 
Eletriptan 
SB 272183 
Zotepine 
Metergoline 
5-HT1E CNS (partly) BRL-54443 Methylergonovine 
5-HT1F SMC; contraction 
CNS 
LY334370 Methysergide 
5-HT2A Platelets; aggregation, 5-HT release 
SMC; contraction 
Heart; contraction 
CNS 
Liver 
Kidney 
TCB-2* 
DOB 
DOI 
Fananserin 
Ketanserin 
LY86057 
Sarpogrelate 
5-HT2B Endothelium; relaxation 
SMC; contraction 
Cardiac valves; proliferation 
Liver 
Kidney 
BW723C86 
LSD 
Methylergonovine 
RS-127445 
BF-1 
EGIS-7625 
5-HT2C CNS 
Resting lymphocytes 
CP-809101
#
 
WAY-163909 
RS-102221 
SB 242084 
5-HT3A,B,C,D,E
6
 N. vagus; Bezold-Jarisch reflex CPBG
#
° Ondansetron*° 
5-HT4 Cardiomyocytes; contraction 
Intestine 
CNS 
RS67506 GR 113808 
5-HT5A CNS LSD methiothepin 
5-HT6 CNS 
Thymus 
WAY-181187 SB399885 
5-HT7 SMC; relaxation 
Cardiomyocytes, contraction 
Aorta 
CNS 
AS-19 
LP-12 
LP-44 
SB269970 
SB 258719 
Lurasidone 
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1.4 The Omnipresence of Serotonin in the Periphery 
Based on all of its previously described chemical properties, biological abilities and physio-
logical interactions one could really call 5-HT a ‘fantastic beast’. 
As mentioned before 5-HT receptors can be widely found in the CNS and organs of the pe-
riphery, such as gut, liver, kidney, adrenal gland, smooth muscle cells (SMCs), heart and 
blood vessels. The same is naturally true for 5-HT which was shown to influence hepatic re-
generation (Lesurtel & Clavien, 2012 and 2012a; Lesurtel & Clavien, 2014; López et al., 
2014; Starlinger et al., 2014) , modulation of the immune system (Cadirci et al., 2013; 
Medina-Martel et al., 2013; Regmi et al., 2014) and indirectly influence peristaltic processes 
via stimulation of the enteric nervous system (ENS-stimulation) (Ahern, 2011; Gershon, 
2012). It was even discussed whether plasma 5-HT has an effect on osteoblast proliferation 
and hence influences bone mass (Cui et al., 2011; Lee et al., 2014; Yadav et al., 2009). Other 
studies could prove that 5-HT is present in testis and breast cells, endothelial cells, pancreatic 
Langerhans cells, some renal cell types, and more (reviewed in Grohmann, 2009). Conse-
quently, peripheral serotonin plays a role in multiple processes, such as embryonic develop-
ment (Buznikov et al., 2001; Nebigil et al., 2000), cardiac development and function (Côté et 
al., 2003), pulmonary hypertrophy (Morecroft et al., 2007), insulin-release from beta-cells 
(Paulmann et al., 2009), and many more. 
In general, 5-HT acts at manifold target sites para-, auto-, and endocrine as hormone or 
growth factor (“autacoid”) (Gershon, 2012). The endocrine pool of 5-HT in the periphery is 
mainly taken up by platelets (thrombocytes) that express SERT and then stored in small dense 
vesicles (Ormsbee & Fondacaro, 1985). This 5-HT pool has a major impact on primary ho-
meostasis and liver regeneration (Lesurtel et al., 2006). 
Regarding all the different tissues and cell types where 5-HT can be found and all the differ-
ent processes in which it is involved it becomes obvious that targeting the 5-HT system with 
any kind of systemically applied medication or genetic modulation may cause several physio-
logical effects in between it might become difficult to differentiate. 
1.5 Serotonin and Atherosclerosis 
As described, 5-HT, 5-HT receptors as well as TPH and SERT can be found throughout the 
mammalian peripheral system. Same is true for macrophages (Nocito et al., 2008; Sternberg 
et al., 1986; Suguro et al., 2006), smooth muscle cells (SMCs) (Höltje et al., 2003; Liu et al., 
2008), endothelial cells (Pakala et al., 1994; Vanhoutte, 1991; Vikenes et al., 1999), mast 
cells (Kushnir-Sukhov et al., 2007) and platelets (Clavien, 2008; Dees et al., 2011; Walther & 
Bader, 2003). All of these cell types are involved in the pathogenesis of atherosclerosis and 
atherosclerotic plaque (AP) formation (Hansson et al., 2006; Ross, 1994) (see Fig. 4). Hence, 
it is reasonable to suppose that 5-HT is involved in atherosclerotic processes. 
1.5.1 A short Introduction to Atherosclerosis 
According to the World Health Organization (WHO) cardiovascular diseases (CVD) are the 
number one cause of death globally: more people die annually from CVDs than from any oth-
er cause. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all 
global deaths. Of these deaths, 85% are due to heart attack and stroke (World Health 
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Organization (WHO), 2017). And these facts are true for people all over the world, independ-
ent from income or other social factors. The major mechanism involved in many types of 
CVDs is atherosclerosis which can be promoted by risk factors, such as high blood pressure, 
smoking, diabetes mellitus, lack of exercise, obesity, high blood cholesterol, poor diet, and 
excessive alcohol consumption (Mendis et al., 2011).  
Atherosclerosis is a chronic disease of arterial blood vessels that causes their narrowing by the 
accumulation of atherosclerotic plaques (APs) at the vascular wall (see Fig. 4, Overview). AP 
formation is a multistep process that initiates by a damage of endothelial cells of the blood 
vessel. This leads to endothelial dysfunction which is characterized by a decreased production 
of nitric oxide (NO) and reduced vasodilation (Endemann & Schiffrin, 2004). Low-density 
lipoproteins (LDL) from the blood stream invade the arterial intima and oxidize. In the fol-
lowing, leukocytes, such as monocytes and neutrophils, were shown to attach to the damaged 
endothelial cells followed by rolling, adhesion and transendothelial migration (von 
Hundelshausen et al., 2009) (see Fig. 4A). This step was shown to be supported by intra-
intimal mast cells which secret pro-inflammatory cytokines (Kelley et al., 2000; Sun et al., 
2007). Monocytes which get in contact with the oxidized LDL differentiate to macrophages 
(see Fig. 4B) These monocyte-derived macrophages inside of the intima bind the oxidized 
LDL via a family of receptors known as scavenger receptors, which recognize LDL exclu-
sively in an oxidized state (Goldstein et al., 1979; Ross, 1994). Uptake of oxidized LDL 
makes the macrophages less mobile, thereby promoting the accumulation of these lipid-laden 
cells in the intima, where they form foam cells (Gerrity, 1981; Yu et al., 2013). At this stage 
of the AP formation the accumulation of cells and debris in the arterial intima is called a ‘fatty 
streak’ (see Fig. 4B,C). Another important cell type in this early stage of AP formation is the 
neutrophil. It was documented that neutrophils produce and excrete chemokines, which de-
termine whether macrophages differentiate towards pro- or anti-inflammatory cells (van 
Leeuwen et al., 2008) (see Fig. 4C), and they could be detected in ruptured APs what suggests 
a role in AP stability (Sasaki et al., 2006). 
Vascular smooth muscle cells (VSMC) are also involved in the AP formation process. They 
migrate from the arterial media through openings in the internal elastic lamina to the intima 
responding to cytokines and growth factors secreted by activated platelets (e.g. platelet-
derived growth factor B (PDGF-B)), monocytes and endothelial cells in arterial lesions (Ross, 
1993) (see Fig. 4D). In the intima they form thickenings by proliferation and secretion of ex-
tracellular matrix (ECM) components. They lose their contractile phenotype by reduction of 
their actin and myosin filaments and become secretory, by an increased formation of endo-
plasmic reticulum and Golgi apparatus (Thyberg et al., 1995). In the AP, VSMC form a fi-
brous cap which covers the fatty streak and provides the plaques with more stability. Further-
more, the secreted growth factors inside of the intima induce collagen accumulation. Collagen 
can constitute up to 60% of the complete AP protein (Smith, 1965). The fragile balance be-
tween collagen synthesis and breakdown  inside of the AP can be crucial for the fibrous cap 
stability (Amento et al., 1991; Rekhter, 1999) (see Fig. 4D). 
At a late stage of atherogenesis it can come to the process of vascular calcification; more pre-
cisely, intimal and medial calcification. Vascular calcification is the pathological deposition 
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of mineral in the vascular system that leads to vascular stiffness and reduced vascular flexibil-
ity (Wu et al., 2013). It could be demonstrated that in human patients the amount of e.g. coro-
nary calcium correlates with hypertension and that it can be used as a reliable predictor for 
future cardiovascular events, such as myocardial infarction. Vascular (here coronary) calcium 
amounts represent an additional and independent risk factor for CVD (Mayer et al., 2007; 
Shaw et al., 2003). 
The final phase of atherogenesis is the severe narrowing of the affected blood vessel (see Fig. 
4E) what can result in a decreased blood flow in the following tissues (e.g. extremities) 
(Derrick et al., 1959). If the AP is big enough the shear stress of the bypassing blood, plus 
instability of the AP fibrous cap will lead to an AP rupture. This results in a release of the 
necrotic core material from the AP into the blood stream where platelets immediately attach 
to the debris and form blood clots (thrombosis) (see Fig. 4F). Those clots or AP compartments 
can also detach and get into the blood stream where they get transported through the vascular 
system and have a high risk to block the following smaller arteries. Blocked arteries cause 
embolic events, such as myocardial infarction or stroke (Falk, 1992; Fuster et al., 1990). 
One, at the first glance, maybe a bit underestimated cell type involved in AP formation (also: 
atherogenesis), is the blood platelet. The role of the blood platelets in atherogenesis goes way 
beyond its obvious functions in haemostasis and thrombosis: It was shown that platelets are a 
crucial player in pro-inflammatory processes (e.g. atherogenesis) and act on all involved cell 
types, from endothelial cells to VSMC, triggering for example chemokine secretion and pro-
liferation (Huo et al., 2003; Lievens & van Hundelshausen, 2011; Weber, 2005). And since 
platelets are the major 5-HT storage in the mammalian blood (Becker, 2008), the story of 
blood platelets in atherosclerosis can be told as a story of 5-HT in atherosclerosis… 
1.5.2 The Role of Serotonin in Atherosclerosis 
It could be shown that patients with atherosclerosis exhibit higher concentrations of plasma  
5-HT (ratio of plasma 5-HT to whole blood 5-HT) than healthy controls (Hara et al., 2004). 
On the other hand patients with hypercholesterolemia were documented to exhibit decreased 
platelet 5-HT levels than controls (Smith & Betteridge, 1997) (see also Tab. 2). These find-
ings taken together with the fact that in mice oxidized LDL stimulates platelets to release      
5-HT from dense granules into the plasma (Zhao et al., 1995) support the image of 5-HT re-
lease from platelets into the plasma is a crucial part of atherogenesis and can be used as a bi-
omarker for the disease.  
In 2008, van Leeuwen and colleagues showed that a long-term high-fat diet, which was de-
scribed previously to induce atherogenetic processes in mice (Nishina et al., 1990), activates 
neutrophils which subsequently tend to accumulate at the lesion sites and secret drastically 
increased levels of myeloperoxidase (MPO). As described above, in this situation 5-HT is 
released from activated platelets, serves as a physiological substrate for MPO and reacts to the 
cytotoxic compound tryptamine-4.5-dione. MPO was shown to be able to injure the endothe-
lium (Ximenes et al., 2009). Furthermore, 5-HT stimulates endothelial cells to produce a neu-
trophil chemoattractants (Charles et al., 1991) which may increase the amount of neutrophils 
in atherosclerotic plaques further and boost their local toxicity. In contrast, 5-HT could also 
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be shown to have a mitogenic effect on arterial endothelial cells which is mediated by 5-HT2 
receptor type (Pakala et al., 1994) (see also Tab. 2). 
The next step in the AP formation process 5-HT actively influences, is the macrophage-
derived foam cell formation in the arterial intima: 5-HT was demonstrated to up-regulate the 
expression of acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) inside of monocyte-
derived macrophages via 5-HT2A receptor pathway which results in an increased intracellular 
transformation of free cholesterol (FC) to cholesterol esters (CE) (Suguro et al., 2006). CE 
can be used for intracellular storage in lipid droplets which is an important step in foam cell 
formation (see also Tab. 2). 
Cultured VSMC express TPH1, are able to synthesize 5-HT and take it up by SERT. In 
VSMC, 5-HT is not stored in vesicles but located in a scattered manner in the cytoplasm     
(Ni et al., 2008). Various studies have shown the potential of 5-HT to induce proliferation and 
migration of VSMC (Guilluy et al., 2009; Lee et al., 1998; Liu et al., 2011; Nemecek et al., 
1986; Tull et al., 2006) (see also Tab. 2).  These processes can be blocked by 5-HT2A receptor 
antagonist application (e.g. sarpogrelate) (Sharma et al., 1999). 
Mast cells, that store and release 5-HT, could also be detected in AP. Mice lacking mast cells 
showed smaller lesion size with less fatty streaks, and with a decreased number of T-cells and 
macrophages in the plaques (Sun et al., 2007) (see also Tab. 2). 
As there is some evidence that 5-HT affects bone mass (Cui et al., 2011; Lee et al., 2014; 
Yadav et al., 2009) it appears plausible that 5-HT might as well act on vascular calcification. 
It was highlighted recently that calcification is a response to the injury that is caused by the 
primary event of atherogenesis (Aherrahrou & Schunkert, 2013) and latest data support the 
hypothesis that a lack of peripheral 5-HT increases cardiac and aortic calcification 
(Aherrahrou & Alenina, unpublished data) (see Tab. 2). 
Lastly, the role of 5-HT in the ECM synthesis needs to be mentioned. It could be demonstrat-
ed that mice lacking peripheral 5-HT (Tph1
-/-
) are protected from bleomycin induced dermal 
fibrosis. The same is true for 5-HT2B
-/-
 which are lacking the 5-HT2B receptor (Dees et al., 
2011) (see also Tab. 2).  Since the accumulation of collagen, which is one of the main com-
pounds of the ECM, is important for AP stability, 5-HT could be crucial for AP composition, 
the prevention of AP rupture and, subsequently, of embolic events.  
In conclusion, there are many possible target sites for 5-HT in the atherogenetic process. 
However, there is no systematic study of the importance of 5-HT in the parthenogenesis of 
atherosclerosis in an animal model. The possible modes of action for 5-HT in atherosclerosis 
are manifold (see Tab. 2) and this study is going to offer a novel approach in this field based 
on a peripherally 5-HT lacking mouse model which may open up new avenue for future scien-
tific questions. 
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5-HT: Serotonin; FB: Fibroblast; MC: Mast Cell; 
VCMS: Vascular Smooth Muscle Cell; EC: Endothelial 
Cell; Mono: Monocyte; PL: Platelet; ox.LDL: oxidized 
Low-density Lipoprotein; Mac: Macrophage; FC: 
Foam Cell; NP: Neutrophil; C: Collagen 
Fig. 4 – Atherogenesis 
Summary of processes during atherogenesis. 
Overview sketch illustrates all phases of 
atherogenesis in one arterial blood vessel.         
A depicts different cell layers of the artery and 
the onset of atherogenesis including endothelial 
damage (yellow lightning) which leads to endo-
thelial dysfunction. B highlights formation of 
fatty streaks including the intra-intimal differen-
tiation of monocyte-derived macrophages and 
the luminal secretion of 5-HT from platelets.    
C shows formation of macrophage-derived foam 
cells, while D depicts late phase including de-
velopment of fibrous cap via migrating VSMC 
and Collagen. E illustrates severe vessel narrow-
ing, whereas F shows AP rupture and throm-
bosis formation. 
 
1 Introduction 
14 
 
Tab. 2 – 5-HT effects in Atherogenesis 
Overview of 5-HT modes of action and their effect during atherogenesis. ↑ indicate an increase;          
↓ indicate a decrease. Data reviewed from text references. 
Involved Tis-
sue/Cell Type 
5-HT Mode of Action Effect 
Platelets  Atherosclerotic lesions/presence of oxidized 
LDL cause 5-HT secretion from platelets in-
to plasma 
 5-HT triggers secretion of chemokines, ad-
hesive proteins and growth factors from 
platelets 
Plasma 5-HT ↑ 
Chemokines ↑ 
Adhesive Proteins ↑ 
Growth Factors ↑ 
Neutrophils  5-HT stimulates endothelial cells to produce 
neutrophil chemoattractants 
 5-HT reacts with neutrophil-derived MPO to 
tryptamine-4.5-dione 
Neutrophils at Lesion ↑ 
Chemokines ↑ 
Endothelial cells  5-HT stimulates endothelial cells to produce 
neutrophil chemoattractants 
 5-HT has a mitogenic effect on endothelial 
cells 
Neutrophils at Lesion ↑ 
Endothelial damage ↓ 
Macrophages/ 
Foam cells 
 5-HT up-regulates ACAT-1 which increases 
FC transformation to CE, this supports foam 
cell formation 
Foam Cell Formation ↑ 
VSMC  5-HT induces VSMC proliferation and mi-
gration 
Fibrous Cap ↑ 
Mast cells  Mast cell-derived 5-HT and pro-
inflammatory cytokines exacerbate 
atherogenetic processes 
Pro-inflammatory Cytokines ↑ 
Fibroblasts/ECM  5-HT appears to be important for ECM syn-
thesis 
Fibrous Cap ↑ 
Fibrous Cap Stability↑ 
Calcification  unknown Calcification ↓ 
 
1.6 Studying Atherosclerosis in a Mouse Model 
The mouse has been used in medical research for decades. Well-known genetic background, 
easy to breed and low cost of maintenance are among advantages of this model. However, 
small size and some physiological characteristics may be considered as limiting factors. For 
example, the plasma lipoprotein profile in mice is very different from that in humans. The 
circulating cholesterol is mainly in high-density lipoprotein (HDL) particles in the mouse, 
while it is in LDL particles in humans. This is probably the main reason that wild-type mice 
do not develop atherosclerosis, but humans do (Kapourchali et al., 2014). 
Today, there are numerous genetically modified mouse models available for basic cardiovas-
cular research and, to be more precise, for the research on atherosclerosis. Among them, LDL 
receptor-knockout (KO), hepatic lipase-KO, human apo B100 expression and human 
cholesterylester transfer protein (CETP) expression can be named (Kapourchali et al., 2014). 
A probably similarly high number of mouse models is accessible for research in the field of  
5-HT and related targets of interest: A broad variety of classical and conditional 5-HT recep-
tor knockout, knock-down or knock-in mouse models is provided as well as genetic models 
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possessing dysfunction in 5-HT production (TPH1, TPH2 or BH4 deficiency), intracellular 
transport (VMAT), re-uptake (SERT) or degradation (MAO) are at hand. 
In the light of this huge spectrum of options, it is very important to choose the right animal 
model for the present scientific question. In case of this study it was important to choose a 
reliable animal model for all phases of atherosclerosis (e.g. the ApoE-deficient mouse) and a 
mouse model which consistently lacks 5-HT at the peripheral system (e.g. the Tph1-deficient 
mouse). Well planned breeding strategies enabled us to combine the properties of interest in 
double KO animals. During the course of the study it became more and more important to 
additionally investigate a mouse model for a depleted re-uptake of 5-HT into the cells (e.g. the 
SERT-deficient mouse). 
1.6.1 The ApoE
-/-
 Mouse 
The ApoE
-/-
 mouse was firstly bred in 1992 by Zhang and colleagues, who successfully delet-
ed the apolipoprotein (Apo) E gene from the mouse genome. The hence generated KO mouse 
exhibits five times normal plasma cholesterol compared to controls (more than 10-times when 
fed high-fat Western-type diet (Plump et al., 1992)) and develops foam-cell rich depositions 
in their proximal aortas by the age of three months. These spontaneous lesions were reported 
to progress and cause severe occlusions of the coronary ostium by an age of eight months 
(Zhang et al., 1992). Later studies confirmed the initial results and demonstrated that the 
ApoE
-/-
 exhibits all phases of atherogenesis throughout the arterial tree and serves as a promis-
ing model system to study atherosclerosis (Nakashima et al. 1994). 
1.6.2 The Tph1
-/-
 Mouse 
As described above, it was in 2003 when Walther and colleagues established a classical KO 
mouse model for TPH1 depletion which resulted in a complete lack of 5-HT in the periphery, 
except for the duodenum which contained approx. 4-10% of the control 5-HT levels. This was 
discussed to be either due to the serotonergic neurons innervating this tissue (Walther et al., 
2003a) or to an alternative 5-HT synthesis pathway via phenylalanine hydroxylase (Matthes 
& Bader, 2018). In Tph1
-/-
 mice the levels of brain 5-HT (e.g. hippocampus and frontal cor-
tex) stay unaltered compared to control. This is of importance since it was shown that brain  
5-HT has a direct influence on cardiovascular parameters, such as heart rate, respiration rate 
and the mean arterial blood pressure (Beis, 2014; Kellett et al., 2005; McCall, 1990) which 
play an important role in atherosclerosis as well. 
1.6.3 The Sert
-/-
 Mouse 
Originally generated via homologous recombination the Sert
-/-
 mouse (Slc6a4
-/-
) lacks the full 
length SERT protein and exhibits an absence of 5-HT reuptake, leading to a decreased rate of 
synaptic 5-HT clearance and a 4-fold to 6-fold increase in basal levels of forebrain extracellu-
lar 5-HT (Bengel et al., 1998; Holmes et al., 2003). In Sert
-/-
 animals the blood 5-HT was 
shown to be zero (Chen et al., 2001). Those absent or decreased intracellular levels of 5-HT in 
platelets may lead to an inhibition of platelet aggregation at atherosclerotic lesion sites and 
inhibited platelet activity in general. That is one possible reason why selective serotonin 
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reuptake inhibitors (short SSRIs
7
) are widely discussed to be beneficial for CVD patients and 
can lower the risk for infarction events (reviewed in Wozniak et al., 2011). Interestingly, it 
could be shown that Sert
-/-
 mice exhibit increased levels of cardiac fibrosis and valvulopathy 
(Mekontso-Dessap et al., 2006) which underlines the close relationship between 5-HT and 
ECM synthesis. 
1.6.4 The Double Knockouts 
Within the framework of this project we generated double KO mice for both, ApoE deficiency 
and Tph1 deficiency, and for ApoE deficiency and Sert deficiency via planned breeding strat-
egy. With these ApoE/Tph1
-/-
, respectively ApoE/Sert
-/-
, animals I had great animal models 
available for the elucidation of the complex systemic connections between all phases of ather-
osclerosis and either the complete lack of peripheral 5-HT or the extensive lack of intracellu-
lar 5-HT combined with an increased baseline level of 5-HT in the extracellular space. The 
latter was especially of interest in the case of blood platelets and their function on 
atherogenesis. 
1.6.5 The Trouble with Background Strains… 
A short comment needs to be made on background strains for biomedical research: It cannot 
be over-emphasized how important it is to consider the appropriate genetic background strain 
for the planned experiment. 
Background strains are supposed to come along with a largely standardized and natural ge-
nome which widely lacks genetic variation in between individuals due to inbreeding over nu-
merous generations. This is important to obtain comparable results for investigated groups of 
animals and for getting stable genetic mutations and phenotypes. However, it was shown that 
in part there are huge differences in treatment effects (e.g. drug effects) between mouse back-
ground strains (Sato et al., 2006) and, that genetic mutations sometimes lead to completely 
different phenotypes when applied to different genetic background strains (reviewed in The 
Jackson Laboratory, 2006). 
For the present study there was evidence that distribution of 5-HT receptors might be different 
in C57Bl/6 (B6) and Friend virus B (FVB/N) mice (Todiras & Bader, unpublished data). 
Hence, to investigate expression and distribution of 5-HT receptors in vascularisation, I de-
cided to use both background strains and their respective Tph1 knockout lines. For all other 
experiments on atherosclerotic processes I opted for genetically modified animals in the B6 
background since the majority of studies was performed similarly and the B6 mouse is known 
to only barely develop atherosclerotic lesions spontaneously (and only under modified diet) 
(reviewed in Whitman, 2004), and is genetically very susceptive for the applied mutations 
(ApoE
-/-
, Tph1
-/-
, Sert
-/-
). 
 
                                                 
7
 Selective serotonin reuptake inhibitors (short SSRIs) are a class of drugs that are typically used as antidepres-
sants in the treatment of major depressive disorder and anxiety disorders. Classical SSRIs are    citalopram, 
escitalopram, fluoxetine (Prozac
TM
), fluvoxamine, paroxetine and sertraline. 
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2 Materials 
2.1 Chemicals 
Chemical Name Abbreviation Company / Supplier 
100bp DNA Ladder 100 bp New England Biolabs GmbH (Germany) 
2-amino-2-methyl-1-propanol  Randox Laboratories Ltd (United King-
dom) 
4’,6-Diamidino-2-phenylindole DAPI Sigma-Aldrich (Germany) 
5-Hydroxytryptamine 5-HT Sigma-Aldrich (Germany) 
5-Hydroxytryptophan 5-HTP Sigma-Aldrich (Germany) 
8-Hydroxyquinoline  Randox Laboratories Ltd (United King-
dom) 
Acetic acid CH3COOH Sigma-Aldrich (Germany) 
Acetone C3H6O Roth (Germany) 
Agarose  Biozym Scientific GmbH (Germany) 
Aniline blue solution  Sigma-Aldrich (Germany) 
Biebrich scarlet-acid fuchsin solution  Sigma-Aldrich (Germany) 
Bouin solution  Sigma-Aldrich (Germany) 
Bromphenol blue  Roth (Germany) 
Butylated hydroxytoluene BHT Sigma-Aldrich (Germany) 
Calcein (Fluorexon)  Sigma-Aldrich (Germany) 
Calcium standard solution  Randox Laboratories Ltd (United King-
dom) 
Carbon dioxide (Dry ice) CO2 MDC Berlin (Germany) 
carboxy-X-rhodamine CRX Promega GmbH (Germany) 
Chloroform CHCl3 Merck KGaA (Germany) 
Citric acid C6H8O7 Merck KGaA (Germany) 
Deoxyribonucleotide dNTP Bioline (Germany) 
Diethylpyrocarbonat DEPC Sigma-Aldrich (Germany) 
DNase I  New England Biolabs GmbH (Germany) 
DNase I reaction buffer (10x)  New England Biolabs GmbH (Germany) 
DNAzol® reagent  Invitrogen (Germany) 
Ethanol C2H5OH BERKEL AHK GmbH & Co.KG (Ger-
many) 
Ethidium bromide EtBr SERVA Electrophoresis GmbH (Germa-
ny) 
Ethylenediaminetetraacetic acid EDTA Sigma-Aldrich (Germany) 
Formaldehyde (37%)  Merck KGaA (Germany) 
Glucose Glc Merck KGaA (Germany) 
Glycerol  Roth (Germany) 
Glycerol Gelatin (Mounting medium)  Sigma-Aldrich (Germany) 
Hematoxylin  Sigma-Aldrich (Germany) 
Heparine  Roth (Germany) 
Hydrochloric acid HCl Roth (Germany) 
Isoflurane  Abbott (Germany) 
Isopropanol C3H7OH BERKEL AHK GmbH & Co.KG (Ger-
many) 
Ketamidor®  WDT eG (Germany) 
Magnesium chloride MgCl2 Merck KGaA (Germany) 
Neo-Mount®  Merck KGaA (Germany) 
Normal Donkey Serum NDS DIANOVA GmbH (Germany) 
O-Cresolphthalein complexone  Randox Laboratories Ltd (United King-
dom) 
Oil Red O ORO Sigma-Aldrich (Germany) 
Paraformaldehyde (4%) PFA Merck KGaA (Germany) 
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Phosphate buffered saline PBS Life Technologies (USA) 
Phosphomolybdic acid solution  Sigma-Aldrich (Germany) 
Phosphotungstic acid solution  Sigma-Aldrich (Germany) 
Proteinase K  Roth (Germany) 
Random Hexamer Primer RHP Roche AG (Switzerland) 
REDTaq® DNA Polymerase RedTaq Sigma-Aldrich (Germany) 
RNAlater  Sigma-Aldrich (Germany) 
RNase A  Promega GmbH (Germany) 
Rnase inhibitor Rnasin ROBOKLON GMBH (Germany) 
Rompun® (Xylazine)  Bayer AG (Germany) 
Sodium chloride NaCl Roth (Germany) 
Sodium chloride solution (0.9%) Saline MDC Pharmacy – PZN: 02737756 (Ger-
many) 
Sodium dodecylsulfate SDS SERVA Electrophoresis GmbH (Germa-
ny) 
Sodium hydroxide NaOH Roth (Germany) 
Sucrose  Merck KGaA (Germany) 
SYBR Green  Promega GmbH (Germany) 
Taq polymerase TaqPol New England Biolabs GmbH (Germany) 
ThermoPol® reaction buffer Pol-Buffer New England Biolabs GmbH (Germany) 
Tissue-Plus OCT
TM
 Compound OCT Newcomer Supply Inc. (USA) 
tris(hydroxymethyl)aminomethane Tris, 
(HOCH2)3CN
H2 
Roth (Germany) 
Tri-sodium citrate (dehydrate)  Sigma-Aldrich (Germany) 
Triton X-100  Merck KGaA (Germany) 
Trizol®  Life Technologies (USA) 
Tween-20  Sigma-Aldrich (Germany) 
Vectashield Mounting Medium with 
DAPI 
 Vector Laboratories Inc. (USA) 
Weigert’s haematoxylin solution  Sigma-Aldrich (Germany) 
Xylol  Roth (Germany) 
2.2 Antibodies 
Marker Host Reactivity (Species) Company / Supplier 
Mac2 (Galectin-3) rat mouse ORIGENE Technologies, Inc. 
(USA) 
2.3 Oligonucleotides… 
2.3.1 …for Polymerase Chain Reaction (PCR) 
Gene of Inter-
est 
Primer Name Oligonucleotide Sequence Sequence Source 
Mouse ApoE ApoE_3 5’- CGAAGCCAGCTTGAGTTACAG BioTeZ (Germany) 
Mouse ApoE ApoE_WT5 5’ - TATCTAAACAGACTCCACAGC BioTeZ (Germany) 
Mouse ApoE ApoE_KO5 5’- GACTGGGCACAACAGACAATC BioTeZ (Germany) 
Mouse Tph1 GTPH3 5’-CAGCTCTGTGATGGACGGTA BioTeZ (Germany) 
Mouse Tph1 GTPH5 5’-GCTTGCAGGAGTTGGTTCTC BioTeZ (Germany) 
Mouse Tph1 Neo3 5’-CTGCGCTGACAGCCGGAACAC BioTeZ (Germany) 
Mouse Slc6a4 IMR8899 5’-AATGGTGAGGAGTGGTGGAG BioTeZ (Germany) 
Mouse Slc6a4 IMR7415 5’-GCCAGAGGCCACTTGTGTAG BioTeZ (Germany) 
Mouse Slc6a4 IMR8890 5’-CCTAGATACCAGGCCCACAA BioTeZ (Germany) 
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2.3.2 … for Quantitative Polymerase Chain Reaction (qPCR) 
Gene of Inter-
est 
Primer Name Oligonucleotide Sequence Sequence Source 
Mouse HTr1a mHtr1a_FW 5’-CCGATCTCATGGTGTCAGTG IIEG Lübeck 
Mouse HTr1a mHtr1a_REV 5’-GGTGATTGCCCAGTACCTGT IIEG Lübeck 
Mouse HTr1b mHtr1b_FW 5’-ATGCGGTGGAGTATTCTGCT IIEG Lübeck 
Mouse HTr1b mHtr1b_REV 5’-TCACAAAGCAGTCCAGCATC IIEG Lübeck 
Mouse HTr1d mHtr1d_FW 5’-CACGGACCTCCTGGTTTCTA IIEG Lübeck 
Mouse HTr1d mHtr1d_REV 5’-GCCCAGTATCTGTCCAGAGC IIEG Lübeck 
Mouse HTr2a mHtr2a_FW 5’-TCATCATGGCAGTGTCCCTA IIEG Lübeck 
Mouse HTr2a mHtr2a_REV 5’-AGGTAAATCCAGACGGCACA IIEG Lübeck 
Mouse HTr2b mHtr2b_FW 5’-GCAGATTTGCTGGTTGGATT IIEG Lübeck 
Mouse HTr2b mHtr2b_REV 5’-AGGGAAATGGCACAGAGATG IIEG Lübeck 
Mouse HTr2c mHtr2c_FW 5’-CCATTGCTGATATGCTGGTG IIEG Lübeck 
Mouse HTr2c mHtr2c_REV 5’-CATGATGGACGCAGTTGAAA IIEG Lübeck 
Mouse HTr3a mHtr3a_FW 5’-CGGCAGTACTGGACTGATGA IIEG Lübeck 
Mouse HTr3a mHtr3a_REV 5’-TCACCTCGATGATGCACGTA IIEG Lübeck 
Mouse HTr3b mHtr3b_FW 5’-ATCCAGAACTGCAGCCTCAC IIEG Lübeck 
Mouse HTr3b mHtr3b_REV 5’-GCTGCCACTCACTGTCATTC IIEG Lübeck 
Mouse HTr4 mHtr4_FW 5’-TCGATCTTTCACCTGTGCTG IIEG Lübeck 
Mouse HTr4 mHtr4_REV 5’-CCTTGCATTATGGGGAGAAA IIEG Lübeck 
Mouse HTr5a mHtr5a_FW 5’-CAGGAAGACCAACAGCGTCT IIEG Lübeck 
Mouse HTr5a mHtr5a_REV 5’-CGTATCCCCTTCTGTCTGGA IIEG Lübeck 
Mouse HTr6 mHtr6_FW 5’-GGTGCCATCTGCTTCACCTA IIEG Lübeck 
Mouse HTr6 mHtr6_REV 5’-GGTGGTCAGACGCCTACTGT IIEG Lübeck 
Mouse HTr7 mHtr7_FW 5’-CTTCTGCAACGTCTTCATCG IIEG Lübeck 
Mouse HTr7 mHtr7_REV 5’-TTGGCCATACATTTCCCATT IIEG Lübeck 
Mouse MAO-A mMaoa _FW 5’-TGTGAGGCAGTGTGGAGGTA IIEG Lübeck 
Mouse MAO-A mMaoa _REV 5’-TTATCCCCAAGGAGGACCAT IIEG Lübeck 
Mouse Slc6a4 mSlc6a4_FW 5’-CTGGACCAGCTGCAAGAACT IIEG Lübeck 
Mouse Slc6a4 mSlc6a4_REV 5’-CCTGGAGTCCCTTTGACTGA IIEG Lübeck 
Mouse Tph1 mTph1_FW 5’-GTGGCTATCGGGAAGACAAC IIEG Lübeck 
Mouse Tph1 mTph1_REV 5’-GGGGATCTGAACTGTGTCTCA IIEG Lübeck 
Mouse Tph2 mTph2_FW 5’-CGGGAGCTCTCCAAACTCTA IIEG Lübeck 
Mouse Tph2 mTph2_REV 5’-AGGTAGCCAGCCACTGGTC IIEG Lübeck 
2.4 Enzymes 
2.4.1 DNA Polymerases 
DNA Polymerase Abbreviation Company / Supplier 
Moloney Murine Leukemia 
Virus Reverse Transcriptase 
M-MLV RT Promega GmbH (Germany) 
REDTaq® DNA Polymerase RedTaq Sigma-Aldrich (Germany) 
Taq polymerase TaqPol New England Biolabs GmbH (Germany) 
2.4.2 Other Enzymes 
Enzyme Company / Supplier 
DNase I Roche AG (Switzerland) 
Proteinase K Roth (Germany) 
RNAse A Promega GmbH (Germany) 
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2.5 Kits 
Kit Company/Supplier 
Calcium assay Randox Laboratories Ltd (United Kingdom) 
Cholesterol (Colorimetric) assay Sede Industrial da Labtest (Brazil) 
NEFA ASC-ACOD assay FUJIFILM Wako Chemicals Europe GmbH 
(Germany) 
Triglycerides (Enzymatic) assay Sede Industrial da Labtest (Brazil) 
2.6 Laboratory Instruments 
Instrument Company / Supplier 
1/4" Ceramic Sphere Banded Satellite MP Biomedicals Inc. (USA) 
384-well optical plate MicroAmp® Biozym (USA) 
96-well clear microplate F-bottom Sarstedt AG & Co.KG (Germany) 
96-well clear microplate U-bottom Sarstedt AG & Co.KG (Germany) 
Accu-Chek® blood glucose meter Roche Diabetes Care GmbH (Germany) 
Agarose gel electrophoresis chamber Biometra (Germany) 
AU480 Chemistry Analyzer Beckman Coulter Inc. (USA) 
Beebee Bone Scissors (15mm cutting edge; 
Straight; Stainless Steel) 
Fine Science Tools GmbH (Germany) 
Binocular Leica MZ 95 Leica Microsystems (Germany) 
Binocular MZFLIII Leica Microsystems (Germany) 
C1000 Thermal Cycler Bio-Rad Laboratories Inc. (USA) 
Centrifuge 5415C Eppendorf AG (Germany) 
Ceramic beads for homogenizer (2.8mm) VWR International (USA) 
Cooling centrifuge 5804R Eppendorf AG (Germany) 
Cooling centrifuge Megafuge 1.0R Heraeus Intruments GmbH/Thermo Fisher 
Scientific Inc. (USA) 
Cryostat CM3050 S Leica Microsystems (Germany) 
Disposable pipettes Cellstar® Greiner bio-one (Germany) 
DRY-CHEM NX500i Analyzer Fujifilm (Japan) 
Dumont #5 Forceps (0.05mm x 0.02mm; Titanium) Fine Science Tools GmbH (Germany) 
Dumont Forceps - Micro-Blunted Tips (Angled 45; 
0.1 x 0.06mm; Inox) 
Fine Science Tools GmbH (Germany) 
Dumont Forceps - Micro-Blunted Tips (Curved – 
12cm; 0.1 x 0.06mm; Titanium) 
Fine Science Tools GmbH (Germany) 
Dumont Forceps - Micro-Blunted Tips (Standard; 
0.1 x 0.06mm; Inox) 
Fine Science Tools GmbH (Germany) 
EDTA tubes MiniCollect® Greiner bio-one (Germany) 
Falcon tubes Greiner bio-one (Germany) 
FastPrep
TM
 lysing matrix tubes MP Biomedicals (France) 
FastPrep
TM
-24 instrument MP Biomedicals (France) 
Filter tips Biozym (USA) 
Fine balance Kern & Sohn GmbH (Germany) 
Fluorescence microscope BZ-9000 Keyence (Germany) 
Mastercycler Nexus GX2 Eppendorf AG (Germany) 
Microbalance Sartorius (Germany) 
Microplate reader Infinite® M200 Tecan Trading AG (Switzerland) 
MiniSpec LF 90II Bruker Corporation (USA) 
Minutien Pins (Tip: 0.0125mm; Stainless Steel) Fine Science Tools GmbH (Germany) 
Multipette® plus Eppendorf AG (Germany) 
NanoDrop
TM
 1000 spectrophotometer Peqlab (Germany) 
Olympus IX70 microscope Olympus Europa SE & CO. KG (Germany) 
Pasteur pipettes Roth (Germany) 
PCR tubes Biozym Scientific GmbH (Germany) 
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pH meter pH Level 1 WTW (Germany) 
Pipetboy acu 2 Integra Bioscience (Switzerland) 
Pipettes Gilson Disposable pipettes CellstarR 1, 2, 
5, 10, 25ml 
Gilson (USA) 
Precision balance 440-43N Kern & Sohn GmbH (Germany) 
Real time PCR system QuantStudio
TM
 5 Applied Biosystems
TM
/Thermo Fisher Sci-
entific Inc. (USA) 
Research Plus Multichannel Pipette Eppendorf AG (Germany) 
Rotable platform Polymax 1040 Heidolph Instruments (Germany) 
Save-Lock tubes Eppendorf AG (Germany) 
Single channel micropipette Transferpette® Brand GmbH & Co KG (Germany) 
Single pipettes Discovery Abimed (Germany) 
Spring Scissors (8mm cutting edge; Straight; Stain-
less Steel) 
Fine Science Tools GmbH (Germany) 
Stereomicroscope Leica M205 FA Leica Microsystems (Germany) 
Student Fine Scissors (23mm cutting edge; 
Straight; Student Stainless Steel) 
Fine Science Tools GmbH (Germany) 
Student Vannas Spring Scissors (5mm cutting 
edge; Straight; Student Stainless Steel) 
Fine Science Tools GmbH (Germany) 
Super Frost Ultra Plus® object slices Menzel Gläser (Germany) 
Surgical Scissors - Sharp-Blunt (41mm cutting 
edge; Straight; Stainless Steel) 
Fine Science Tools GmbH (Germany) 
Syringe filter Sartorius (Germany) 
Thermomixer 5437 Eppendorf AG (Germany) 
Thermomixer comfort Eppendorf AG (Germany) 
Ultrasound Sonopuls Bandelin Electronic (Germany) 
UV Gel Documentation System c600 Biozym Scientific GmbH (Germany) 
Vannas Spring Scissors (4mm cutting edge; 
Curved; Stainless Steel) 
Fine Science Tools GmbH (Germany) 
Vortex Genie 2 Bender & Hobein AG (Switzerland) 
2.7 Software and Online Programs 
Software / Program Company / Supplier / Webpage 
BZII Analyzer Keyence GmbH (Germany) 
Dataquest ART system, version 2.1 Data Sciences International (USA) 
GraphPad Prism5 GraphPad Software (USA) 
GraphPad QuickCalcs Outlier Calculator https://www.graphpad.com/quickcalcs/Grubbs1.cfm 
Guide to Pharmacology – 5-HT receptors https://www.guidetopharmacology.org/ 
GRAC/FamilyDisplayForward?familyId=1 
ImageJ v1.52o National Institutes of Health (USA) 
Kyoto Encyclopedia of Genes and Genomes https://www.genome.jp/kegg/ 
Leica Application Suite X (LASX) Leica Microsystems (Germany) 
Leica QWin v3 Leica Microsystems (Germany) 
Mendeley Reference Manager Mendeley Ltd./Elsevier B.V. (Netherlands) 
MS Office 2007 Excel Microsoft Ireland Operations Limited (Ireland) 
MS Office 2007 Power Point Microsoft Ireland Operations Limited (Ireland) 
MS Office 2007 WORD Microsoft Ireland Operations Limited (Ireland) 
PASW Statistics 18, SPSS IBM (Germany) 
Photoshop, Adobe CS5 Adobe Systems GmbH (Germany) 
QuantStudio
TM
 Design & Analysis Software 
1.3.1 
Applied Biosystems
TM
/Thermo Fisher Scientific 
Inc. (USA) 
Reactome Pathway Finder https://reactome.org/PathwayBrowser/ 
Statistica 8 StatSoft (Europe) GmbH (Germany) 
Tecan i-Control
TM
 V1.40 Tecan Trading AG (Switzerland) 
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3 Animals 
All animal experiments described in the present thesis were in accordance with the ethical 
principles and guidelines for safety, care and use of laboratory animals adopted by German 
local authorities (Landesamt für Gesundheit und Soziales, LAGeSo, Berlin) corresponding to 
the standards prescribed by the American Physiological Society. 
3.1 Mice Strains 
3.1.1 C57Bl/6 wildtype mice 
One of the most commonly used inbred mouse line in science is the C57Bl/6 (short B6). B6 
mice have been bred for almost a century, now and substrains of the B6 mouse developed. 
But most of the original traits of the B6 mouse stayed unaltered. The B6 mouse is associated 
with typical black coat which is due to a homozygously carried mutated nonagouti (a) allele. 
Beside this external trait, the B6 mouse is known to be a permissive background for maximal 
expression of most mutations. B6 mice could be shown to exhibit an increased corticosteroid-
metabolism, age-related vulnerability for deafness, diet induced adiposity, and amyloid 
plaques, but not for spontaneous atherosclerotic plaque development. The B6 mouse is a 
commonly used animal model in cardiovascular research and the C57BL/6J (originally from 
The Jackson Laboratory, https://www.jax.org/) substrain was even used for the mouse ge-
nome project. For this thesis, B6 mice were obtained from an internal MDC-breeding pool 
that is refreshed by Charles Rivers C57BL/6N mice approximately each third year. 
3.1.2 FVB/N wildtype mice 
Another commonly used inbred mouse line is the albino FVB/N, which was originally gener-
ated by NIH from the N:GP (NIH general purpose) Swiss mouse strain and has been bred 
since 1966. It could be shown that FVB/N mice appear to behave more aggressively and are 
more active than other strains. The here used FVB/N mice where as well obtained from an 
internal MDC-breeding pool. 
3.1.3 ApoE deficient mice 
ApoE
-/-
 mice lack the apolipoprotein E and develop spontaneous hypercholesterolemia and 
atherosclerotic lesions throughout the complete aortic tree due to an impaired transport mech-
anism for VLDL and LDL and reduced lipoprotein binding performance to hepatocytes and 
other peripheral tissues that leads to increased levels of circulating VLDL and LDL and thus, 
increased circulating lipids such as cholesterol. ApoE
-/-
 mice used for this study were original-
ly generated by Zhang et al. (1992) and obtained from The Jackson Laboratory (USA). 
3.1.4 Tph1 deficient mice 
Mice lacking the first isoform of tryptophanhydroxylase (TPH1) do not synthesize 5-HT in 
the periphery (~4% left), but central 5-HT levels stay unaltered. Tph1
-/-
 mice were originally 
generated by our research group (Walther et al., 2003a) and kept at the MDC-breeding facili-
ty. Tph1
-/-
 mice were backcrossed for 10 generations to the C57BL/6N genetic background. 
3.1.5 Sert deficient mice 
Sert deficient mice used in this study were originally generated by Bengel et al. (1998). They 
are lacking the gene function for the murine Slc6a4 gene which codes for the SERT protein. 
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Consequently, Sert
-/-
 mice exhibit unaltered 5-HT synthesis, but since SERT is not present to 
transport 5-HT into the cells, the total blood 5-HT level in these animals is 0% (Chen et al., 
2001). 
3.1.6 Double Knockouts 
For this study, double knockout mice with deficiencies for ApoE and either Tph1 or Sert were 
generated at the MDC-breeding facility via well planned breeding strategies: Homozygous 
ApoE
-/-
 mice were crossed to either homozygous Tph1
-/-
 or Sert
-/-
 mice to generate double het-
erozygotes which were subsequently intercrossed to generate homozygous double knockout 
animals. 
3.2 Animal Husbandry and Test Materials 
3.2.1 Animal Husbandry and Breeding 
All mice were kept in individually ventilated cages (IVC), either group or single housed (only 
if aggressive behavior caused injuries) with constant temperature of 22 ± 2 °C and humidity 
of 65 ± 5%. Animals were exposed to a 12h/12h light/dark cycle (lights on at 7 am) with free 
access to standard chow and drinking water ad libitum, unless otherwise specified. Cage 
changing and regular supervision of animal health status was performed by the staff of the 
animal house of the MDC Berlin. If an animal showed signs of sickness, tumors or other 
health limitations, it was excluded from any experimental cohorts. If the health status did not 
normalized within a day the responsible veterinary was informed and/or the animal was ter-
minally anaesthetized. Offspring were weaned at around post natal day PND 21 and geno-
typed by ear-mark biopsies. If young animals had to be genotyped tail-cut biopsies were per-
formed before PND 6. For tail-cut biopsies pre-heated sterile scissors (60°C) were used to 
make the wound desolate. 
All animal tests were in accordance with the ethical principles and guidelines for safety, care 
and use of laboratory animals adopted by German local authorities (Landesamt für 
Gesundheit und Soziales, LAGeSo, Berlin) corresponding to the standards prescribed by the 
American Physiological Society. 
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3.2.2 Food and Water 
Diet Company / Supplier 
Drinking water (not acidified) Autoclaved tap water of the animal facility 
(MDC-Berlin, Germany) 
Normal chow (0.25% sodium) Sniff Spezialdiäten GmbH (Germany) 
Western Type Diet (2071mg/kg cholesterol) Sniff Spezialdiäten GmbH (Germany) 
3.2.3 Drugs 
Drug Active Ingredient Company / Supplier 
Isoflurane (RS)-Difluormethoxy-1-chlor-2,2,2-
trifluorethan 
Abbott (Germany) 
Ketamidor® Ketamin WDT eG (Germany) 
Rompun® Xylazinhydrochlorid Bayer AG (Germany) 
Saline 0.9% Sodiumchloride MDC Pharmacy – PZN: 
02737756 (Germany) 
Betadine 10% Povidone-iodine (PVP-I) Mundipharma (Germany) 
Heparine Heparine Sodium Roth (Germany) 
3.2.4 Material for Animal Tests and Husbandry 
Material Company / Supplier 
200ml water bottle Tecniplast Deutschland GmbH (Germany) 
Accu-Chek® blood glucose meter Roche Diabetes Care GmbH (Germany) 
EDTA tubes MiniCollect® Greiner bio-one (Germany) 
Individually ventilated cages (IVC), 34x19x13cm Tecniplast Deutschland GmbH (Germany) 
Single housing cages (SHC), 27x21x13cm Tecniplast Deutschland GmbH (Germany) 
Ear notching tool Fisher Scientific International Inc. (USA) 
Restrainer (Bodycomposition) MDC Workshop (Germany) 
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4 Methods 
4.1 Methods for Genetic Modifications 
As described above, the genetically modified mouse lines where either obtained from The 
Jackson Laboratory (USA) (ApoE
-/-
) or generated as described in Walther et al., 2003a   
(Tph1
-/-
) and Bengel et al., 1998 (Sert
-/-
). The double KO animals that were used for this study 
were generated via breeding in the MDC animal facility and respective genotypes were con-
trolled throughout the whole experiment via DNA amplification as described below (see page 
37). 
4.2 Animal Treatments 
4.2.1 Western Diet 
Male and female animals of the ApoE
-/-
 and ApoE/Tph1
-/-
genotypes were fed a high fat West-
ern type diet (21.2% crude fat, 0.21% cholesterol; TD88137 from Sniff Spezieldiäten GmbH, 
Germany) over a period of 8 or 12 weeks (see Fig. 5) to quickly induce atherosclerotic pro-
cesses. Furthermore, three experimental groups were tested in the exact same manner, only 
that they were not provided with high fat Western type diet, but normal chow. In these groups 
atherosclerosis was supposed to be induced naturally by the animals’ age: animals were dis-
sected at the ages of 45, 60 and 100 weeks (see Fig. 5). Diet and water were always provided 
ad libitum, only diet was removed one day before sacrifice to guarantee sober blood glucose 
measurements. Western diet pellets were changed latest 4 days after administration to avoid 
spoiling which happens quicker to diet with high fat content. 
4.2.2 Anesthesia of mice 
Mice were anaesthetized via intraperitoneal (i.p.) Rompun®/Ketamidor® injection and if ap-
plicable, anesthesia was deepened via isoflurane inhalation. Rompun®/Ketamidor® solution 
was freshly prepared right before each experiment as follows: 10% Ketamidor® 
(ketaminhydrochloride, 100.0 mg/ml) and 5% Rompun® (xylazinhydrochlorid, 23.3 mg/ml) 
were added to 0.9% saline. Each animal got an injection of 10µl Rompun®/Ketamidor® solu-
Fig. 5 – Schedule for Atherosclerosis Experiments 
Overview of all experiments investigating induced atherosclerosis including time schedule. Time-
scale indicates age of the animals: from 0 to 100 weeks. Events are highlighted with either red ar-
rows for time periods (8 and 12 weeks of Western diet) or black arrows for time points (BCA: body 
composition analysis; date of sacrifice). Five experimental groups were investigated: 2x Western 
diet and 45, 60 and 100 weeks naturally aged animals. 
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tion per 1g of bodyweight resulting in 2 – 4mg/animal (100mg/kg) Ketamidor® and 0.2 – 
0.4mg/animal (11.5mg/kg) Rompun®. Before any treatment the level of anesthesia was vali-
dated by reflex tests on tail, hind and front legs. Operations or treatments were only per-
formed if all reflex responses were totally lost. If re-anesthesia was necessary, only 
Ketamidor® was injected again. For terminal anesthesia, animals were left under the respec-
tive isoflurane concentration until breathing stopped and cardiovascular failure under deep 
anesthesia occurred. 
4.2.3 Perfusion 
Mice were deeply anesthetized via i.p. Rompun®/Ketamidor® injection (see above). After 
deep anaesthesia was visible and all reflexes disappeared, mice were fixed to an operation 
table under permanent isofluran inhalation. A small incision was applied right under the ster-
num and the abdominal wall was carefully opened without harming any bones. The abdominal 
wall was slightly lifted and an EDTA rinsed cannula was used to transperitoneally puncture 
the heart, precisely the ventricle. Blood was removed (see page 27) until the animal collapsed 
and breathing was no longer visible. Right after this had happened, the thorax was opened, so 
that the heart region became visible. The right atrium was opened minimally and another can-
nula was inserted into the ventricle through the lesion which was used for the blood removal 
before. The remaining blood was then removed by an ice cold heparinized saline (solution 1, 
see Tab. 3) exchange which was performed manually with constant pressure on the syringe. 
After approximately 2ml of solution 1 were applied and tissues like liver or lung were visibly 
loosing reddish color the second cannula was connected to the animal’s circulation and a se-
cond ice cold solution, based on PBS containing the antioxidant butylated hydroxytoluene 
(BHT) (solution 2, see Tab. 3) was used to remove remaining blood compartments. Subse-
quent to these two blood exchanging steps all organs and tissues that were used for biochemi-
cal analysis got removed and only after that the last perfusion step was performed using ice 
cold paraformaldehyde (PFA) solution (solution 3, see Tab. 3) and thus fixating the remaining 
tissues, especially heart and aorta of the animals. 
Tab. 3 – Perfusion Solutions 
Composition of solutions used for manual perfusion. Amounts are specified in percent, but additional-
ly in volume weight calculated for 250ml of solution. Application of the respective solution during 
dissection is also stated. 
 
Perfusion 
Solution 
Composition (%) in 250ml Application 
Solution 1 NaCl (0.9%)...................99.995% 
Heparine (5000 U/ml)....0.005% 
248.75ml 
1.25ml 
Physiological blood exchange, 
inhibited blood clotting 
Solution 2 PBS (1x, pH 7.4)……....99.98996% 
EDTA (0.2M)………….0.01% 
BHT (0.5M)…………....0.00004% 
247.49ml 
2.5ml 
10µl 
Physiological blood exchange, 
inhibited blood clotting, impaired 
cellular oxidation 
Solution 3 PFA (4%)………………94.98996% 
Sucrose…………………5.0% 
EDTA (0.2M)…………..0.01% 
BHT (0.5M)……………0.00004% 
247.49ml 
12.5g 
2.5ml 
10µl 
Tissue fixation, cryoprotection, 
inhibited blood clotting, impaired 
cellular oxidation 
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4.3 Physiological Measurements 
4.3.1 Monitoring of Bodyweight Gain and Food Consumption under Western Diet 
Animals that were fed Western diet (WD) stayed under very close monitoring and their food 
intake, as well as their bodyweight gain was documented accurately. When diet administra-
tion started, all animals got weighed and marked via ear notching (if applicable) to guarantee 
individual documentation. WD chow was weighed before administration and reweighed after 
it had to be changed (latest after 4 days). Food consumption was then calculated per cage and 
per animal by dividing the cage consumption by the animal number per cage. Furthermore, 
individual bodyweight gain was calculated each week and at the end of the experiment for the 
complete 8 or 12 weeks of WD always using the start bodyweight as 100%. 
4.3.2 Body Composition Analysis (BCA) 
After 8 and/or 12 weeks of WD, animals were fasted over night (≤16 hours) and underwent a 
non-invasive body composition analysis (BCA) to determine the relative amount of body fat, 
muscle mass and water. BCA was performed in collaboration with Stefanie Schelenz and 
Martin Taube of the Pathophysiology core facility of the MDC Berlin. All measurements 
were executed with a nuclear magnetic resonance (NMR) spectrometer (MiniSpec LF90II, 
Bruker Corporation, USA) and lasted about 3 minutes with the animal being completely re-
strained in a warm-temperate chamber rendering anesthesia unnecessary. 
4.3.3 Blood Sampling 
4.3.3.1 Blood Glucose Measurement 
Animals were starved over night before the experiment to allow measurement of sober blood 
glucose levels; access to water was given ad libitum. For measuring the blood glucose level 
unchallenged animals were quickly grabbed and fixated by hand. A very small cut was ap-
plied at the tail tip using student fine scissors (Fine Science Tools GmbH, Germany) and the 
small amount of blood was directly transferred to a fresh test strip and analyzed via blood 
glucose meter (Accu-Chek®, Roche Diabetes Care GmbH, Germany). Only after the blood 
glucose measurement further experimental treatments (e.g. anesthesia) were applied since 
elevated stress levels in the animals may influence the data. 
4.3.3.2 Whole Blood Sampling 
Animals were deeply anaesthetized, fixated and the abdominal cavity was opened (see above). 
The abdominal wall was slightly lifted and an EDTA rinsed cannula was used to 
transperitoneally puncture the ventricle. Blood was removed to the greatest possible extend 
(0.5-1.5ml) with a EDTA coated syringe and sampled into EDTA MinCollect tubes (Greiner 
bio-one, Germany). The physiological status of the animals during blood sampling: naturally 
positioned (no pressure on any organs) and widely unharmed (only small incision) with stable 
circulation allowed an extraction of a large blood volume compared to other methods        
(e.g. complete thorax opening). 
4.3.3.3 Generation of Plasma (and Haematocrit) 
Anti-coagulated blood, sampled in EDTA MinCollect tubes (Greiner bio-one, Germany) was 
centrifuged at 3000 rpm for 15 minutes at 4°C. Supernatant was transferred into a fresh tube 
4 Methods 
28 
 
and stored at -80°C until usage. The lower phase (pellet) contained the haematocrit and was 
also stored at -80°C. 
4.3.3.4 Liver Parameters AST and ALT 
Undiluted plasma samples from 45 week old mice, as well as from mice after WD were 
thawed on ice and pipetted into 50µl aliquots. Measurement of the plasma liver parameters 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were performed in 
close collaboration with Patrick Langner of the MDC Pathophysiology core facility with a 
DRY-CHEM NX500i Analyzer (Fujifilm, Japan). Therefore, plasma samples were applied to 
dry-chemical test plates and color change was measured photometrically. 
4.3.3.5 Cholesterol and Triglycerides in Plasma 
Undiluted plasma samples from 45 week old mice and from mice after WD were thawed on 
ice and pipetted into 50µl aliquots. Measurements of plasma cholesterol and triglycerides 
were performed in close collaboration with Patrick Langner of the MDC Pathophysiology 
core facility with an AU480 Chemistry Analyzer (Beckman Coulter Inc., USA). Enzymatical-
ly induced color change of cholesterol in plasma samples was measured at 540/600nm, of 
triglycerides at 660/800nm. In case of severe hemolysis, samples were excluded from analy-
sis; in case of severe lipemia, samples were adequately diluted in ddH2O and measurement 
was repeated; the original cholesterol and triglyceride values were then calculated for the un-
diluted samples. 
4.4 Tissue and Organ Processing 
4.4.1 Standardized Protocol for Organ Dissection 
All organs and tissues for later biochemical analysis (e.g. enzyme-linked colorimetric assays, 
real time PCR, etc.) were dissected after the second perfusion step (see page 26) and in a quick 
and accurate manner, such that loss of physiologically unimpaired tissue was as little as pos-
sible. 
The mice’ abdominal cavity was opened with a cut along the entire length of the abdomen 
using surgical scissors (Sharp-Blunt, Fine Science Tools GmbH, Germany). Thorax was 
opened bilaterally using Beebee bone scissors (Fine Science Tools GmbH, Germany) and the 
ventral part of the mice’ ribcage was removed to allow a completely unobstructed dissection 
of the thoracic cavity. 
4.4.1.1 Liver 
Liver and adhered gallbladder were removed from the abdomen entirely and without injuring 
the tissue. They got transferred to a dissection dish and covered slightly with solution 2 (see 
Tab. 3) to avoid drying. The gallbladder was carefully removed without harming it since leak-
ing bile (containing bile salts and digestion enzymes) may affect liver tissue. Several liver 
samples were taken for histology and biochemical analysis (see Fig. 6). 
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4.4.1.2 Spleen, Visceral Fat, 
Kidney & Lung 
Spleen was dissected and 
cleaned from surrounding 
tissue. Visceral fat was com-
pletely extracted bilaterally, 
weighed and two cuts of ap-
proximately 50µg, as well as 
one complete half (right body 
part) were stored. The right 
kidney was taken and 
decapsulated. Additionally, 
the left lung was dissected 
from some animals. One half 
of spleen and kidney, as well 
as the entire right visceral fat 
sample and the entire lung 
were fixated in 4% PFA for 
one week, cryoprotected in 
30% sucrose solution (in 1x 
PBS) and subsequently stored 
at -20°C. The remaining sam-
ples (half spleen and kidney 
and the visceral fat samples 
F1 and F2) were stored at       
-80°C for further biochemical 
analysis. 
4.4.1.3 Aorta and Heart 
Heart and the entire aorta for histology were dissected after the last perfusion step, hence after 
fixation via 4% PFA (see Tab. 3). The dissection was performed under a binocular (MZFLIII, 
Leica Micro-Systems, Germany). In a first step the surrounding fat and muscle tissue was 
removed using Spring Scissors (8mm cutting edge, Fine Science Tools GmbH, Germany). As 
soon as the aorta became visible, it was slightly lifted up (several fine forceps, Fine Science 
Tools GmbH, Germany) to detach it from the underlying tissue with careful and accurate cuts 
performed with Student Vannas spring scissors (5mm cutting edge, Fine Science Tools 
GmbH, Germany). Aorta was loosened over the complete length of the abdomen and thorax   
- from aortic bifurcation up to aortic arch – but is was not yet cut axially. In a second step the 
aorta was detached from arteria brachiocephalica, arteria carotis communis and arteria 
subclavia, whereat the bifurcation of arteria brachiocephalica was as well dissected and 
stored in 4% PFA. Only after that step the entire structure of heart and aorta was loosened 
from both arteriae iliaca communis and hence extracted from the body. It was stored one 
week in solution 3 (see Tab. 3) before further dissection. 
Fig. 6 – Liver Dissection 
Overview of all liver samples and their sampling locations. The 
liver was extracted from the abdomen and transferred to a dis-
section dish were the gallbladder was removed. All liver lobes 
were spread like depicted and samples were taken from left 
lateral lobe and right medial lobe. Samples from left lateral lobe 
were transferred into 4% PFA or embedded into Tissue Tek® 
OCT
TM
 Compound (Newcomer Supply Inc., USA) and imme-
diately frozen at -20°C to use them for histology (2x PFA and 
OCT). Further, one sample of approximately 100µg was taken 
from the left lateral lobe and used for later biochemical analysis 
(L1). Three samples from the right medial lobe were dissected 
and used for biochemical analysis (L2 & L3: ~50µg; L4: 
~100µg). 
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Dissection of aorta and other vessels for quantitative polymerase chain reaction (qPCR) anal-
ysis is described below (see page 31). 
4.4.2 Fixation and Cryoprotection of Organs and Tissues 
Dissected organs and tissues were fixated using 4% PFA or solution 3 (see Tab. 3) which is 
based on 4% PFA. All samples were incubated in the respective fixative at 4°C for at least 
one week and no longer than two weeks. Cryoprotection was applied using 30% sucrose solu-
tion in 1x PBS at pH 7.4 for at least 5 days or until the sample was saturated. 
4.4.3 Cryocutting of Organs 
(Hearts) 
Cryoprotected organs were 
cut with help of the cryostat 
CM3050 S (Leica Microsys-
tems, Germany). 
For thin sections, hearts were 
fixed upright (with the peri-
cardium upwards) with OCT 
(Tissue-Plus OCT
TM
 Com-
pound, Newcomer Supply 
Inc., USA) on a prepared 
OCT platform previously 
fixed on a metal table (briefly 
at -40°C, permanent -18°C) 
and cut inside the cryostat 
(chamber temperature -19°C, table temperature -19°C) to 10µm slices. The cuts were directly 
transferred to adhesion glass-slides. 
Samples were put into 4 sets (A, B, C, D) of 10 slices with always 5 slices per glass slide, 
such that one glass slide carried each fourth section and at least two glass slides represented 
400µm of the complete aortic root area (see Tab. 4). Section sampling was started at the point 
where all three aortic valves became visible, latest when two valves where fully distinct. If 
necessary, more than two glass slides were prepared per set. 
4.4.4 Dissection of the Aortic Arch 
Aortas that were fixated for one week in solution 3 were rinsed with 1x PBS and transferred 
to a Petri dish containing solid 1% agarose gel. The gel served as a flexible, translucent dis-
section surface to which aortas could be fixated using minutien pins (Tip: 0.0125mm, Fine 
Science Tools GmbH, Germany) and what allowed optimal illumination of the working area. 
Aortas were cut from the heart as tight as possible to avoid any loss of aortic tissue. For dis-
section of the aortic arch, each aorta was shortened to exact 15mm after the bifurcation of 
arteria subclavia. Aortic arch dissection was performed using 5mm Student Vannas Spring 
Scissors, Dumont #5 Forceps and Angled 45 Dumont Forceps (Fine Science Tools GmbH, 
Germany). 
Tab. 4 – Scheme of Heart Sections 
Description of the sampled heart section from cryostat. 10µm 
thin heart sections where transferred to glass slides, forming 4 
sets of 10 sections each (400µm in total). Hence, all 4 sets are 
maximally comparable amongst each other. 1A-2D: Slide 
names; 1A1-2D5: Section names; (#1)-(…): slice number; 
[200µm]: total covered sample thickness. 
 Slide Name 1A 1B 1C 1D 
Sections 1A1(#1) 
1A2(#5) 
1A3 
1A4 
1A5 
1B1(#2) 
1B2(#6) 
1B3 
1B4 
1B5 
1C1(#3) 
1C2(…) 
1C3 
1C4 
1C5 
1D1(#4) 
1D2 
1D3 
1D4 
1D5 [200µm] 
Slide Name 2A 2B 2C 2D 
Sections 2A1(#21) 
2A2 
2A3 
2A4 
2A5 
2B1(#22) 
2B2 
2B3 
2B4 
2B5 
2C1(…) 
2C2 
2C3 
2C4 
2C5 
2D1 
2D2 
2D3 
2D4 
2D5 [400µm] 
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4.4.4.1 Situs preparation of the Aortic Arch 
After shortening, the aorta was covered with 1x PBS to avoid drying and the remaining parts 
of arteria brachiocephalica, arteria carotis communis and arteria subclavia were cut to stubs 
≤ 1mm. Hence, only atherosclerotic plaques located directly at a distinct part of the aorta were 
analyzed in subsequent histological staining and colorimetric calcium assay. 
In the following, the aorta was entirely cleaned from attached tissue material by removal of 
the tunica adventitia. For this purpose, a small rip (two forceps) was applied to the tunica 
adventitia at the rostral end of the aorta, such that a gap arose between tunica adventitia and 
the rest of the aorta. With the help of two forceps this gap was opened further and by only 
holding the loose parts of tunica adventitia and carefully pulling them, it could be detached 
from the aorta more and more. In the end there was only a little part of the tunica adventitia 
being connected to the caudal end of the aorta which was then detached by very carefully 
pushing the aorta into the flexible agarose surface with one forceps and ripping the adventitia 
off with the second forceps. As a result, the clean, translucent aorta was ready for ORO stain-
ing, which was performed before en face preparation. Microscopic images were taken similar-
ly from closed and opened (en face) aortas. 
4.4.4.2 En face preparation of the Aortic Arch 
The cleaned and ORO stained aortic arch was transferred to the 1% agarose filled Petri dish 
and got covered with 1x PBS to avoid drying. A longitudinal cut was set at the outer flexure 
of the aortic arch (crossing all three arterial bifurcations) and the aorta was completely 
opened. With the help of minutien pins (Tip: 0.0125mm, Fine Science Tools GmbH, Germa-
ny), the aorta was stepwise opened and fixed to the agarose gel surface, such that as few 
minutien pins as possible were used and without puncturing any atherosclerotic plaque area 
(red ORO staining) to avoid rupture and loss of plaque material. In the end, the aorta inner 
face was completely exposed and microscopic images were taken by Leica M205 FA (Leica 
Microsystems, Germany) with the following settings: 12.5 magnification, transmitted light 
with fully opened light shade (mirror at 20°), exposure: 20.00ms, digital gain: 2.0, saturation: 
50%, color balance: red (18%), green (15%), blue (50%). White reflections must not be visi-
ble. Examined aortas where transferred to 200µl of 0.6N HCl. 
4.4.5 Dissection of Blood Vessels (and Nervus vagus) for qPCR 
Blood vessels (arteria carotis communis, arteria femoralis, aorta (thoracic aorta and arch), 
vena cava, vena saphena arteria mesentrica, arteria pulmonaria and vena porta) and as con-
trol tissues nervus vagus, as well as multiple organs (spleen, liver, intestine, thymus, brain and 
heart) of male B6, FVB/N, B6/Tph1
-/-
 and FVB/N/Tph1
-/-
 mice (5-6 per group and experiment) 
at the age of 8-12 weeks were dissected for RNA extraction followed qPCR analysis. There-
fore, mice were quickly decapitated without any anesthesia to assure a minimum stress level 
in the animals and avoid side effects of anesthesia on the 5-HT system. All organs were 
cleaned from surrounding tissue and dissected in a highly rapid manner, such that inherent 
RNA degradation was put to a minimum. The specimens were immediately put to FastPrep
TM
 
lysing matrix tubes (MP Biomedicals, France) containing 1ml of Trizol® (Life Technologies, 
USA) and     5 ceramic beads (2.8mm, VWR International, USA) or (for aortas) one 1/4" Ce-
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ramic Sphere Banded Satellite (MP Biomedicals Inc., USA) and stored at -80°C for subse-
quent RNA extraction.  Complete dissection of one animal took no longer than 5 minutes. 
 
4.5 Histology 
4.5.1 Oil Red O Staining 
Oil red O (ORO) staining in whole aortas (aortic arch and thoracic aorta) and cryo slices of 
the heart aortic root region was performed to visualize and analyze size and distribution of 
atherosclerotic plaques. ORO is a lysochrome diazo dye
8
 that stains neutral triglycerides and 
lipids, such as mainly present in atherosclerotic plaques, in fresh and PFA fixated samples. 
For the staining protocol a ORO saturated stock solution was freshly prepared by dissolving 
0.5g ORO powder (Sigma-Aldrich, Germany) in 100ml of 99% isopropanol. From this satu-
rated stock solution a 60% working solution was prepared by mixing 60ml ORO stock with 
40ml ddH2O and incubating it at room temperature (RT) for 1 hour. Afterwards, the ORO 
working solution was filtered twice through standard filter paper to avoid pigment particle 
contamination. The working solution was freshly prepared for each experiment. 
4.5.1.1 Oil Red O Staining of whole Aortas 
4.5.1.1.1 Staining Protocol 
Aortas were stained for ORO before en face preparation. For this purpose, the samples were 
dehydrated in 60% isopropanol for 10 minutes at room temperature (RT). In the second step, 
the aortas were transferred to 60% ORO working solution and incubated for 30-60 minutes at 
RT on a shaker (Rotable platform Polymax 1040, Heidolph Instruments, Germany). After-
wards, the samples underwent a 10 minute cleaning step with 60% isopropanol and were re-
hydrated by ddH2O (2 minutes) at RT. The ready-stained aortas were stored in 1xPBS at 4°C 
and microscopic images were taken before and after en face preparation. 
4.5.1.1.2 Image Acquisition 
Microscopic images of closed and opened (en face preparation) aortas were taken by using the  
Leica M205 FA stereomicroscope (Leica Microsystems, Germany) with the following set-
tings: 12.5 magnification, transmitted light with fully opened light shade (mirror at 20°), ex-
posure: 20.00ms, digital gain: 2.0, saturation: 50%, color balance: red (18%), green (15%), 
blue (50%). White reflections must not be visible. Afterwards, examined aortas where trans-
ferred to 200µl of 0.6N HCl for subsequent colorimetric calcium assay (see page 43). 
4.5.1.1.3 Image Analysis with ImageJ and Data Acquisition 
Each microscopic image of aortas was acquired featuring an equal 2500µm scale bar, which 
allowed the unit translation from pixels to µm and µm
2
. Unit translation was performed using 
the ImageJ (v1.52o, National Institutes of Health, USA) command ‘Analyze’ > ‘Set Scale…’ 
on the before defined scale bar length (‘Straight’ tool). The known distance was translated 
into 2500µm with a pixel aspect ratio of 1.0. The ‘Global’ box was ticked to use the scale for 
                                                 
8
 Azo dyes are the biggest group of synthetic dyes and contain at least one azo compound (-N=N-). Diazo dyes, 
such as Oil red O contain two azo compounds. 
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each analyzed image. In a first step, the blue background of each aorta image was knocked 
out using the ‘Polygon selection’ tool; at the same time each aorta was cropped to exactly 
11.  mm length after arteria subclavia bifurcation and the aortic area was measured using the 
command ‘Analyze’ > ‘Measure’. Additionally, in images of aortic en face preparation, 
minutien pins were knocked out using the ‘Polygon selection’ tool after the measurement of 
the whole aortic area. In the next step, the red ORO stained area was measure by using the 
command ‘Image’ > ‘Adjust’ > ‘Color Threshold…’: In the RGB color space the red and 
green channels were accepted entirely (0-255), whereas the blue channel threshold was set to 
120. Hitting ‘Select’ resulted in the complete red stained area becoming selected, what al-
lowed the area measurement by the command ‘Analyze’ > ‘Measure’. As a result two areas 
were defined: ‘whole aorta’ and ‘plaque area’, and a % ratio was calculated by dividing 
‘plaque area’ by ‘whole aorta’ and multiplying the result with 100. 
4.5.1.2 Oil Red O Staining of Heart Sections 
4.5.1.2.1 Staining Protocol 
Set A of heart cryo slice was used for ORO staining which was performed at RT in         
200ml glass cuvettes. In a first step, cryo slices were dehydrated by immersing them 10 times 
in 60% isopropanol. Subsequently, slices were incubated for 15 minutes in 60% ORO work-
ing solution and then again immersed 10 times in 60% isopropanol to remove excess ORO 
solution. Afterwards, slices were rinsed 5 minutes with running tap water and counterstained 
for 3 minutes with hematoxylin solution (Sigma-Aldrich, Germany). Bluing was obtained by 
5 minute rinsing in running tap water. Wet slices were immediately embedded in 55-60°C 
warm glycerol-gelatin (Sigma-Aldrich, Germany) and cover slips were added. After one night 
storage at 4°C, cover slips were sealed with commercially available nail polish. 
4.5.1.2.2 Image Acquisition 
Image acquisition on cryo heart slices was performed at our partner institute in Lübeck and at 
the MDC in Berlin. In Lübeck, microscopic images of cryo heart slices stained for ORO and 
Masson’s trichrome from 100 week old animals were taken on the Olympus IX70 microscope 
(Olympus Europa SE & CO. KG, Germany) with a 4 fold magnification and brightfield illu-
mination as described elsewhere (Segura-Puimedon et al., 2016). In Berlin, microscopic im-
ages of cryo heart slices stained for ORO and Masson’s trichrome from 45 week old animals 
were taken by using the fluorescence microscope BZ-9000 (Keyence, Germany) with a 5 fold 
magnification (2x ocular and 2.5x digital magnification) and brightfield illumination. For 
ORO staining, images of 10 consecutive slices were taken and analyzed. 
4.5.1.2.3 Image Analysis with ImageJ and Data Acquisition 
Images of 100 week old animals, which were acquired at our partner institute in Lübeck were 
analyzed immediately after acquisition using the Leica software QWin v3 (Leica Microsys-
tems, Germany) with the self-made software application for plaque analysis. This application 
calculates the total aortic ring area, subtracts the aortic lumen and then counts the red stained 
zones. As a result, the total plaque area per slice was calculated in µm2. Images of 45 week 
old animals, acquired in Berlin, were analyzed via ImageJ. Scaling was performed via the 
command ‘Analyze’ > ‘Set Scale…’ as described for aorta analysis (see page 32). In the first 
step, the image background was knocked out (‘Polygon selection’ tool) remaining only the 
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aortic ring which was then measured (‘Analyze’ > ‘Measure’). Afterwards, the ORO staining 
allowed an exact free hand masking of all atherosclerotic plaques which were then measured 
(‘Analyze’ > ‘Measure’). In both analysis procedures, the results were calculated as the mean 
atherosclerotic plaque size per animal by analyzing 10 consecutive slices and calculating the 
mean of them. 
4.5.2 Masson’s Trichrome Staining 
The Masson’s trichrome staining is a staining combination of multiple histological dyes 
which allows an optical differentiation of tissue types, such as muscles and connective tissue, 
in histological specimens. The methods is based on the chemical characteristics of different 
tissue types and was used in this study to investigate the collagen amount within atheroscle-
rotic plaques in cryo slices of the aortic root area. 
4.5.2.1 Staining Protocol 
Masson’ trichrome staining was performed on sample set B in 200ml glass cuvettes at RT. 
Cryo slices were prepared for 15 minutes in a 56°C preheated Bouins solution what ensured 
an optimal fixation of the slices and promoted later staining steps. Afterwards, the samples 
were cooled down to 18-26°C in tap water and excess Bouins solution was removed by run-
ning tap water. In the next step, cell nuclei were stained black by 5 minute incubation in 
Weigert’s haematoxylin solution followed by a 5 minute blacking step under running tap wa-
ter. After washing in ddH2O, samples were incubated for 5 minutes in Biebrich scarlet-acid 
fucsin solution, what stained muscles red and cytoplasm pink; samples got washed in ddH2O 
again. Subsequently, the red staining was removed from connective tissue by 5 minute incu-
bation in a 1:1 Phosphomolybdic acid/ Phosphotungstic acid solution. Instantaneously, the 
collagen fibers of the connective tissue could be stained in blue by incubating the samples for 
5 minutes in Aniline blue solution. Subsequent 2 minute incubation in 1% Acetic acid stabi-
lized the blue staining and gently removed excess dyes from the samples. In the last step, cryo 
slices were treated with a dehydration series (30%, 50%, 70%, 80%, 90% ethanol), cleared 
with Xylol and embedded in NeoMount® (Merck KGaA, Germany). 
4.5.2.2 Image Acquisition 
Images of Masson’s trichrome stained cryo heart slices were acquired by using the fluores-
cence microscope BZ-9000 (Keyence, Germany) as described above (see page 33). For the 
collagen analysis, images of 5 consecutive slices were taken. 
4.5.2.3 Image Analysis with ImageJ and Data Acquisition 
Scaling was performed via the command ‘Analyze’ > ‘Set Scale…’ as described for aorta 
analysis (see page 32). In the first step of collagen analysis, atherosclerotic plaques were se-
lected via ‘Polygon selection’ tool and the image background was knocked out (white matte). 
A reliability analysis for atherosclerotic plaque selection was performed on 10+ randomly 
chosen images and resulted in a reliability score of ≥99%. In the second step, the ImageJ 
plugin ‘Color Deconvolution’ was used with vectors for ‘Masson Trichrome’ and a threshold 
(‘Image’ > ‘Adjust’ > ‘Threshold…’) was set for the channel ‘Color 1’ (blue one) with the 
following frame: 0-140. Applying the threshold area allowed a measurement (‘Analyze’ > 
‘Measure’) of the clearly blue stained parts of the previously selected plaques. As a result, a 
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collagen per plaque percentage was calculated for 5 consecutive slices and the mean per ani-
mal was extrapolated. 
4.5.3 Calcein Staining 
Calcein, or Fluorexon, is a fluorescence dye which is able to cross the cell membrane and 
forms chelates with intracellular calcium. In this study, calcein was used to stain intraintimal 
calcium deposits in cryo slices of the aortic root area and hence, make calcification of athero-
sclerotic plaques visible. Due to very weak results, an analysis on the stained samples could 
not be performed, but representative images are depicted (see Fig. 16A-C). 
4.5.3.1 StainingProtocol 
For calcein staining, set D was used. Staining was operated in 200ml glass cuvettes at RT. 
Samples were incubated for 30 minutes with calcein (Sigma-Aldrich, Germany) working so-
lution (0.1mM calcein in 50mM Trisbase TBS (pH 9.0)) in a dark chamber. Afterwards, sam-
ples were washed 3 times with TBS on a shaker and incubated with DAPI working solution 
(0.01% DAPI in 50mM in 50mM Trisbase TBS (pH 9.0)) for 2 minutes. Wet samples were 
immediately embedded in 55-60°C warm glycerol-gelatin (Sigma-Aldrich, Germany) and 
cover slips were added. After one night storage at 4°C, cover slips were sealed with commer-
cially available nail polish. 
4.5.3.2 Image Acquisition 
Images of calcein staining were acquired using the fluorescence microscope BZ-9000 
(Keyence, Germany) with 5 fold magnification (2x ocular and 2.5x digital magnification), 
480nm excitation and 2.5ms exposure time for calcein and 355nm excitation and 1/1.1ms ex-
posure time for DAPI. 
4.6 Immunhistochemistry (IHC) 
4.6.1 αMac2 Staining 
To examine the amount of macrophages invaded into the intraintimal space, 
immunohistochemical staining with an antibody against galectin-3 (αMac2, ORIGENE Tech-
nologies, Inc., USA) was performed on cryo slices of the aortic root region. The galectin-3 
protein is known to be associated with activated macrophages and binds macrophage excreted 
β-galactosides. 
4.6.1.1 Staining Protocol 
αMac2 staining was performed on set C of the cryo heart slices. Samples were rehydrated in 
1x PBS for 1 hour at RT and subsequently washed in fresh 1xPBS for 5 minutes. For 
permeabilization, the samples were incubated for 10 minutes in PBST (0.1% TritonX100 in 
1x PBS) at RT. The blocking step was operated for 60 minutes at RT in 10% NDS. After-
wards, samples were incubated with the first antibody (αMac2; 1:500 in PBST) at 4°C over 
night. In the next step, samples were washed 3 times in 1x PBS for 5 minutes at RT. The se-
cond antibody (αRat Cy3; 1:1000 in PBST) was added and samples were incubated for           
2 hours at RT in a dark chamber. Finally, samples were washed 3 times each for 5 minutes in 
1xPBS, air dried and embedded in Vectashield mounting medium with DAPI (Vector Labora-
tories Inc., USA). 
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4.6.1.2 Image Acquisition 
Images of immunohistochemical staining were acquired using the fluorescence microscope 
BZ-9000 (Keyence, Germany) with 5 fold magnification (2x ocular and 2.5x digital magnifi-
cation), 550nm excitation and 3.5ms exposure time for Cy3 (αMac2) and 355nm excitation 
and 1/1.1ms exposure time for DAPI. For both channels, a black balance in the image center 
was applied and a dynamic filter (‘Enhanced Edge (weak)’) was used. For the macrophage 
analysis, images of 5 consecutive slices were taken. 
4.6.1.3 Image Analysis with ImageJ and Data Acquisition 
Scaling was performed via the command ‘Analyze’ > ‘Set Scale…’ as described for aorta 
analysis (see page 32). In the first step of macrophage analysis, atherosclerotic plaques were 
selected via ‘Freehand selection’ tool and the image background was knocked out (black 
matte). In the second step, channels were split via the command ‘Image’ > ‘Color’ > ‘Split 
Channels’ and a threshold was set on the red channel: ‘Image’ > ‘Adjust’ > ‘Threshold…’. 
The threshold was set from 50-255 and got applied. Subsequently, the area was measured 
using ‘Analyze’ > ‘Measure’. As a result the total stained macrophagic area was counted per 
sample and the sum of 5 samples per animal was generated since the inhomogeneous distribu-
tion did not allow using means. Hence, the results are given in macrophagic area sum per 
5x10µm atherosclerotic plaque. 
4.7 Molecular Biology 
4.7.1 Extraction of Genomic DNA (gDNA) from Tissue 
Buffer Composition 
TE-buffer 10 mM Tris-HCl (pH 8.0), 1mM EDTA 
Digestion (‘Ear’) buff-
er 
100mM Tris (pH 8.5), 5mM EDTA, 200mM NaCl, 0.2% SDS, 1mg/ml 
proteinase K 
TE/RNase buffer 20µg/ml RNase A in TE-buffer (1x) 
To extract genomic DNA (gDNA) from tissue biopsies (e.g. tail cuts or ear-biopsies) samples 
were incubated overnight on shaker at 55°C in 100 μl digestion buffer. The dissolved samples 
were briefly vortexed and heat-inactivated for 10 min at 95°C. Afterwards cold 600 μl 
TE/RNase buffer was added, incubated for 15 min at RT and stored either at -20°C or imme-
diately used for genotyping PCRs. 
If genotyping PCRs from the extracted gDNA did not obtain clear results, an alternative 
method for gDNA extraction was used: gDNA precipitation via DNAzol® reagent (Invitro-
gen, Germany). Therefore, 25mg of deep frozen liver samples was transferred to FastPrepTM 
lysing matrix tubes (MP Biomedicals, France) containing 1ml of DNAzol® reagent and 5 
ceramic beads (2.8mm, VWR International, USA) and homogenized 3 times for 40 seconds in 
a FastPrep
TM
-24 instrument (MP Biomedicals, France). Centrifugation of the homogenate at 
4°C and 10,000 x g for 10 minutes allowed removal of insoluble tissue fragments, RNA and 
excess polysaccharides and was followed by transferring the supernatant to a fresh 2ml tube. 
The precipitation step was operated by adding 0.5ml of 100% ethanol, inverting the sample 
several times and incubating it for 3 minutes. The visible DNA precipitate was then spooled 
onto a pipette tip and the supernatant was decanted carefully and aspirated from the tube bot-
tom. Afterwards, gDNA was 2 times washed by adding 1ml of 75% ethanol and inverting 3-6 
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times. Upright storage of the tube led to the gDNA settling to the tube bottom and ethanol was 
removed by pipetting. After 10 seconds of air dry, the gDNA was resuspended in 0.4ml 8mM 
NaOH by slowly passing through a pipette tip and cleaned from insoluble materials by cen-
trifugation at RT and 12,000 x g for 10 minutes. The gDNA containing supernatant was then 
transferred to a fresh tube and stored either at -20°C or immediately used for genotyping 
PCRs. 
4.7.2 Amplification of DNA Segments 
4.7.2.1 Polymerase Chain Reaction for murine ApoE deficiency (3 Primers, 1Reaction) 
Deletion of the ApoE allele in mice was done by homologous recombination with an expres-
sion / selection cassette (neomycin-resistance cassette against ganciclovir-antibiotic treat-
ment). Therefore it is possible to differentiate between unaffected and deleted ApoE alleles by 
a three primer PCR in which one primer is specific for the neo-sequence (ApoE_KO5) and 
another for the intact Ex4 region (ApoE-WT5) while the third primer attaches to the 3’-UTR 
(untranslated region) of both alleles (ApoE_3). As a result, PCR products on agarose gel be-
come visible as a 560 bp DNA band for the wild type allele and/or 850 bp DNA band for the 
knockout allele (Fig. 7A). 
4.7.2.2 Polymerase Chain Reaction for murine Tph1 deficiency (3 Primers, 1 Reaction) 
Deletion of the Tph1 allele in mice was also done by homologous recombination with a Neo 
selection cassette, but here, sophisticated cloning strategies using several restriction digestion 
steps caused a replacement of Ex2 with the shorter Neo selection cassette. This leads to a pos-
sible differentiation between unaffected and deleted Tph1 alleles by a three primer PCR in 
which one primer binds specifically to the Neo-sequence (Neo3), the second primer binds to 
the intact gene locus region (GTPH3) and the third primer attaches to the 5’- end of both al-
leles (GTPH5). This results in PCR products of 590 bp (wild type) and/or 300 bp (knockout) 
length (Fig. 7B). 
  
Protocol for ApoE PCR 
Protocol for Tph1 PCR 
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4.7.2.3 Polymerase Chain Reaction for mu-
rine SERT deficiency (3 Primers, 2 Reac-
tions) 
For generation of Sert
-/-
 mice a similar ho-
mologous recombination approach was used 
with a Neo cassette replacing Ex2 of the Sert 
gene. Hence, the differentiation between 
unaffected and deleted alleles is also possi-
ble; however the very small difference in 
size of the two alleles requests for a 3 primer 
– 2 reactions PCR with one primer pair bind-
ing specifically to the Neo-sequence and the 
3’-UTR (PCR C: IMR7415 and IMR8899) 
and one primer pair binding to the wild type 
Ex2 and the 3’-UTR (PCR D: IMR8890 and 
IMR8899). As a result, Sert
-/-
 PCR only de-
livers products for knockout samples, while 
Sert
+/+
 PCR only delivers products for wild 
type samples (Fig. 7C+D). 
  
Fig. 7 – Genotyping of ApoE, Tph1 and Sert 
Deficiencies 
UV gel images of amplified DNA fragments (PCR 
products) after PCRs for ApoE (A), Tph1 (B) and 
Sert (C and D) deficiencies. 2% agarose gel; 120V 
for 15 minutes; Light source: UV302; Exposure 
time: 1s (ApoE), 2.4s (Tph1), 4.5s (Sert); Marker: 
100 base pair DNA ladder; #1 - #4: animal sample 
numbers, in which PCR was performed; +/+: ho-
mozygous wild type control DNA; +/-: heterozy-
gous control DNA; -/- homozygous knockout con-
trol DNA. A: ApoE PCR products: wild type 
(560bp) and knockout (850bp); B: Tph1 PCR 
products: wild type (590bp) and knockout (300bp); 
C: Sert
-/-
 PCR product: knockout (210bp);           
D: Sert
+/+
 PCR product: wild type (318bp). 
Protocol for Sert PCRs 
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4.7.3 Tissue Homogenization and RNA Extraction (via TRIzol®) 
Compound Composition 
0.1% DEPC ddH2O, C6H10O5 
Chloroform 99% CHCl3 
75% Ethanol (DEPC) 75% undenatured ethanol, 30% DEPC (0.1%) 
Isopropanol 99% C3H8O 
TRIzol® 30-60% phenol, 15-40% guanidinium thiocyanate, 7-13% ammonium 
thiocyanate 
1x PBS 0.8% NaCl, 0.02% KCl, 0.14% Na2HPO4, 0.18% Na2HPO4-2H2O, 
0.03% KH2PO4 
For RNA extraction from different tissues and volumes, a tissue homogenization protocol 
containing TRIzol® (Life Technologies, USA) was used. 50mg of tissue (spleen, liver, intes-
tine, thymus, brain and heart) as well the entire amount of extracted blood vessels (arteria 
carotis communis, arteria femoralis, aorta (thoracic aorta and arch), vena cava, vena saphena 
arteria mesentrica, arteria pulmonaria and vena porta) and nervus vagus was transferred to 
FastPrepTM lysing matrix tubes (MP Biomedicals, France) containing 1ml of TRIzol® rea-
gent and 5 ceramic beads (2.8mm, VWR International, USA) respectively one 1/4" Ceramic 
Sphere Banded Satellite (MP Biomedicals Inc., USA; for aortas) and homogenized 3 times for 
40 seconds respectively 5 times for 40 seconds (spleen and aorta) in a FastPrep
TM
-24 instru-
ment (MP Biomedicals, France). Homogenates were incubated for 5 minutes at RT and sub-
sequently replenished with 0.2ml chloroform. Each sample was vortexed for 15 seconds and 
incubated for 10 minutes at RT. Afterwards, samples were centrifuged at 12,000 x g for       
10 minutes at 4°C and the supernatant (aqueous phase containing only RNA) was transferred 
to a fresh 1.5ml tube. RNA was then precipitated by adding 0.5ml of ice cold isopropanol, 
inverting the tubes several times and incubating for 10 minutes at 4°C. The following centrif-
ugation step at 12,000 x g for 10 minutes at 4°C led to the RNA forming a white gel-like pel-
let at the tube bottom and the supernatant was removed to the greatest possible amount. The 
RNA pellet was then washed by adding 1ml of 75% ethanol (DEPC) and centrifugation at 
12,000 x g for 10 minutes at 4°C. This step was repeated 2-3 times. Afterwards, ethanol was 
removed and the pellets air dried for 20 minutes under the hood. Resuspension was performed 
in 50µl respectively 10µl (vessels and n. vagus) DEPC-H2O and by 10 minutes incubation at 
55°C and on the shaker. 
Concentration and purity of the resuspended RNA was measured using a NanoDrop
TM
 1000 
spectrophotometer (Peqlab, Germany). 1 μl of the respective RNA solution in DEPC-H2O 
was rayed and optical densities (OD) at 230, 260 and 280 nm were measured. A 260/280 ratio 
of ~2.0 was considered “pure” RNA. Lower ratios indicated contaminations of proteins, phe-
nols, and other components absorbing strongly at 280 nm. Those samples were excluded if 
possible. The ratio of 260/230 was used as a second parameter for contaminations and was 
supposed to be around 1.8-2.2. Lower values were also indicating co-purified contaminants 
and samples were excluded if possible. Measurements at 340 nm were used for normalization 
and DEPC-H2O was used to blank. RNA was stored at -80°C until use. 
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4.7.4 DNAse Treatment 
Compound Composition 
DNAse I DNase I recombinant, RNase-free 
Rnasin RNase-free Ribonuclease Inhibitor 
DNAse I reaction buffer (10x) 10mM Tris-HCl, 2.5 mM MgCl2, 0.5mM CaCl2 
To clean RNA samples from possible DNA contamination, a DNAse digestion was performed 
using the endonuclease DNase I (New England Biolabs GmbH, Germany). A 20µl reaction 
solution (Master Mix - MM) was prepared for each sample containing 0.5µl DNAse I, 0.3µl 
RNAsin, 2.0µl DNAse I reaction buffer (10x) and RNA solution and nuclease free H2O in a 
proportion resulting in 500ng RNA/µl MM. Samples were incubated at 25°C for 30 minutes, 
followed by a heating stop of the reaction at 75°C for 5 minutes. RNA concentration and puri-
ty was measured as described above (see page 39). 
4.7.5 cDNA Synthesis 
MM for 1 reaction Thermo cycler protocol 
M-MLV 5x reaction buffer 4.0 µl Primer annealing 25°C 15 min 
dNTPs (5mM) 2.5 µl DNA polymerization 37°C 60 min 
Rnasin 0.5 µl Enzyme deactivation 70°C 15 min 
M-MLV (200U) 0.8 µl Storage 4°C forever 
Synthesis of complementary DNA (cDNA) from RNA samples was performed following this 
protocol: 1µl of random hexamer (RH) primer was combined with volumes of RNA sample 
and nuclease free H2O such that a final total RNA amount of 2µg was present in each 12.2 µl 
reaction and the final cDNA concentration was 100ng cDNA/µl. In a first step, the secondary 
structure of the RNA was melted for 5 minutes at 70°C, followed by a quick cool-down on ice 
to prevent the secondary structure from reforming. 7.8µl of the MM was added to each sam-
ple and cDNA synthesis was achieved via the adequate thermo cycler protocol. 
4.7.6 Quantitative Polymerase Chain Reaction (qPCR) Analysis 
As preparation for qPCR analysis, a primer optimization on 100ng cDNA was performed us-
ing standard PCR protocol with gradient annealing temperatures (52.0-65.0°C, see Fig. 8A) 
and primer testing in several tissues with an annealing temperature of 60°C (Fig. 8B). qPCR 
analysis was performed on cDNA samples from blood vessels (arteria carotis communis, 
arteria femoralis, aorta (thoracic aorta and arch), vena cava, vena saphena arteria 
mesentrica, arteria pulmonaria and vena porta) and nervus vagus, as well as from multiple 
organs (spleen, liver, intestine, thymus, brain and heart) of male B6, FVB/N, B6/Tph1
-/-
 and 
FVB/N/Tph1
-/-
 mice (5-6 per group and experiment) at the age of 8-12 weeks. Primers were 
used for the 5-HT receptors 1A, 1B, 1D, 2A, 2B, 2C, 3A, 3B, 4, 5A, 6, 7 as well as for the    
5-HT related substances MAO A, SERT, TPH1 and TPH2. 5µl of diluted cDNA was added to 
6.11µl of qPCR MM resulting in a concentration of 10ng cDNA per reaction. For qPCR a      
2 step temperature protocol was performed with 15 seconds of denaturation at 95°C and       
60 seconds of annealing at 60°C and 40 cycles using the Real time PCR system 
QuantStudio
TM
 5 (Applied Biosystems
TM
/Thermo Fisher, USA). Melting curve analysis and 
primer efficiency analysis via standard curve method were performed for each primer and 
data were analyzed via ddCT method using the QuantStudio
TM
 Design & Analysis Software 
1.3.1 (Applied Biosystems
TM
/Thermo Fisher, USA). 
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A 
B 
Fig. 8 – Primer Optimization 
for qPCR 
Gradient PCR (A) and primer 
testing in various tissues (B) as 
preparation for qPCR analysis. 
3% agarose gel; Light source: 
UV302; Exposure time: 0.5s (A), 
0.4s (B, upper panel) and 1.9s 
(B, lower panel); Marker: 100 
base pair ladder. A: Example for 
gradient PCR performed with 
primers for 5-HTr 2A in cDNA 
pool (spleen, liver, gut, thymus 
and brain); 52.0 – 65.0: Anneal-
ing temperatures in °C. B: Ex-
ample for PCR products from 
one PCR run (anneal: 60°C) with 
primers for 5-HTr 1A, performed 
in several tissues (carotid artery 
– cDNA pool) of FVB/N (upper 
panel) and B6 (lower panel). 
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4.7.7 Lipid Extraction and Quantification (via FOLCH) 
Lipid extraction via FOLCH solution with subsequent total lipid quantification as well as 
preparation and execution of colorimetric assays for hepatic cholesterol, triglycerides and 
NEFA was performed in close collaboration with Prof. Dr. Luíza A. Rabêlo and Dr. Valéria 
Nunes de Souza. 
For lipid extraction, approximately 100mg from similar liver samples (sample L1, see Fig. 6) 
was isolated, weighed and transferred to their 20-fold volume of a 2:1 chlorofrom/methanol 
solution. Liver samples were homogenized using a tissue lyser system and 400µl of methanol 
was added. The samples were centrifuged at 3,000 x g for 10 minutes at RT and subsequently 
the supernatant was collected while the sediment was discarded. 800μL of chloroform and 
640μL of 0.73% NaCl were added and the sample was centrifuged once more at 3,000 x g for 
10 minutes at RT. The upper phase was discarded and washing was performed 3 times by 
adding 600µl FOLCH solution, centrifuging (3,000 x g, 10 minutes, RT) and discarding of the 
upper phase. Afterwards, the samples were dried by covering them with perforated aluminum 
foil and incubate them at 37°C over night. Total lipid amount was measured by weighing the 
dried samples and comparing them to the originally applied liver sample volume (g/g). 
For detailed lipid analysis (colorimetric assays of cholesterol, triglycerides and NEFA), the 
lipid pellet was resuspended in 500µl isopropanol and vortexed for 20 seconds. The suspen-
sion was transferred to 2ml tubes and diluted in 1x PBS (1:20 for cholesterol, 1:40 for triglyc-
erides and 1:10 for NEFA). Samples were stored at -20°C until use. 
4.7.8 Enzyme Linked Colorimetric Assays 
4.7.8.1 Cholesterol Assay 
100µl duplicates of ddH2O and 1x PBS blanks as well as of the standard curve (P1-P7) were 
pipetted on ice into a 96-well flat bottom microplate (96-well clear microplate F-bottom, 
Sarstedt AG & Co.KG, Germany). Further, 100µl duplicates of the previously prepared liver 
lipid dilution samples were added to the wells following a previously determined scheme. In 
the next step, 100µl of the cholesterol reagent was added to all wells with a multichannel pi-
pette (Research Plus Multichannel Pipette, Eppendorf AG, Germany) and possible blisters 
were removed as quickly as possible by using a small pipette tip. Samples incubated for       
20 minutes at 37°C and in a dark chamber. Finally, absorbance was read at 492nm in the 
Microplate reader Infinite® M200 (Tecan Trading AG, Switzerland) and cholesterol concen-
trations were recalculated to the original lipid concentration. 
4.7.8.2 Triglycerides (TG) Assay 
100µl duplicates of ddH2O and 1x PBS blanks as well as of the standard curve (P1-P7) were 
pipetted on ice into a 96-well flat bottom microplate (96-well clear microplate F-bottom, 
Sarstedt AG & Co.KG, Germany). Further, 100µl duplicates of the previously prepared liver 
lipid dilution samples were added to the wells following a previously determined scheme. In 
the next step, 100µl of the triglyceride reagent was added to all wells with a multichannel 
pipette (Research Plus Multichannel Pipette, Eppendorf AG, Germany) and possible blisters 
were removed as quickly as possible by using a small pipette tip. Samples incubated for       
10 minutes at 37°C and in a dark chamber. Finally, absorbance was read at 492nm in the 
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Microplate reader Infinite® M200 (Tecan Trading AG, Switzerland) and triglyceride concen-
trations were recalculated to the original lipid concentration. 
4.7.8.3 Not Esterified Fatty Acids (NEFA) Assay 
5µl duplicates of ddH2O blank as well as of the standard curve (P1-P7) were pipetted on ice 
into a 96-well flat bottom microplate (96-well clear microplate F-bottom, Sarstedt AG & 
Co.KG, Germany). Further, 5µl duplicates of the previously prepared liver lipid dilution sam-
ples were added to the wells following a previously determined scheme. In the next step, 
150µl of the reagent 1 from the NEFA kit was added to all wells with a multichannel pipette 
(Research Plus Multichannel Pipette, Eppendorf AG, Germany) and the samples incubated for 
3 minutes at 37°C. Afterwards, 75µl of the reagent 2 from the NEFA kit was added to each 
sample and possible blisters were removed as quickly as possible by using a small pipette tip. 
Samples incubated for 4 minutes and 30 seconds at 37°C. Finally, absorbance was read at 
546nm and 600nm in the Microplate reader Infinite® M200 (Tecan Trading AG, Switzerland) 
and NEFA concentrations were extrapolated from the difference of absorbance values  
(546nm and 600nm) and the originally diluted lipid concentration. 
4.7.8.4 Colorimetric Calcium Measurement in Aortas  
After en face preparation, aortic arches and thoracic aortas were transferred to 200µl of 0.6N 
HCl were they incubated for at least 14 days at 4°C. HCl dissolved possible calcium deposits 
out of the aortas. Following the instructions of the Randox Calcium assay kit (Randox La-
boratories Ltd, United Kingdom), a fresh 1:1 R1/R2 reaction reagent was prepared and 500µl 
of it were added to 12.5µl sample, respectively 12.5µl of 0.6N HCl blank. For the standard 
curve, 40µl standard solution were mixed with 800µl of R1/R2 and from that S2-S7 were 
generated vie 1:1 dilution. 150µl duplicates of standards (S1-S7), 0.6N HCl blank and sam-
ples were added to a 96-well flat bottom microplate (96-well clear microplate F-bottom, 
Sarstedt AG & Co.KG, Germany) and absorbance was immediately measured at 562nm in the 
Microplate reader Infinite® M200 (Tecan Trading AG, Switzerland). Measurements were 
compared to standard curve and directly converted to total calcium amount of aortas. 
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4.8 Statistics  
Statistical analyses were performed in Prism5 (GraphPad Software, USA), PASW Statistics 
18 (SPSS18, IBM, Germany) and Statistica 8 (StatSoft (Europe) GmbH, Germany). For all 
tests the significance threshold was set to α≤0.05, probabilities of error between 0.05 and 
0.099 were considered as statistical trends. If applicable, two-tailed tests were always per-
formed. 
4.8.1 Outlier Analysis in Excel and GraphPad QuickCalcs 
Outliers were detected by graphical presentation in histograms and boxplot-diagrams (criteria 
for outliers: >3.0 x interquartile range (IQR)). For numerical identification of outliers, either 
outlier analysis in Excel (criteria for outliers: >1.5 x interquartile range (IQR)) or Grubb’s test 
for outliers at GraphPad QuickCalcs (https://www.graphpad.com/quickcalcs/Grubbs1.cfm) 
with a significance level of α≤0.05 was performed. Only if typos could not be corrected and 
outliers were biological incomprehensible, data-points or respective animal was excluded 
from the analysis. 
4.8.2 Determination of Distribution Type in Statistica 
Distribution type was determined via Kolmogorow-Smirnow & Lilliefors test for normality. 
The following statistical tests as well as the graphical data representation were selected for the 
respective results of these pre-tests, e.g. parametrical tests and data representation as mean     
± SEM or non-parametrical tests and median ± IQR. 
4.8.3 Two-group Analysis in GraphPad 
Two group analyses were performed using unpaired t-test (T, parametrical test for unconnect-
ed data), after checking for homologous or heterologous variance using the F-test. Mann-
Whitney U-test (U, non-parametrical data) was used if application of unpaired t-test was not 
allowed due to inappropriate data distribution or variance homogeneity. Both tests were oper-
ated in Prism5. 
4.8.4 Multi-group Analysis in GraphPad 
For comparisons involving more than two groups, but one variable, One-way ANOVA (para-
metrical data sets) or Kruskal–Wallis One-way analysis of variance by ranks (non-
parametrical data sets) were used. For group analysis an adequate post-Hoc test was per-
formed subsequently (e.g. Tukey’s Multiple Comparison or Dunn’s Multiple Comparison 
Post-Hoc test). 
4.8.5 Correlations in SPSS 
Correlations between data-sets were calculated separately for each experimental group either 
with Pearson's product-moment or Spearman's rank correlation coefficient (depending on 
distribution type). An r
2
-score between 1.0 and 0.8 was taken as positive correlation while an 
r
2
-score between 0.8 and 0.7 was defined as tendency, if the alpha-level of p<0.05 was 
crossed.  
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5 Results 
5.1 The Serotonin System in Vessels of Tph1 deficient Mice in different Genetic 
Backgrounds 
At first, a characterization of the serotonergic system in vessels of wild type and Tph1 defi-
cient mice on two different genetic background strains (B6 and FVB/N) was elaborated. 
Therefore, RNA expression levels of 12 5-HT receptors and 4 other 5-HT related proteins 
were quantified via qPCR in different vascular beds. For this purpose the respective primers 
were designed and PCR protocols were established in 10 different vascular tissues and pool 
RNAs from brain and liver (1:1). This comprised optimization of the primer concentrations 
and annealing temperatures via gradient PCR. Only after successful optimization of the PCR 
protocol, qPCR was performed on cDNA from all 10 tissues and primer efficiencies (via 
standard curve method) and RNA expression levels relative to wild type B6 animals were 
quantified. 
5.1.1 5-HT Receptor Distribution in Vessels of B6 and FVB/N Mice 
In the first step of primer optimization equal amounts of cDNA were used for all tissues and 
PCR products were applied to agarose gels (see Fig. 8B) which allowed a semiquantitative 
comparison of the resulting DNA bands and gave a first impression of the distribution of      
5-HT receptors and other 5-HT related genes MAO A, SERT, TPH1 and TPH2. The results 
are summarized in Tab. 5. 
The most striking finding here is the great alteration of 5-HT receptor distribution among the 
different blood vessel types of the two tested mouse strains: For instance, strong bands could 
be detected for 5-HTr 2A and 2B in arteria femoralis and aorta of FVB/N mice, but none or 
only faint bands could be found in respective vessels of B6 mice. The same is true for           
5-HTr 3A in vena cava and by trend for 5-HTr 1A, 1D and 2B in vena saphena. On the other 
hand there are 5-HTr 1B and 1D (see Tab. 5) which exhibit stronger bands on the gel in the 
aorta of B6 than in FVB/N and in the arteria mesenterica bands were stronger in B6 than in 
FVB/N for 5-HTr 1D and 2A. Differences could also be detected in the pool RNA (liver and 
brain, 1:1): Stronger bands for FVB/N for 5-HTr 1A, 2B, 3A, 4, 5A, 6 and 7 and for MAO A, 
SERT and TPH1. However, B6 had presumably more mRNA in the pool for 5-HTr 1B, 2C 
and for TPH2. These first findings demonstrate clear differences between 5-HT receptor dis-
tribution in the vessels of B6 and FVB/N mice. 
The almost exclusive expression of the 5-HTr 3A in samples of nervus vagus could be con-
firmed and served as a second methodological control. Generally, 5-HT receptors 3B – 7 gave 
only poor results in the regular PCR protocol in both strains and arteria carotis communis and 
vena porta appeared to express 5-HT receptor and 5-HT related gene RNAs only at very low 
levels (see Tab. 5). 
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Tab. 5 – 5-HT Receptor Distribution in B6 and FVB/N 
Overview of all tested 5-HT receptors and the related substances Mao A, SERT, TPH1 and TPH2 in 
10 different tissues of B6 and FVB/N mice optically quantified via gel bands of PCR products. The 
table additionally gives all tested primers with sequence, cDNA and gDNA fragments, optimal an-
nealing temperature and PCR product result (gel band) for B6/FVB/N. -: no band detectable; (+): 
only very faint band; +: faint band; ++: regular band; +++: strong band; ++++: very strong band; 
n.a.: not applicable. 
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5.1.2 RNA Expression Levels of 5-HT Receptor Subtypes 1 and 2 
As the RT-PCR data suggested, qPCR and determination of RNA expression levels was only 
successful for 5-HTr 1B, 1D, 2A and 2B, but surprisingly not for 5-HTr 1A. Furthermore, the 
mentioned 5-HT receptor RNA levels could only be quantified in RNA extracts from aorta, 
arteria femoralis, arteria mesenterica and vena cava, but surprisingly not in samples from 
vena saphena (cf. Tab. 5). Pooled samples from brain and liver were successfully used for 
standard curve calculation and all tested primers (except 5-HTr 3B) featured efficiencies of 
80-100% (data not shown). Samples from B6, FVB/N, B6/Tph1
-/-
 and FVB/N/Tph1
-/-
 animals 
were examined and ddCT values were extrapolated from each sample and normalized to B6 
and the housekeeping gene GAPDH to define relative RNA expression levels. 
Relative RNA expression levels appear to be quite variable among different tissues, but sur-
prisingly, as well between different genetic background strains. The here presented data pro-
vide evidence for two major phenomena: First, FVB/N animals, as well as Tph1
-/-
 animals 
bred in the FVB/N background tend to have higher RNA expression levels for most 5-HT 
receptor types and in the majority of the tested vessels. However, the second observation was 
that in most cases the inter-group variances are too high to allow the differences to reach sta-
tistical significance. Hence, individual factors seem to play an important role. This was true 
for all tested genetic groups and organs, such that genotype or organ specific tissue processing 
issues could be widely excluded (see Fig. 9). 
In the aorta 5-HT receptor RNAs appear to be expressed at similar levels in all tested geno-
types (Fig. 9A-D). Only in FVB/N/Tph1
-/-
, receptors 1D and 2B tend to exhibit higher relative 
expression levels than the other genetic groups (Fig. 9B and D), this was statistically signifi-
cant for 5-HTr 2B compared to B6/Tph1
-/-
(Fig. 9D). 
In the arteria femoralis (see Fig. 9E-H) the situation is different: The relative expression level 
for 5-HTr 1D is more than 10-fold increased in FVB/N/Tph1
-/-
 compared to B6 and signifi-
cantly increased compared to B6/Tph1
-/-
(Fig. 9F). On the other hand, relative 5-HTr 2B ex-
pression is decreased in all groups compared to B6 (Fig. 9H: p<0.1 trend for FVB/N). Relative 
expression levels for 5-HTr 1B and 2A appear to be similar for all groups in arteria femoralis 
(see Fig. 9E and G). 
In the arteria mesenterica (Fig. 9I-L) a trend is visible for FVB/N and FVB/N/Tph1
-/-
 showing 
higher relative expression levels for all receptors compared to the two B6 groups. This was 
statistically significant for 5-HTr 2A at p≤0.01 for FVB/N/Tph1-/- compared to B6/Tph1-/- (Fig. 
9K). 
In vena cava (Fig. 9M-P) the relative RNA expression of 5-HTr 1B and 2A is elevated in all 
groups compared to B6 (Fig. 9O: statistic trend, p<0.1 for 5-HTr 2A in FVB/N). Levels of    
5-HTr 1D and 2B are relatively lower or comparable to B6 (Fig. 9N and P). 
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Concluding, the results for qPCR are very variable but with a trend of FVB/N and 
FVB/N/Tph1
-/-
 expressing relatively more 5-HT receptor RNA than B6 and B6/Tph1
-/-
 what 
supports the findings from first quantification of DNA bands on agarose gels (cf. Tab. 5).  
  
Fig. 9 – 5-HT Receptor RNA Levels in Different Blood Vessel Types measured by qPCR 
Relative RNA expression levels normalized to GAPDH and compared to B6. Graphic display of 
RNA expression levels in aorta (A-D), arteria femoralis (E-H), arteria mesenterica (I-L) and vena 
cava (M-P) of B6, FVB/N, B6/Tph1
-/-
 and FVB/N/Tph1
-/-
 mice. Bars represent Medians; error bars 
show the interquartile range (IQR). Closed bars represent B6 (4-5n), open bars FVB/N (3-5n), dark 
grey B6/Tph1
-/-
 (5-6n) and light grey FVB/N/Tph1
-/-
 (5-6n). Sample size varied with applicable 
sample number per qPCR run and tissue. *p≤0.05; **p≤0.01; Kruskal-Wallis with subsequent 
Dunn’s Multiple Comparison test (trends are indicated with p≤0.1). 
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5.1.3 5-HTr 1B and 2A RNA Expression Levels after Tissue Cleaning 
In order to exclude contributions of adventitial tissue to the RNA expression of 5-HT system 
components aortas were cleaned from the surrounding fat tissue. For this analysis the tissue 
cleaning protocol was applied to freshly collected aortas (aortic arch and thoracic aorta) from 
animals of all 4 genetic groups. 
Again, quantification of relative RNA expression levels in cleaned aortas was only possible 
for receptor types 1B, 1D and 2A (Fig. 10), but not for 5-HTr 2B - even though all available  
5-HTr primers were tested and achieved good results for standard curves in pooled cDNA 
from liver and brain (data not shown). Due to several samples performed only poorly during 
qPCR (threshold cycle larger than 40), the analysis for 5-HTr 1D was only possible for some 
samples and sample sizes varied from 2 to 4 per group. For 5-HTr 1B and 2A qPCR analysis 
could be performed unobstructed and the comparable low variability of data even allowed a 
parametric statistical analysis. These first results strongly support the idea of 5-HTr 1B and 
2A being the major players in mammalian blood vessels. 
It could be shown that the relative RNA expression for 5-HTr 1B is twice as high in FVB/N 
as in B6, but surprisingly, it is on a comparable level in FVB/N/Tph1
-/-
 and B6. Interestingly, 
in B6/Tph1
-/-
 the RNA expression is significantly increased (more than 3-fold) compared to 
B6. Additional unpaired t-tests revealed that FVB/N/Tph1
-/-
 RNA expression is even signifi-
cantly lower than in FVB/N and B6/Tph1
-/-
 (Fig. 10A). 
As mentioned, the analysis for 5-HTr 1D was impaired, but there might be a tendency of 
FBV/N/Tph1
-/-
 animals exhibiting elevated RNA expression levels compared to the other 
groups. FVB/N as well as B6/Tph1
-/-
 show slightly decreased expression levels compared to 
B6 (Fig. 10B). Due to very low sample size, none of the results for 5-HTr 1D could be statisti-
cally proven. 
Fig. 10 - 5-HT Receptor RNA Levels in Cleaned Aorta measured by qPCR 
Relative RNA expression levels normalized to GAPDH and compared to B6. Graphic display of 
RNA expression levels for 5-HTr 1B (A), 1D (B) and 2A (C) in cleaned aortas of B6, FVB/N, 
B6/Tph1
-/-
 and FVB/N/Tph1
-/-
 mice. Bars represent Means; error bars show the standard deviation 
of the mean (SEM). Closed bars represent B6 (2-5n), open bars FVB/N (3-5n), dark grey   
B6/Tph1
-/-
 (4-6n) and light grey FVB/N/Tph1
-/-
 (2-4n). Sample size varied with applicable sample 
number per qPCR run and was always lowest for 5-HTr 1D. Single unpaired t-tests: *p≤0.05; 
***p≤0.001 for comparison with B6, #p≤0.05; ###p≤0.001 for comparison with FVB/N; 
$$$p≤0.001 for comparison with B6/Tph1-/-. 
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Relative RNA expression level for 5-HTr 2A was significantly lower in FVB/N than in B6, 
but significantly raised in B6/Tph1
-/-
. Interestingly, FVB/N/Tph1
-/-
 appeared to exhibit strongly 
significantly higher relative RNA expression than FVB/N. These results clearly show that     
5-HTr 2A RNA expression in Tph1 deficient animals in elevated compared to their wild type 
controls (Fig. 10C). 
In summary, the detection of RNA expression alterations between groups of animals could be 
performed more precisely after a tissue cleaning protocol. The genetic background strains 
appear to express 5-HTr RNA differently and so do the Tph1 deficient animals generated in 
these strains, but not always in a comparable manner. Results from the first qPCR analysis in 
uncleaned tissues could be at least partly confirmed (cf. Fig. 9 and Fig. 10), but data from the 
RT-PCR assays differed from these results (cf. Tab. 5 and Fig. 10). 
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5.2 Characterization of Newly Established ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 Animals 
The double knockout mouse lines ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 were generated by breeding 
and the genotype for each animal was determined via PCR as described above (see page 37). 
The following data sets give an overview of the ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 physiology in 
aged animals (45 weeks and older) with regard to atherosclerosis development. 
5.2.1 Bodyweight and Blood Glucose Levels 
Bodyweight of representative groups of B6, ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 males and 
females was measured at the age of 45 weeks and before any experimental procedure. Fur-
thermore, fasting blood glucose was measured in similarly untreated ApoE
-/-
, ApoE/Tph1
-/-
 
and ApoE/Sert
-/-
 males and females (only one ApoE/Tph1
-/-
 animal) to avoid elevation of 
blood glucose levels due to stress. The results are summarized in Fig. 11. 
In males the median bodyweight in B6 animals was 36.95g. The median bodyweight of  
ApoE
-/-
 (36.30g) and ApoE/Sert
-/-
 (34.60g) males did not significantly differ from B6. Howev-
er, ApoE/Tph1
-/-
 males appeared 
to have a significantly lower me-
dian bodyweight (31.80g) than B6 
and ApoE
-/-
 males (Fig. 11A). In 
females the median bodyweights 
were measured at 30.90g (B6), 
27.80g (ApoE
-/-
), 24.80g 
(ApoE/Tph1
-/-
) and 28.65g 
(ApoE/Sert
-/-
). Hence,  
ApoE/Tph1
-/-
 females were signif-
icantly lighter than B6 controls 
(Fig. 11B). 
Male fasted blood glucose levels 
in all groups ranged around nor-
mal fasted blood glucose of adult 
B6 mice (65 – 90 mg/dl; Sun et 
al., 2016), but were elevated by 
trend in ApoE/Tph1
-/-
 and signifi-
cantly in ApoE/Sert
-/-
compared to 
ApoE
-/-
(Fig. 11C). In females, 
fasted blood glucose levels in 
ApoE
-/-
 and ApoE/Sert
-/-
 were sim-
ilarly distributed in the normal 
range. However, the only exam-
ined ApoE/Tph1
-/-
 female (due to 
instrument failure) appeared to 
have an elevated blood glucose 
value (Fig. 11D). 
  
Fig. 11 – Bodyweight and Blood Glucose in 45 Week old 
Double Knockout Animals 
Median bodyweight with IQR (A and B) and mean fasted 
blood glucose with SEM (C and D) in untreated, 45 week 
old B6, ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 males and 
females. Bodyweight: *p≤0.05; **p≤0.01; Kruskal-Wallis 
with subsequent Dunn’s Multiple Comparison test. Blood 
Glucose: *p≤0.05; One-way ANOVA with Tukey’s Multiple 
Comparison test. Grey area: normal range for fasted B6. 
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5.2.2 Plasma Cholesterol and Triglycerides 
To investigate whether levels of free cholesterol and triglycerides in the blood of double 
knockouts at the age of 45 weeks differ from B6 controls, plasma of representative groups 
was examined photometrically (see page 28). 
The results in Fig. 12A and B show clearly, that fasting plasma cholesterol levels in all three 
groups and both sexes are highly significantly increased compared to fasting B6 control which 
ranges slightly below the normal physiological values for B6 mice (117 – 164 mg/dl in ad 
libitum fed mice, Weibust, 1973). In males it could be shown that ApoE/Sert
-/-
 exhibits even 
higher plasma cholesterol levels compared to ApoE
-/-
 (p≤0.05) and ApoE/Tph1-/- (p≤0.05). In 
females this effect could not be verified. However, ApoE/Tph1
-/-
 animals of both sexes tend to 
exhibit slightly lower plasma cholesterol levels than ApoE
-/-
 and ApoE/Sert
-/-
; this is even sig-
nificant when female ApoE/Tph1
-/-
 vs. ApoE
-/-
 animals are statistically re-analyzed via single 
two-tailed t test (p≤0.05, Mann-Whitney-U test, data not shown). 
Plasma triglycerides in male and female ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 animals are 
not drastically altered when compared to B6 and range around innate levels of B6                
(37 – 109 mg/dl, (Zhang et al., 1992)). However, all tested groups of females appear to have 
generally lower plasma triglyceride levels than males. In males, ApoE
-/-
 and ApoE/Sert
-/-
 could 
be demonstrated to have higher plasma triglycerides levels than ApoE/Tph1
-/-
 (see Fig. 12C; 
re-analysis of ApoE
-/-
 vs. ApoE/Tph1
-/-
, Mann-Whitney-U test: p≤0.05). In females this effect 
is not significant (Fig. 12D). 
Concluding, the results strongly support the image of ApoE deficiency leading to high plasma 
cholesterol levels and elevated plasma triglyceride levels in regular ApoE
-/-
 as well as in the 
double knockouts ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 compared to B6 animals. However, the ef-
fects seem to be even increased in ApoE/Sert
-/-
, whereas ApoE/Tph1
-/-
 animals could be shown 
to be at least partly protected. 
Fig. 12 – Plasma Cholesterol and 
Triglycerides in 45 Week old 
Double Knockout Animals 
Summarized results for photometric 
measurement of fasting plasma cho-
lesterol (A and B) and triglycerides 
(C and D) in untreated, 45 week old 
B6, ApoE
-/-
, ApoE/Tph1
-/-
 and 
ApoE/Sert
-/-
 males (▲) and females 
(●). Grey area shows normal physi-
ological range of measured parame-
ters for ad libitum fed B6 mice. 
Lines represent means, error bars 
depict SEM. ***p≤0.001 (vs. B6); 
#p≤0.05 (vs. ApoE-/-); $p≤0.05 (vs. 
ApoE/Tph1
-/-
); One-way ANOVA 
with Tukey’s Multiple Comparison 
test. 
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5.2.3 Liver Weight and Plasma Liver Parameters 
Since blood cholesterol, triglycerides and liver status are closely connected, it was very im-
portant to investigate the liver status, as done via relative organ weight measurement, and 
levels of liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT) in 
plasma, which are used as indicators for possible liver damage. The results for the liver status 
in all groups of 45 week old animals are summarized in Fig. 13. 
The relative liver weight (normalized to total bodyweight) in all animals ranged from 4 to 6 % 
and was very similar in all tested genetic groups of males (see Fig. 13A), but significantly in-
creased in ApoE/Tph1
-/-
 females compared to ApoE
-/-
 and ApoE/Sert
-/-
 (see Fig. 13B). The level 
of AST in ApoE
-/-
 males and females lied above the normal range of 50 – 100 U/l (Fraulob et 
al., 2010; Maletzki et al., 2019), whereas it stayed within the normal range in ApoE/Tph1
-/-
 
and ApoE/Sert
-/-
 males and ApoE/Tph1
-/-
 females. However, ApoE/Sert
-/-
 males were shown to 
exhibit significantly lower AST values than ApoE/Tph1
-/-
 males. In females, the difference of 
AST levels in between ApoE
-/-
 and ApoE/Tph1
-/-
 was statistically significant (Fig. 13C and D). 
ALT levels could be detected inside of the normal range of 25 – 60 U/l (Fraulob et al., 2010; 
Maletzki et al., 2019) for all tested groups. However, male ApoE/Sert
-/-
 mice appeared to have 
significantly lower ALT levels compared to ApoE/Tph1
-/-
(Fig. 13E and F). The De Ritis quo-
tient (AST/ALT) was at comparable levels in all tested groups and close to the normal value 
of 2 (Maletzki et al., 2019). Only in females, it tended to be slightly raised (Fig. 13G and H). 
Summing up, liver status was comparable in all tested groups and liver enzyme levels were 
close to normal range. Nevertheless, it needs to be highlighted, that ApoE/Sert
-/-
 males tend to 
be protected from ALT and AST increase and liver status is slightly worse in females. 
Fig. 13 – Liver Status in 45 Week old Double Knockout Animals 
Relative liver weight (A and B) and liver enzymes AST (C and D), ALT (E and F) and AST/ALT 
ratio (De Ritis quotient; G and H) measured photometrically in plasma of male (▲) and female (●) 
mice. Lines and error bars: mean ± SEM; grey areas in C – F and dashed line in G and H represent 
normal levels in B6 mice. Relative liver weight: *p≤0.05; **p≤0.01; One-way ANOVA with 
Tukey’s Multiple Comparison test. AST and ALT in males (C and E): *p≤0.05; Kruskal-Wallis 
with subsequent Dunn’s Multiple Comparison test. AST in females (D): *p≤0.05; Mann-Whitney-U 
test. 
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5.2.4 Atherosclerotic Plaque Formation in Whole Aorta 
The major focus of this study was the elucidation of possible correlations between the lifelong 
systemic absence of 5-HT in the periphery and the development of atherosclerotic lesions. 
Therefore, the analysis of atherosclerotic plaques in tissues like the aortic arch, preferentially 
performed in an en face preparation (Fig. 14A and B), is indispensable. Aortic arches of repre-
sentative groups of ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 males and females were dissected, 
processed to en face specimens and analyzed for atherosclerotic plaque size as described 
above (see page 32); results are presented in Fig. 14. 
Males and females of all tested groups develop aortic plaques similarly (2 – 20% of the aortic 
surface covered by atherosclerotic plaque) and with comparable distribution along the dissect-
ed part of the aortic arch (data not shown). However, in both groups, males and females of 
ApoE/Sert
-/-
 genotype could be demonstrated to develop significantly larger aortic plaques 
(Fig. 14C and D). In males, this difference is statistically significant for ApoE/Sert
-/-
 vs. 
ApoE/Tph1
-/-
, not least because of ApoE/Tph1
-/-
 tending to develop relatively smaller aortic 
plaques than ApoE
-/-
(Fig. 14C). In females, ApoE/Sert
-/-
 were shown to have significantly larg-
B 
en face  
preparation 
Fig. 14 – Aortic Plaques in 45 Week old Double Knockout Animals 
Representative ORO stained en face preparation of an aortic arch from an ApoE/Sert
-/-
 female with 
atherosclerotic plaques in red (A and B) and results for aortic plaque analysis in males (C) and 
females (D). Lines indicate Mean relative aortic plaque size with SEM (error bars). *p≤0.05; sin-
gle unpaired t-tests. 
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er aortic plaques compared to ApoE
-/-
. This is also true because of ApoE/Tph1
-/-
 females tend-
ing to exhibit larger aortic plaques than ApoE
-/-
 controls (Fig. 14D). 
Concluding, in aortas of the tested animal groups the largest atherosclerotic plaques could be 
detected in ApoE/Sert
-/-
 animals, independently from animals’ sex. A similar tendency was 
seen in ApoE/Tph1
-/-
 females, but not in ApoE/Tph1
-/-
 males. 
5.2.5 Atherosclerotic Plaque Formation at Aortic Roots 
For deeper analysis of atherosclerotic status and processes in the 45 weeks old animal groups, 
but as well in 100 weeks old males (B6, Tph1
-/-
, ApoE
-/-
and ApoE/Tph1
-/-
), 10µm cryo slices 
of the aortic root region where generated and subsequently processed. In order to perform 
atherosclerotic plaque size analysis, histological Oil Red O (ORO) staining (Fig. 15C) was 
applied to one set of 10 slices per animal and from these the mean atherosclerotic plaque size 
was calculated and summarized in Fig. 15A,B and D. 
Surprisingly, no statistically significant difference in between the genetic groups of 45 week 
old animals could be detected. However, the pattern of ApoE/Sert
-/-
 exhibiting bigger athero-
sclerotic plaques than ApoE/Tph1
-/-
 could again be observed by trend in samples of the aortic 
root (Fig. 15A and B), similarly to aortic arches (cf. Fig. 14C and D). Nevertheless, none of the 
double knockout groups appeared to have altered atherosclerotic plaque size in the aortic root 
region compared to ApoE
-/-
. Interestingly, 45 week old males and females of all tested genetic 
groups developed atherosclerotic lesions of comparable size, only in ApoE
-/-
 a sex difference 
could be found with females having significantly larger atherosclerotic plaques than males 
(p≤0.01, Mann-Whitney-U test, data not shown). 
In 100 week old males no statistically significant alteration of atherosclerotic plaque size 
could be detected for ApoE/Tph1
-/-
 compared to ApoE
-/-
 (Fig. 15D). ApoE/Sert
-/-
 males could 
not be examined because of too small sample size occurring naturally in this very advanced 
age. However, it could very clearly be demonstrated that B6 and Tph1
-/-
 males do not develop 
atherosclerotic plaques of mentionable size, even at the age of 100 weeks (Fig. 15D). Hence, 
B6 and Tph1
-/-
 control groups were no longer used for this project. 100 week old ApoE
-/-
 and 
ApoE/Tph1
-/-
 males were the only tested animal groups where calcification in atherosclerotic 
plaques could be observed occasionally (Fig. 15C, arrow head). 
In summary, there were no drastic alterations in atherosclerotic plaque size in animals lacking 
peripheral 5-HT. Therefore, further analysis of atherosclerotic plaque composition, such as 
calcification, collagen and macrophage amount was performed. 
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5.2.6 Aortic Calcification 
The analysis of calcification in cryo slices of the aortic root region via Calcein staining       
(cf. Fig. 16A – C) failed due to issues during tissue processing caused by the physical charac-
teristics of calcified atherosclerotic plaques. A more promising technique was the colorimetric 
calcium assay, which was performed in aortic arches and thoracic aorta of 45 week old   
ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 mice; results are illustrated in Fig. 16D and E. 
Remarkably, calcification could not be detected in ApoE
-/-
and ApoE/Tph1
-/-
 males and in the 
majority of ApoE/Sert
-/-
 males (Fig. 16D). In females, calcification in aortic plaques occurred 
more often with highest values in ApoE
-/-
 and ApoE/Tph1
-/-
 (Fig. 16E). In ApoE/Sert
-/-
 females, 
calcification was significantly lower than in ApoE/Tph1
-/-
 females (Fig. 16E). 
 
Fig. 15 – Atherosclerotic Plaques at Aortic Root in 45 and 100 Week old Animals 
Mean total area of ORO stained atherosclerotic plaques, extrapolated from 10 cryo slices (10µm) 
of the aortic root (aortic valve area) per animal. Lines represent Means, error bars SEM of 45 week 
old males (▲, A), 45 week old females (●, B) and 100 week old males (▲, C). ****p≤0.0001; 
One-way ANOVA with Tukey’s Multiple Comparison test. Representative 10µm cryo slice of a 100 
week old ApoE
-/-
 animal (D), red areas: atherosclerotic plaques, arrow head: purple stained 
calcification. 
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5.2.7 Collagen Fibers and Macrophages 
For the composition of atherosclerotic plaques two intraintimal compartments are of im-
portance: First, the amount of collagen fibers, which play a major role in the atherosclerotic 
plaque stability and can be detected via image analysis of Masson’s trichrome stained sam-
ples. And second, the quantity of macrophages, which are known to accumulate inside of ath-
erosclerotic plaques and can be immunohistochemically flagged and analyzed. Both types of 
examination were performed in sets of 5 cryo slices per animal in males and females of  
ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
; results are summarized in Fig. 18 and Fig. 17. 
Analysis of Masson’s trichrome stained 10µm cryo slices (Fig. 18A) revealed that mean rela-
tive collagen amounts of atherosclerotic plaques in male ApoE
-/-
 (58.7%) and ApoE/Sert
-/-
 
(60.8%) mice are quite similar, whereas male ApoE/Tph1
-/-
 (69.6%) tend to exhibit relatively 
more collagen inside their plaques. This observation could not be statistically proven (Fig. 
18B). 
 
DAPI 
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B 
Overlay 
C 
D E 
Fig. 16 – Calcification in 45 Week old Double Knockout Animals 
A – C: Representative example of fluorescent Calcein staining in 10µm aortic root slices of a 100 
week old ApoE
-/-
 male with blue cell nuclei (DAPI) and green calcification (Calcein). Arrow 
head: location of calcification inside of atherosclerotic plaque. (Images are only illustrative and 
were not used for any data analysis.) D and E: Total calcium amounts in aortic arches of males (D) 
and females (F) measured via photometric assay. Lines indicate medians, error bars indicate IQR. 
In some groups calcium could not be detected at all (0), hence, statistical analysis could not be 
performed. *p≤0.05; single Mann-Whitney-U test. 
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In females, ApoE
-/-
 (55.5%) appeared to have similar relative collagen amounts as observed in 
males of the same genotype. The mean relative collagen amount in ApoE/Tph1
-/-
 females 
tended to be elevated (62.0%) and was significantly increased in ApoE/Sert
-/-
 females (69.3%; 
Fig. 18C). 
Immunohistochemical staining of 10µm cryo slices of the aortic root region with an antibody 
binding to macrophages (αMac2, see Fig. 17A - C) and the subsequent analysis of the total 
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Fig. 17 – Macrophages in Atherosclerotic Plaques of 45 Week old Double Knockout Animals 
A - C: Representative 10µm slice (aortic root) of an ApoE/Sert
-/-
 female immunohistochemically 
stained against macrophages (αMac2) with blue cell nuclei (DAPI) and red macrophages. Arrow 
heads point at intraintimal macrophage areas. D + E: Quantification of total intraintimal macro-
phage area from 5 specimens per animal for males (▲) and females (●). Lines and error bars indi-
cate Means and SEM. 
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Fig. 18 – Collagen in Atherosclerotic Plaques of 45 Week old Double Knockout Animals 
Representative 10µm slice (aortic root) of an ApoE/Sert
-/-
 female stained via Masson’s trichrome 
protocol (A). Collagen is stained in blue. Mean relative collagen amount per plaque area in males 
(B) and females (C); extrapolated from set of 5 slices for each animal. Lines and error bars repre-
sent means and SEM. *p≤0.05; One-way ANOVA with Tukey’s Multiple Comparison test. 
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amount of Mac2 positive area in 5 slices per animal showed that there are no statistically sig-
nificant alterations in macrophage amount or distribution inside the atherosclerotic plaques in 
any of the tested genetic animal groups (Fig. 17D and E). 
Concluding, analysis of atherosclerotic plaque composition in aortic root cryo slices of   
ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 animals could not definitely answer the question for an 
effect of peripheral 5-HT absence on atherosclerotic processes. However, as reported for the 
majority of the described experiments in 45 week old double knockout animals, the 
ApoE/Sert
-/-
 group tended to stand out from the other groups with regard to plaque composi-
tion and was shown to have higher levels of intraintimal collagen. 
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A B 
C D 
E 
Fig. 19 – Bodyweight in ApoE/Tph1-/- animals after 8 and 12 Weeks of Western Diet 
Graphical representation of mean bodyweight in male and female ApoE/Tph1
-/-
 mice after 8 (A and 
C) and 12 weeks (B and D) of Western diet (WD), compared to age matched ApoE
-/-
 controls. 
Lines indicate means, error bars SEM; **p≤0.01; n.s.: not significant; unpaired t-test. E: One-
graph comparison of all tested animal groups before and after 8 and 12 weeks of WD. Closed icons 
represent ApoE
-/-
; open icons represent ApoE/Tph1
-/-
; **p≤0.01 vs. ApoE-/- (same sex); ); #p≤0.05; 
##p≤0.01 vs. ‘before WD’; One-way ANOVA with Tukey’s Multiple Comparison test. 
 
5.3 Physiological Alterations in ApoE/Tph1
-/-
 Animals after Long-term Western 
Diet 
The Western or High Fat/High Cholesterol diet (WD) enables the experimenter to artificially 
induce hypercholesterolemia and atherosclerosis in animals at a relatively young age and in a 
very quick way – first atherosclerotic lesions are detectable after 4 weeks of diet. For this pro-
ject, young (10 week old) male and female ApoE
-/-
and ApoE/Tph1
-/-
 mice got fed Western diet 
for either 8 or 12 weeks. Physiological changes, especially atherosclerotic processes, were 
analyzed in tissues of these animals and in 22 week old control groups. 
5.3.1 Bodyweight, Body Fat and Blood Glucose Levels 
Total bodyweight of all animals was documented before and after 8 respectively 12 weeks of 
WD. Furthermore, animals of all groups underwent body composition analysis (BCA) via 
non-invasive Time-Domain-Nuclear-Magnetic-Resonance imaging (TD-NMR) after 8 and 
after 12 weeks of WD, shortly before the end of the respective experiment. Blood glucose 
levels were detected in overnight fasted animals. All results are summarized in Fig. 19, Fig. 20 
and Fig. 21. 
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Results of the bodyweight measurements clearly showed that in both sexes the 5-HT lacking 
ApoE/Tph1
-/-
 group was significantly lighter after 8 weeks of WD compared to ApoE
-/-
 (Fig. 
19A and C). Interestingly, this effect was only observed by trend after 12 weeks of WD in 
both sexes (Fig. 19B and D). The summary of all tested groups before and after 8 and 12 
weeks of WD revealed that males significantly gain bodyweight under WD, whereas females 
are about to keep their initial bodyweight (Fig. 19E). 
The body composition analysis (BCA) in WD treated ApoE
-/-
 and ApoE/Tph1
-/-
 mice showed 
that in all tested animal groups relative body fat (Fig. 20A – D) and water (Fig. 20E – H) 
amounts are reduced in ApoE/Tph1
-/-
 mice, whereas relative muscle portion (Fig. 20I - L) ap-
peared to be higher in ApoE/Tph1
-/-
 compared to ApoE
-/-
. Surprisingly, the described effects 
where stronger in both sexes after 8 weeks of WD than after 12, but could only be statistically 
confirmed by trend for ApoE/Tph1
-/-
 females after 8 weeks of WD (Fig. 20C and G). One more 
finding that should be highlighted at this point is the tendency of females exhibiting relatively 
less body fat (p=0.1; unpaired t-test; females 8 weeks vs. 12 weeks; data not shown) and rela-
tively more muscles (p=0.06; unpaired t-test; females 8 weeks vs. 12 weeks; data not shown) 
after 12 than after 8 weeks of WD. In males, the opposite effect was observed (cf. Fig. 20B 
and D and Fig. 20F and H). 
A B C D 
E F G H 
I J K L 
Fig. 20 – Body Composition Analysis in ApoE/Tph1-/- animals after 8 and 12 Weeks of West-
ern Diet 
Results of the body composition analysis in all groups after 8 and 12 weeks of WD. A – D: Means 
and SEM of relative  body fat amount; E – H: Means and SEM of relative amount of muscles;      
I – L: Means and SEM of relative water amount. All groups were statistically tested ApoE-/- vs. 
ApoE/Tph1
-/-
 via unpaired t-test, trends are indicated by p values. 
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Data indicate that in all tested groups (except females after 8 weeks) the mean fasted blood 
glucose level after WD is increased over normal B6 range. Interestingly, ApoE/Tph1
-/-
 animals 
of all groups exhibited slightly but not significantly higher blood glucose levels than ApoE
-/-
 
controls (Fig. 21). Comparing both experiments with each other showed that females of both 
genotypes had higher blood glucose levels after 12 weeks of WD than after 8 weeks (p≤0.05; 
One-way ANOVA with Tukey’s Multiple Comparison test). 
5.3.2 Plasma Cholesterol and Triglycerides 
Photometric detection of cholesterol in the plasma of ApoE
-/-
 and ApoE/Tph1
-/-
 animals after 
WD and in age matched control groups of same genotypes, revealed that, as expected, plasma 
cholesterol was drastically increased in animals lacking ApoE, compared to normal B6 levels 
(Fig. 22A - D). Plasma triglycerides in the same animal groups were shown to be approximate-
ly at normal B6 levels (Fig. 22E - H). 
Furthermore, it could be statistically proven that 12 weeks of WD caused elevated plasma 
cholesterol values in all treated animal groups similarly, when compared to untreated animals 
of the same genotype (Fig. 22B and D). Contrasting, levels of plasma triglycerides appeared to 
be decreased by trend after 12 weeks of WD, compared to untreated mice (Fig. 22F and H). 
In ApoE/Tph1
-/-
 animals of both sexes it could be shown that after 8 weeks of WD, plasma 
cholesterol is decreased by trend (Fig. 22A and C) and also plasma triglycerides are signifi-
cantly lower than in ApoE
-/-
 mice (Fig. 22E and G). 
 
A B 
C D 
Fig. 21 – Blood 
Glucose in 
ApoE/Tph1
-/-
 
animals after 8 
and 12 Weeks 
of Western Diet 
Fasted blood 
glucose levels in 
males (A and B) 
and females (C 
and D) after 8 
and 12 weeks of 
WD. Lines indi-
cate Means, 
error bars SEM. 
Grey area: nor-
mal blood glu-
cose range for 
fasted B6 ani-
mals. 
 
5 Results 
63 
 
 
5.3.3 Hepatic Cholesterol 
Colorimetric quantification in liver extracts from ApoE
-/-
 and ApoE/Tph1
-/-
 animals after 8 and 
12 weeks of WD suggested that there is a trend for ApoE/Tph1
-/-
 to develop lower hepatic 
cholesterol levels than ApoE
-/-
 animals (Fig. 23A - D). 
Very interestingly, females of both genotypes exhibited drastically increased hepatic choles-
terol levels after 8 weeks of WD compared to all other experimental groups (p≤0.001; One-
way ANOVA with Tukey’s Multiple Comparison test), including females after 12 weeks of 
WD (Fig. 23C). 
5.3.4 Hepatic Triglyceride, Non-esterified Free Fatty Acid and Total Lipid Levels 
Data from different colorimetric assays revealed that a general trend for decreased hepatic 
lipid parameters is visible in male ApoE/Tph1
-/-
 mice after 12 weeks of WD and in females 
ApoE/Tph1
-/-
 mice after 8 weeks of WD (Fig. 23B + C; F + G; J + K and N + O). 
In detail, the presented data show that while hepatic triglycerides could be detected at similar 
levels for ApoE
-/-
 and ApoE/Tph1
-/-
 males after 8 weeks of WD (Fig. 23E) and for ApoE
-/-
 and 
ApoE/Tph1
-/-
 females after 12 weeks of WD (Fig. 23H), they are significantly lower in 
ApoE/Tph1
-/-
 males after 12 weeks of WD (Fig. 23F). 
A B C D 
E F G H 
Fig. 22 – Plasma Cholesterol and Triglycerides in ApoE/Tph1-/- animals after 8 and 12 Weeks 
of Western Diet 
Photometrically measured total amounts of cholesterol (A – D) and triglycerides (E – H) in plasma 
of ApoE
-/-
and ApoE/Tph1
-/-
 male (▲) and female (●) mice after 8 and 12 weeks of WD. Graphs for 
animals after 12 weeks of WD additionally contain data from 22 week old control groups which 
did not obtain WD (open icons). Lines indicate means, error bars represent SEM. Grey area de-
picts normal ranges of plasma cholesterol (118 – 164 mg/dl) and triglycerides (37 – 109 mg/dl). 
*p≤0.05; ***p≤0.001; One-way ANOVA with Tukey’s Multiple Comparison test. 
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The same was shown for hepatic not esterified free fatty acids (NEFA): Equal levels in livers 
of ApoE
-/-
 and ApoE/Tph1
-/-
 males after 8 weeks of WD (Fig. 23I) and for ApoE
-/-
 and 
ApoE/Tph1
-/-
 females after 12 weeks of WD (Fig. 23L) and slightly, statistically not provable, 
decreased NEFA levels in ApoE/Tph1
-/-
 males after 12 weeks of WD (Fig. 23J). 
The amount of total lipids after Folch’s extraction from liver was comparable in ApoE-/- and 
ApoE/Tph1
-/-
 males after 8 weeks of WD (Fig. 23M) and in ApoE
-/-
 and ApoE/Tph1
-/-
 females 
after 12 weeks of WD (Fig. 23P). However, total hepatic lipids in ApoE/Tph1
-/-
 males after 12 
weeks of WD tended to be decreased compared to ApoE
-/-
 (Fig. 23N). 
A B C D 
E F G H 
I J K L 
M N O P 
Fig. 23 – Hepatic Cholesterol, Triglycerides, NEFA and Total Lipids in ApoE/Tph1-/- animals 
after 8 and 12 Weeks of Western Diet 
Results of enzyme-linked colorimetric measurements for cholesterol (A - D), triglycerides (E – H), 
NEFA (non-esterified fatty acids) (I – L) and total lipids (M – P) in extracts from ApoE-/-and 
ApoE/Tph1
-/-
 livers. Lines represent medians, error bars depict IQR. *p≤0.05; Mann-Whitney-U 
test; trends are indicated by  respective p values. Grey areas/dashed lines represent physiological 
ranges of respective substance in healthy wild type (B6) liver if applicable. 
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A noticeable effect that occurred during all executed enzyme-linked colorimetric analyses in 
liver extracts was the clearly visible tendency of both female groups after 8 weeks of WD to 
have drastically increased liver parameters than animals from all other experimental groups: 
As mentioned, ApoE
-/-
 and ApoE/Tph1
-/-
 females after 8 weeks of WD were shown to have 
elevated hepatic cholesterol (Fig. 23C; p=0.0005; Mann-Whitney-U test; females 8 weeks vs. 
females 12 weeks), but also hepatic triglycerides (Fig. 23G; p<0.0001; Mann-Whitney-U test; 
females 8 weeks vs. females 12 weeks), NEFA (Fig. 23K; p<0.0001; Mann-Whitney-U test; 
females 8 weeks vs. females 12 weeks) and total lipids after Folch’s extraction (Fig. 23O). 
Except from NEFA, those parameters were all shown to be slightly lower in ApoE/Tph1
-/-
 
females than in ApoE
-/-
. 
5.3.5 Liver Weight and Plasma Liver Parameters 
Also in WD treated animals, the liver status was examined via relative liver weight documen-
tation and measurement of plasma AST and ALT and the resulting De Ritis quotient 
(AST/ALT; normal value for B6: 2) to determine to what extend the long term WD admin-
istration affects liver health in ApoE
-/-
 and ApoE/Tph1
-/-
 mice. The results are summarized in 
Fig. 24. 
It could be shown that independently from sex or WD duration, ApoE/Tph1
-/-
 animals tend to 
exhibit lower relative liver weight than ApoE
-/-
 (Fig. 24A - D). This effect was even significant 
in ApoE/Tph1
-/-
 females after 12 weeks of WD (Fig. 24D). 
The liver parameter AST was elevated above normal B6 values in nearly all tested groups 
after WD and reached highest levels in ApoE
-/- 
males after 8 weeks of WD (Fig. 24E). Interest-
ingly, ApoE/Tph1
-/-
 males and females after 12 weeks of WD had approximately normal AST 
levels, while levels in both ApoE
-/- 
groups were comparably higher (Fig. 24F and H). 
ALT levels were similarly elevated above normal range in almost all tested groups after WD 
(Fig. 24I - L), but again, after 12 weeks of WD, male and female ApoE/Tph1
-/-
 mice appeared 
to have plasma ALT at normal levels (Fig. 24J and L). Generally, there was a tendency of 
ApoE/Tph1
-/-
 to have lower plasma ALT than ApoE
-/-
 (Fig. 24J). 
Calculation of the De Ritis quotient, a marker for liver damage if raised above a value of 2 
(Fig. 24M – P, dashed lines), revealed that animals of all groups had AST/ALT ratios very 
close to normal level. However, after 8 weeks of WD, mean De Ritis quotients in ApoE
-/- 
males and females were slightly increased: Males at 2.13, females at 2.31, whereas levels in 
ApoE/Tph1
-/-
 animals of both sexes appeared to be normal (Fig. 24M and O). Interestingly, in 
ApoE
-/- 
males after 12 weeks of WD the De Ritis quotient was with 1.71 slightly lower than 
normal (Fig. 24N). 
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5.3.6 Aortic Plaque Development under Long-term Western Diet 
Relative size of atherosclerotic plaques and their distribution along the vessel compartment 
was analyzed via ORO staining with subsequent en face preparation of equally dissected 
fragments of aortic arches and thoracic aorta (entire aortic arch plus exactly 15mm after the 
bifurcation of arteria subclavia). Results from microscopic image analysis of aortic plaque 
size are illustrated in Fig. 25. 
After 8 weeks of WD, there was no obvious difference in aortic plaque size between ApoE
-/-
 
and ApoE/Tph1
-/-
 males (Fig. 25A).  
A B C D 
E F G H 
I J K L 
M N O P 
Fig. 24 – Liver Status in ApoE/Tph1-/- animals after 8 and 12 Weeks of Western Diet 
Relative liver weight (A - D) and liver enzymes AST (E - H), ALT (I - L) and AST/ALT ratio   
(De Ritis quotient; M - P) measured photometrically in plasma of male (▲) and female (●) mice. 
A – D: Lines represent medians, error bars show IQR; E – P: Lines and error bars represent 
means ± SEM; grey areas in A - L and dashed line in M - P represent normal levels in B6 mice.   
A – D: *p≤0.05; Mann-Whitney-U test. 
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A B 
C D 
E 
Fig. 25 – Aortic Plaques in ApoE/Tph1-/- animals 
after 8 and 12 Weeks of Western Diet 
Results of aortic plaque (AP) analysis in ORO 
stained aortic arches of ApoE
-/-
and ApoE/Tph1
-/-
 
males (▲) and females (●) after 8 (A and C) and 
12 (B and D) weeks of WD. Lines indicate mean 
relative aortic plaque size (%), error bars show 
SEM. E: Summary of mean relative aortic plaque 
size in all tested animal groups after 8 and 12 
weeks of WD; closed icons: ApoE
-/-
; open icons: 
ApoE/Tph1
-/-
. **p≤0.01; ***p≤0.001; single un-
paired t-tests either ‘8 weeks WD’ vs. ‘12 weeks 
WD’ or ‘all males’ vs. ‘all females’. F: Repre-
sentative example of ORO stained en face prepara-
tion of an aorta (ApoE/Tph1
-/-
 female) with red 
atherosclerotic plaques. 
F 
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However, after 12 weeks of WD, the relative size of aortic plaques was increased in both gen-
otypes compared to the 8 week groups, but apparently to a slightly lower extend in 
ApoE/Tph1
-/-
 males (p=0.28; Fig. 25B). Due to large data variation, this effect could not be 
statistically proven. 
In females, the mean aortic plaque size was at similar levels in ApoE
-/-
 and ApoE/Tph1
-/- 
after 
8 weeks of WD (Fig. 25C). Also, both tested female groups developed larger aortic plaques 
after 12 weeks of WD compared to the 8 week groups, but surprisingly, ApoE/Tph1
-/- 
females 
tended to have an increased relative aortic plaque size compared to ApoE
-/-
 (p=0.19; Fig. 25D). 
This finding contrasts with the results from male ApoE/Tph1
-/-
 mice after 12 weeks of WD. 
Generally, all tested animal groups exhibited significantly larger aortic plaques after 12 weeks 
of WD than after 8 weeks (Fig. 25E) and females of both genotypes were proven to develop 
highly significantly larger aortic plaques than males (Fig. 25E). 
Atherosclerotic plaques appeared to be similarly distributed along the analyzed compartments 
of aortic arch and thoracic aorta of both, males and females of both tested genotypes and after 
8 and 12 weeks of WD: The majority of plaques was located at the aortic arch (up to 90%) 
and scattered small plaques could be detected at the thoracic aorta (exemplified in Fig. 25F). 
5.3.7 Aortic Calcification 
after Western Diet 
Photometric examination of 
calcium amounts in extracts 
from aortas showed that cal-
cium accumulation in aortic 
plaques appears only very 
rarely in ApoE
-/-
 and 
ApoE/Tph1
-/-
 animals after 
WD (Fig. 26). The only ex-
perimental groups in which 
some animals developed 
markedly calcification were 
males after 12 weeks of WD 
(Fig. 26B). Out of 29 tested 
female mice, there was only 
one exhibiting a measurable 
calcium amount in extract of 
the aorta (Fig. 26C and D). 
  
A B 
C D 
Fig. 26 – Calcification in ApoE/Tph1-/- animals after 8 and 12 
Weeks of Western Diet 
Total calcium amounts in aortic arches of males (A and B) and fe-
males (C and D) measured via photometric assay in aortic extracts. 
Lines indicate means, error bars indicate SEM. In some groups 
calcium could not be detected at all (0), hence, statistical analysis 
could not be performed. 
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5.4 Conclusion of Results 
There are three major results of this study: 
First, it could clearly be shown that some 5-HT receptors are differently distributed in vessels 
of B6 and FVB/N animals and hence, in Tph1 deficient animals generated in these back-
ground strains. This was convincingly shown for 5-HT receptor subtypes 1B and 2A in aorta: 
5-HTr 1B RNA expression was 2-fold increased in FVB/N and even more than 3-fold in-
creased in B6/Tph1
-/-
 animals compared to B6. 5-HTr 2A RNA expression was decreased in 
FVB/N, but increased in B6/Tph1
-/-
 compared to B6 (see Tab. 6). 
Second, in 45 week old ApoE deficient animals, it could be demonstrated that Tph1 deficiency 
results in significantly decreased bodyweight, plasma cholesterol and AST levels and signifi-
cantly increased relative liver weight, whereas Sert deficiency causes significant increases in 
blood glucose, plasma cholesterol, atherosclerotic plaque size in aortas and collagen amounts 
in atherosclerotic plaques. The majority of these effects appear to have a sex dependent com-
pound (see Tab. 6). 
And third, in ApoE/Tph1
-/-
 animals after long term Western Diet, it was shown that body-
weight was significantly reduced, plasma and hepatic cholesterol as well as hepatic triglycer-
ide and total lipid levels were significantly lower, and relative liver weight was also signifi-
cantly reduced in comparison to ApoE
-/-
 mice (see Tab. 6). Sex differences, including con-
trasting non-significant trends for reduced atherosclerotic plaque size in ApoE/Tph1
-/-
 males 
and increased atherosclerotic plaque size in ApoE/Tph1
-/-
 females, were detected in these 
groups as well.  
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Tab. 6 – Summary of Complete Study Results 
Overview of all results, gained from the present study. Male Tph1
-/-
 mice are described with either a 
higher (↑) or lower (↓) relative RNA expression of the respective receptor, compared to B6 or FVB/N 
males. Male and female ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 mice are described with either an in-
crease/higher level of the examined feature (↑ or (↑) in case of weak effects), a decrease/lower level of 
the examined feature (↑ or (↑) in case of weak effects) or an equality of the examined feature (-) in 
comparison to the respective ApoE
-/-
 group. Missing data are indicated with n.a. (not applicable). 
 Males Females 
 Tph1
-/-
  
Expression in Aorta:    
5-HTr 1B ↑(B6), ↓(FVB/N) n.a. 
5-HTr 1D ↓(B6), ↑(FVB/N) n.a. 
5-HTr 2A ↑(B6), ↑(FVB/N) n.a. 
5-HTr 2B 
 
↓(B6), ↓(FVB/N) n.a. 
45 Week old Animals: ApoE/Tph1
-/-
 ApoE/Sert
-/-
 ApoE/Tph1
-/-
 ApoE/Sert
-/-
 
Bodyweight ↓ (↓) (↓) (↑) 
Blood Glucose (↑) ↑ (↑) - 
Plasma Cholesterol - ↑ ↓ - 
Plasma Triglycerides (↓) (↑) (↓) (↑) 
Rel. Liver Weight - - ↑ - 
AST (↓) (↓) ↓ n.a. 
ALT (↑) (↓) - n.a. 
De Ritis Quotient (↓) (↓) (↓) n.a. 
Aortic Plaques (↓) (↑) (↑) ↑ 
Plaques Aortic Root (↑) (↑) (↓) - 
Calcification - - - (↓) 
Plaque Collagen (↑) - (↑) ↑ 
Plaque Macrophages 
 
- - - (↑) 
After long term WD:     
Bodyweight ↓ n.a. ↓ n.a. 
Blood Glucose (↑) n.a. (↑) n.a. 
Rel. Body Fat (↓) n.a. (↓) n.a. 
Rel. Muscles (↑) n.a. (↑) n.a. 
Rel. Water (↓) n.a. (↓) n.a. 
Plasma Cholesterol (↓) n.a. (↓) n.a. 
Plasma Triglycerides ↓ n.a. ↓ n.a. 
Hepatic Cholesterol ↓ n.a. (↓) n.a. 
Hepatic Triglycerides ↓ n.a. (↓) n.a. 
Hepatic NEFA (↓) n.a. (↑) n.a. 
Hepatic Lipids ↓ n.a. - n.a. 
Rel. Liver Weight (↓) n.a. ↓ n.a. 
AST (↓) n.a. (↓) n.a. 
ALT (↓) n.a. - n.a. 
De Ritis Quotient - n.a. - n.a. 
Aortic Plaques (↓) n.a. (↑) n.a. 
Calcification - n.a. - n.a. 
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6 Discussion 
6.1 Differently Expressed 5-HT Receptors in B6 and FVB/N Mice and their Pos-
sible Effects 
As this study could cogently demonstrate, the distribution of 5-HT receptors in mouse vessels 
is not invariable between different genetic background strains (e.g. B6 and FVB/N) and with-
in genetically modified mouse lines generated in these strains. While alterations of 5-HT re-
ceptor distribution and expression were expected for Tph1 deficient animals in different ge-
netic background similarly, it was very surprising that 5-HT receptors in vessels of B6 and 
FVB/N mice seem to be expressed differently, depending on background strain, genetic modi-
fication and the receptor subtype itself. 
Classically, it could have been supposed, that under the lifelong drastic 5-HT reduction, as 
true in Tph1
-/-
 animals, 5-HT receptors are upregulated as an innate mechanism of the cells to 
increase the 5-HT sensitivity and ensure 5-HT dependent physiological processes, such as 
blood pressure regulation. Alternatively, it was also conceivable that the lack of peripheral 5-
HT synthesis from the beginning on caused developmental alterations in the animals’ systems 
and 5-HT receptors may have been downregulated to save resources and allow replacement 
through other signaling pathways.  
An effect, such as the one shown for 5-HTr 1B in the aorta of B6, FVB/N and the two knock-
outs: B6/Tph1
-/-
 and FVB/N/Tph1
-/-
, where receptor expression is upregulated in B6/Tph1
-/-
, 
but downregulated in FVB/N/Tph1
-/-
, seems to be conflicting at the first sight, but may appear 
reasonable in the light of intra background strain homeostasis: While the cellular strategy of 
B6 is to upregulate the 5-HTr 1B under Tph1 deficiency to increase cell sensitivity for 5-HT; 
it might be more effective for FVB/N animals which already have a 2-fold higher amount of 
5-HTr 1B, to downregulate the receptor expression under Tph1 deficiency in favor of other 
signaling mechanisms and to save the energy which would be necessary for 5-HTr 1B 
maintenance. 
This explanation becomes even more convincing when looking at the case of 5-HTr 2A. Here, 
the initial situation is a different one: Receptor expression in FVB/N is lower than in B6 ani-
mals and under Tph1 deficiency both lines upregulate expression to a similar level. It might 
be that the classical strategy of vascular cells (endothelial) of both background strains is the 
upregulation of 5-HT receptor synthesis under Tph1 deficiency, but since they start already at 
different expression levels it might only be suitable to upregulate 5-HT receptor expression if 
a particular level is not exceeded.  
In case of 5-HTr 1B in FVB/N mice, this particular level could have been reached, hence the 
vessels did not upregulate the receptor expression under Tph1 deficiency, but downregulated 
it. 
The fact that the serotonergic system in vessels differs between the genetic background strains 
B6 and FVB/N and their Tph1
-/-
 variants also matches the latest findings of our partner group 
in Lübeck. There, it could be shown that FVB/N/Tph1
-/-
animals develop higher levels of dys-
trophic cardiac calcification than FVB/N after freeze-thaw injury, but interestingly, this could 
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not be shown for B6 and B6/Tph1
-/-
 animals (Aherrahrou & Alenina, unpublished data). Also, 
the here presented data from ApoE
-/-
 and ApoE/Tph1
-/-
 animals, bred in B6 background, sug-
gest that calcification in atherosclerotic plaques in the aorta occurs very rarely and is not in-
creased in Tph1 deficient animals compared to ApoE
-/-
 alone. The possible protective effect of 
B6 genetic background against calcification events, which was also reported in other studies 
(Cooley, 2007; Sontag et al., 2014), may be linked to the altered serotonergic situation in the 
vessels of B6 compared to FVB/N in which these events happen to a larger extent. It might 
very well be that the 5-HT receptors involved in calcification are only upregulated in 
FVB/N/Tph1
-/-
animals, following the before described cellular strategy. A downregulation of 
calcification protective 5-HT receptors in FVB/N/Tph1
-/- 
animals is also conceivable. 
In summary, for future cardiovascular research it might be of great importance that 5-HT re-
ceptor subtypes are differently expressed in vessels of different mouse strains, such as B6 and 
FVB/N and hence, the omnipresent hormone 5-HT is potentially able to cause completely 
different effects in these strains, as well as in genetically modified lines that base on these 
strains. Further analysis in different blood vessel types and on additional 5-HT receptors 
needs to be done to elucidate the relationship of 5-HT receptors in different mouse strains and 
their potential effects on atherosclerotic processes, as well as on angiogenesis.  
For this study, it was very important to show that the physiological situation in vessels of ge-
netically modified animals (here Tph1
-/-
) can not only be influenced by the lack of direct ef-
fects of the respective substance (here 5-HT signaling), but can further be changed indirectly 
by altered receptor expression and subsequently by altered substance sensitivity. Since it was 
reported that 5-HT in Tph1 deficient animals is alternatively synthesized (via phenylalanine 
hydroxylase, see Matthes & Bader, 2018), a changed vessel morphology with overexpressed 
receptors (as shown for 5-HTr 1B) could cause completely unexpected effects on e.g. athero-
sclerotic processes. This means that even if the animal is Tph1 deficient and initially lacks the 
majority of peripheral 5-HT (up to 10% are left!) only small amounts of 5-HT from the duo-
denum or other than the primary synthesis sources could cause enormous serotonergic effects 
in the vessels. Hence, a 5-HT lack must not automatically result in an absence of 5-HT signal-
ing.  
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6.2 Effects of 5-HT Deficiency on Metabolic and Atherosclerotic Processes in aged 
ApoE deficient Animals 
A homozygous deficiency of the ApoE gene in mice (of B6 background) is widely known to 
cause not just hypercholesterolemia (Plump et al., 1992; Zhang et al., 1992), followed by a 
development of all stages of atherosclerosis (Nakashima et al., 1994), but also lowered body-
weight levels (reviewed in Pendse et al., 2009) , increased parameters for liver steatosis 
(Kampschulte et al., 2014) and a tendency for lowered fasting blood glucose levels 
(Kawashima et al., 2009; Li et al., 2011). All these effects could be consistently reproduced in 
this study in naturally aged ApoE
-/-
 animals of both sexes. The novel approach of this study 
was to elucidate whether a peripheral 5-HT absence in ApoE
-/-
 animals leads to changes in this 
characteristic phenotype. 
The great chance of this study was the accessibility of two different murine models for 5-HT 
reduction/absence: First, the Tph1
-/-
 mouse which lacks peripheral 5-HT synthesis and was 
shown to exhibit lowered bodyweight levels and body fat accumulation (Crane et al., 2015; 
Watanabe et al., 2016), an exacerbation of induced liver toxicity (Zhang et al., 2015) and de-
creased insulin secretion, hence higher blood glucose levels (under high fat diet) (Kim et al., 
2015). And second, the Sert
-/-
 mouse which lacks the 5-HT transporter (SERT) and was 
demonstrated to exhibit a complete absence of blood 5-HT (Chen et al., 2001). Sert
-/-
 mice 
could be shown to develop higher bodyweight, body fat levels, blood glucose and liver 
steatosis than controls, even though they had reduced food intake (Chen et al., 2012). None of 
the two peripherally  5-HT lacking mouse models was characterized for impacts on athero-
sclerosis before and the establishment of double knockout mouse lines allowed a direct com-
parison between ApoE
-/-
, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 with regard to atherosclerotic process-
es. 
6.2.1 Metabolic Effects in Double Knockouts 
In this study it was shown that ApoE
-/- 
animals tend to have lower bodyweight than wild type 
controls, what was earlier discussed to be due to an impaired delivery of very low density 
lipoproteins (VLDL) to adipocytes in ApoE
-/-
 (Pendse et al., 2009). Further, it could be shown 
that ApoE/Tph1
-/-
 animals exhibit significantly lower bodyweight levels than ApoE
-/- 
what is 
presumably caused by the earlier demonstrated increase of mitochondria uncoupling protein 1 
(UCP1) mediated thermogenesis in brown adipose tissue (BAT) under Tph1 inhibition (Crane 
et al., 2015). Surprisingly, ApoE/Sert
-/-
 animals were demonstrated to have bodyweight levels 
comparable to ApoE
-/- 
, hence, lower than B6 controls. This could be explained by the earlier 
reported Sert
-/-
 -related decrease in food intake, what was not documented in this study or by 
the alternatively balanced nutrient partitioning towards fat but without an overall increase in 
body mass in Sert deficient mice (Chen et al., 2012). Combined with the impaired fat metabo-
lism, caused by ApoE deficiency, this may lead to a lowered bodyweight in ApoE/Sert
-/-
 ani-
mals compared to B6 controls. Data for blood glucose in 45 week old animals suggest that 
while ApoE
-/- 
mice exhibit normal to low values, ApoE/Tph1
-/-
 and ApoE/Sert
-/-
 mice, tend to 
exhibit hyperglycemic phenotypes what completely goes in line with the findings of 
Paulmann et al., 2009, showing that 5-HT and serotonylation being crucial for insulin secre-
tion and blood glucose homeostasis. 
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The elevated plasma cholesterol levels in all tested groups of mice completely match the idea 
of ApoE being crucial for maintenance of blood cholesterol balance, but it needs to be high-
lighted that, at least in males, ApoE/Sert
-/-
 exhibited even higher plasma cholesterol values 
what might be caused by either the mentioned altered nutrition balance or by a generally im-
paired locomotive behavior in Sert deficient animals (Kalueff et al., 2007). A similar trend 
was revealed for plasma triglycerides which were slightly increased in all tested ApoE defi-
cient males, but significantly elevated in ApoE/Sert
-/-
 males, what might also be due to 
hypolocomotion. These findings could also explain why the ApoE/Sert
-/-
 group was shown to 
develop significantly bigger atherosclerotic plaques in the aortas. 
Naturally, plasma cholesterol and triglycerides have large impact on liver homeostasis and 
vice versa (reviewed in Arguello et al., 2015 and Trapani et al., 2012). Hence, it could have 
been supposed that relative liver weight, as well as plasma liver parameters AST and ALT 
and the resulting De Ritis quotient are increased in ApoE/Sert
-/-
 males which were shown to 
exhibit elevated cholesterol and triglyceride levels in plasma compared to ApoE
-/- 
. Interest-
ingly, the opposite was the case: ApoE/Sert
-/-
 males exhibited very low liver values. One pos-
sible explanation is that the impairment of 5-HT uptake to hepatocytes attenuates liver dam-
age what is also supported by the findings of Nocito et al., 2007. Another very interesting 
finding was the relatively high liver weight in ApoE/Tph1
-/-
 females, as well as the quite low 
AST value in this group. It might be that even though ApoE deficiency leads to increased liver 
damage parameters, the reduction of peripheral 5-HT acts protective on liver cells, as demon-
strated for Tph1
-/-
 mice (Lesurtel et al., 2006; Nocito et al., 2007). This could presumably be 
caused by beneficial effects on liver perfusion or hepatic fibrosis (Lesurtel et al., 2012). 
6.2.2 Effects on Atherosclerosis in Double Knockouts 
As mentioned, one of the most striking findings in this study was the significantly increased 
relative aortic plaque size in both, ApoE/Sert
-/-
 males and females. This finding completely 
correlates with the results of Rami and colleagues, which were published in 2018. In this 
study it was reported, that the chronic treatment of ApoE
-/- 
animals with the SSRI fluoxetine 
(SERT inhibitor) promotes atherosclerotic plaque formation after HFD. Increased atheroscle-
rotic plaque size and adhesion of myeloid cells to the vessel wall together with an enhanced 
C-C motif chemokine ligand 5 (CCL5) -induced integrin activation and consequently in-
creased vascular permeability and leukocyte recruitment indicated that fluoxetine treatment 
promoted atherosclerotic phenotypes in ApoE
-/-
 mice after HFD. Further, the study showed 
that these effects were strongest after 2 and 4 weeks of HFD, hence in the onset of 
atherogenesis, and became weaker after 16 weeks of HFD. This also matches the results of the 
present study where the proatherogenic effect of the genetic SERT inhibition was not visible 
in cryo slices of the aortic root: Here, all tested groups appeared to have quite large (10 times 
larger than in animals after 2 weeks of HFD from Rami et al., 2018) atherosclerotic plaques. 
Earlier studies reported that the aortic root is one of the predilected areas of atherosclerotic 
plaque development (Nakashima et al., 1994; Whitman, 2004). Hence, it might be that at the 
age of 45 weeks, the development of atherosclerotic plaques at the aortic root area was so 
advanced in all genetic groups that potential differences between them could no longer be 
detected and that in whole aortas the differences were still visible because of the third dimen-
sion (longitudinal plane) which was examined. 
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Another very interesting question is whether the proatherogenic effect in ApoE/Sert
-/-
 animals 
is linked to 5-HT absence. Since the genetically induced Sert deficiency in mice used in this 
study, as well as the pharmacologically induced SERT inhibition via fluoxetine and addition-
ally via escitalopram in mice (Rami et al., 2018) and further the pharmacologically induced 
SERT inhibition via sertraline in monkeys (Shively et al., 2015) resulted in increased athero-
sclerotic lesion size, it is very likely that the blocking of SERT generally promotes 
atherogenesis. And since it was shown that blood levels of 5-HT in Sert
-/-
 animals reach zero 
(Chen et al., 2001), whereas in Tph1
-/-
 animals they do not go lower than 4-10% (Walther et 
al., 2003a) of wild type levels it appears to be plausible that the total 5-HT absence plays a 
role in the proatherogenic effect of SERT inhibition. It further also explains why this study 
could not report a similar proatherogenic effect of Tph1 deficiency. 
Putting everything into context, it appears more than plausible that ApoE/Sert
-/-
 animals which 
presumably lack the complete blood 5-HT, appeared to have very high plasma cholesterol and 
triglyceride levels and which were earlier shown to have an imbalanced nutrient partitioning 
towards fat tissue (Chen et al., 2012) and an impaired locomotive activity (Kalueff et al., 
2007), develop larger atherosclerotic lesions under ApoE deficiency than animals without 
these deficits. It could further be discussed whether the inhibition of SERT, what also affects 
the CNS and PNS causes altered sleep behavior, vessel contractility or other effects that influ-
ence atherosclerotic processes (reviewed in Kadoya & Koyama, 2019 and Sheng & Zhu, 
2018). 
Further, it is comprehensible that ApoE/Tph1
-/-
 males which lack the proatherogenic factor 
due to an assumed remainder of blood 5-HT and which were shown to accumulate less body 
fat and have by trend lower plasma cholesterol and triglyceride levels than ApoE
-/- 
males, 
tended to develop smaller atherosclerotic lesions. Nevertheless, this whole concept seems to 
be exclusively working in males, since female ApoE/Tph1
-/-
 mice were indeed also shown to 
accumulate less body fat and by trend lower plasma cholesterol and triglyceride levels, but 
atherosclerotic lesions in their aortas tended to be of increased size compared to those in 
ApoE
-/- 
females. The classical known sex difference in atherosclerosis pathogenesis only oc-
curs in young animals (16 weeks of age), but disappears in aged animals (Caligiuri et al., 
1999; Paigen et al., 1987) probably due to lower steroid hormone levels in aged females. The 
45 week old animals in this study did also only exhibit non-significant differences in lesion 
size between males and females; hence it is unlikely that Tph1 deficiency only boosts an ex-
isting independent phenomenon. A possible explanation might be found in the altered 5-HT 
receptor distribution which could be substantiated in vessels of Tph1 deficient animals. If it is 
assumed that under Tph1 deficiency, particular 5-HT receptors are not only alternatively ex-
pressed in the vessels, but also in other tissues, such as gonads, this may lead to changed gon-
adal hormone production or sensitivity which might then influence the onset and the progres-
sion of atherosclerosis (Sirotkin & Schaeffer, 1997; Paigen et al., 1987). 
The detailed analysis of atherosclerotic plaque composition revealed that while in males both 
groups with impaired 5-HT homeostasis did not exhibit alterations of calcification, plaque 
collagen or intraintimal macrophages. However, ApoE/Sert
-/-
 females tended to have lower 
calcification levels and non-significantly elevated collagen and macrophage counts compared 
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to ApoE
-/- 
females. It is known that the female steroid hormone 17β-estradiol has a protective 
effects on vascular calcification (Peng et al. in 2017), but how this should be exclusively pre-
sent in ApoE/Sert
-/-
 females remains unclear and needs further research. For the observed in-
crease of plaque collagen content an interesting explanation was discussed in 2009 by Pavone 
et al., who found elevated cardiac fibrosis in Sert
-/-
 animals and hypothesized that this could 
be caused by a local 5-HT excess (due to the inhibition of 5-HT transport), which increased  
5-HTr 2A activation which was then followed by an activation of TGF-beta 1
9
 signaling and 
consequently by an up-regulation of the α-SMA10 protein and collagen production. Why this 
effect could exclusively be observed in female ApoE/Sert
-/-
 mice remains unclear. It is likely 
that complex interactions between metabolic alterations, such as increased cholesterol and 
altered steroid hormone levels caused by ApoE deficiency and 5-HT deficiency (in Tph1
-/-
) / 
temporary 5-HT excess (in Sert
-/-
) cause cross effects on multifactorial processes, such as 
atherogenesis. The uptake of oxidized LDL into macrophages for example, is affected by 5-
HT and very concentration sensitive (Aviram et al., 1992). If it is assumed, that female mice 
generally produce lower 5-HT amounts than males and a Sert deficiency causes temporary 
increased levels of free 5-HT (e.g. after food intake), it might be that this results in the opti-
mal 5-HT concentration for intraintimal macrophages to ingest oxidized LDL and form tran-
sient foam cells in the intimal space to a larger extend than any other examined animal group, 
what could explain the finding of this study.   
                                                 
9
 TGF-beta 1: First isoform of the transforming growth factor-beta family, which controls proliferation, differen-
tiation and other functions in many cell types via TGF-beta receptors. 
10
 α-SMA: Alpha smooth muscle actin is the predominant actin isoform within VSMCs. 
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6.3 Western Diet Regime Discloses Contrary Effects of 5-HT Absence 
6.3.1 Diminished Body Fat Accumulation in Tph1 and ApoE deficient Animals 
Similarly as in aged animals, ApoE/Tph1
-/-
 animals of both sexes were shown to exhibit sig-
nificantly lower bodyweight under WD than ApoE
-/- 
animals. In consistence with this finding 
were the relative body fat levels also lower in ApoE/Tph1
-/-
 animals, whereas the amount of 
muscle mass was higher than in ApoE
-/-
. As mentioned above, it was reported earlier that 
Tph1 deficiency leads to lower body fat accumulation under high fat diet (HFD) due to an 
upregulation of UCP1 and the subsequent activation of UCP1 dependent thermogenesis in 
BAT (Crane et al., 2015; Oh et al., 2015; Watanabe et al., 2016). This effect appears to be so 
stable in itself that even the changed lipid metabolism under ApoE deficiency could not dis-
rupt it. The same can be stated for blood glucose levels in ApoE/Tph1
-/-
 animals of both sexes 
under WD: They are consistently higher (but never statistically significant) in ApoE/Tph1
-/-
 
than in ApoE
-/-
. The lack of peripheral 5-HT affects serotonylation-dependent insulin secretion 
and hence, causes hyperglycemic phenotypes, not only in Tph1
-/-
 (Paulmann et al., 2009; 
Watanabe, Rose, & Aso, 2011) but also in ApoE/Tph1
-/-
 animals. 
Interestingly, females of both genotypes appeared to be protected from WD induced obesity 
and even lost bodyweight after 8 weeks of WD (more prominent effect in ApoE/Tph1
-/-
 fe-
males). It is very likely that here again an interplay of several physiological phenomena be-
comes visible: First, female mice could be shown to be partly protected from obese phenotype 
under HFD. This was discussed to be caused by gonadal hormones, such as estradiol, since 
ovariectomized females did not show any protective effect (Hong et al., 2009). Female protec-
tion against obesity, genetically combined with an impaired delivery of VLDL to adipocytes, 
caused by ApoE
 
deficiency (Pendse et al., 2009) might lead an impairment of bodyweight gain 
in tested female mice. Further, the bodyweight loss in ApoE/Tph1
-/-
 females after 8 weeks of 
WD is supposably caused by the reported upregulated thermogenesis in these animals (Crane 
et al., 2015). 
6.3.2 Effects of Tph1 Deficiency on Lipid Metabolism under Western Diet 
Under long term WD, fasting plasma cholesterol levels in ApoE deficient animals reach dras-
tically high values of 900mg/dl and above. This was supposed as ApoE is the major lipopro-
tein clearance mediator in the mouse (Plump et al., 1992) and a lack of ApoE results in in-
creasing circulating LDL and VLDL levels due to a diminished uptake to the liver and other 
tissues. In contrast, plasma triglyceride levels in ApoE deficient animals under WD were 
shown to be at normal range and even lower by trend than in normal diet controls. Only in 
ApoE
-/- 
males after 8 weeks of WD plasma triglyceride levels were elevated above normal 
range as expected for all ApoE deficient groups since ApoE is also essential for triglyceride 
transport and uptake to liver and other peripheral tissues (von Zychlinski et al., 2014). How-
ever, ApoE/Tph1
-/-
 animals under WD tended to exhibit slightly lower plasma cholesterol lev-
els and significantly lower plasma triglyceride levels after 8 weeks of WD. Interestingly, pe-
ripheral 5-HT was shown to decrease plasma lipids, such as cholesterol and triglycerides, 
postprandially by stimulation of e.g. hepatocytes. Regulation of plasma lipid concentrations 
was discussed to be mediated by different 5-HT receptor types (reviewed in Watanabe et al., 
2011) and hence, alternatively expressed 5-HT receptors in Tph1 deficient animals (as 
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demonstrated in this study) together with an alternative 5-HT synthesis pathway (Matthes & 
Bader, 2018) might lead to alterations in lipid uptake and consequently in plasma lipid con-
centrations.  
Another interesting approach is the analysis of different metabolic balance or coping strate-
gies in the different animal models: While ApoE
-/- 
males for example, were shown to exhibit 
higher plasma triglyceride levels after 8 weeks than after 12 weeks of WD, ApoE
-/-
 and 
ApoE/Tph1
-/-
 females were clearly demonstrated to exhibit higher hepatic lipids (cholesterol, 
triglycerides, NEFA and total lipids) after 8 than after 12 weeks of WD. It was reported be-
fore, that plasma as well as hepatic cholesterol levels increase under HFD, but can drop to 
relatively low levels in wild type mice after 6-8 weeks of the diet (Campbell et al., 1982). 
Hence, it might be possible that depending on genotype and sex, this metabolic balance 
mechanism is impaired. 
6.3.3 No clear Effect of Tph1 Deficiency on Atherosclerosis after Long Term WD 
Similarly as in 45 week old animals, it was shown that while male ApoE/Tph1
-/-
 mice exhibit 
smaller atherosclerotic lesions in the aortic arch than controls, female ApoE/Tph1
-/- 
mice ex-
hibit larger aortic plaques than controls even if this effect was neither statistically significant 
in 45 week old animals nor in animals after long term WD (8 or 12 weeks). Possible explana-
tions might be the lower body fat and cholesterol accumulation only in ApoE/Tph1
-/- 
mice. It 
might be that greater animal cohorts will result in statistically significant results for a sex and 
Tph1 deficiency dependent protective effect from atherosclerotic processes in males and for 
the opposite effect in females. Additionally, future studies should definitely focus on WD 
treatment in ApoE/Sert
-/-
 animals to strengthen the idea of Sert deficiency being a crucial 
proatherogenic factor und to elucidate the underlying mechanisms. 
However, this study clearly confirmed that there is a strong sex difference in atherosclerotic 
phenotype induced by ApoE deficiency which is most prominent at young age (animals under 
WD) and becomes smaller at advanced age (45 week old animals). As discussed previously, 
this effect appears to be more influenced by immunological factors that are affected by the 
female gonadal hormone 17β-estradiol than by hormonal effects on the lipoprotein metabo-
lism. As the hormonal status in both males and females changes with age, it was discussed 
that age- and sex-dependent variations of cell-mediated immune responses could modulate the 
onset and the progression of atherosclerosis (Caligiuri et al., 1999).  
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7 Conclusion 
Since this study was created more exploratory than confirmatory, it is important to mention 
that the reported results (statistically significant as well as biologically relevant) cover a wide 
spectrum of atherosclerosis related biological processes affected by genetic modifications in 
the used animal models, but not all of them. Further research will be needed to elucidate and 
confirm the findings and deepen the insights especially into the underlying mechanisms. 
Nevertheless, it could be clearly shown that peripheral 5-HT reduction and absence have 
strong effects on general vascular physiology and atherosclerosis relevant parameters, but 
only a complete 5-HT absence (as assumed in Sert deficient animals) affects atherogenesis 
itself. However, there are more factors than simply ‘5-HT or no 5-HT’, that need to be con-
sidered: This study proved that animal background strains, sex and age, genetically induced or 
artificially accelerated pathogenesis as well as type of 5-HT absence (via Tph or Sert) play 
important roles in the disease process and characteristics. The latter is the most promising 
projection for future research, since ApoE/Tph1
-/- 
and ApoE/Sert
-/- 
animals partly delivered 
very contrasting results. While the transgenic inhibition of 5-HT synthesis in ApoE deficient 
animals (ApoE/Tph1
-/- 
mice) did not affect atherogenesis mentionable, the inhibition of intra 
cellular 5-HT transport in these animals (ApoE/Sert
-/- 
mice) delivered clearly proatherogenic 
effects and might be a target for future therapeutic approaches including SERT enhancement 
(e.g. via tianeptine; Mennini et al., 1987). 
As an overall conclusion it can be stated that 5-HT is not a main determinant of atherosclero-
sis but small 5-HT dependent alterations were found in this study. 
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Appendix 
Table of Abbreviations 
5-HIAA 5-hydroxyindole acetic acid 
5-HIAL 5-hydroxyindole acetalde-
hyde 
5-HT 5-hydroxytryptamine (sero-
tonin) 
5-HT[#] 5-HT receptor subtype # 
(number) 
5-HTP 5-hydroxytryptophan 
5-HTr 5-HT receptor 
5-HTr [#] 5-HT receptor subtype # 
(number) 
5-HTT serotonin transporter (also 
SERT) 
AA (Fig. 14 
and 25) 
aortic arch 
AADC aromatic amino acid decar-
boxylase 
ACAT-1 acyl-coenzyme A:cholesterol 
acyltransferase-1 
ALDH aldehyde dehydrogenase 
ALT alanine aminotransferase 
ANOVA analysis of variance 
AP atherosclerotic plaque 
Apo apolipoprotein 
apoB100 human apolipoprotein B (full 
length) 
ApoE apolipoprotein E 
ApoE ApoE gene 
ApoE
-/- ApoE knockout 
ApoE/Sert
-/- ApoE and Sert double 
knockout 
ApoE/Tph1
-/- ApoE and Tph1 double 
knockout 
AST aspartate aminotransferase 
B6 see C57Bl/6 
B6/Tph1
-/- Tph1 knockout in B6 back-
ground 
BAT brown adipose tissue 
BBB blood brain barrier 
BCA body composition analysis 
BH4 tetrahydrobiopterin 
bp base pairs 
C (Fig. 4) collagen 
C57Bl/6 wild type black 6 (B6) 
CCL5 C-C motif chemokine ligand 
5 
cDNA complementary DNA 
CE cholesterol esters 
CETP cholesterylester transfer pro-
tein 
cf. confer (compare) 
CNS central nervous system 
CVD cardiovascular disease 
ddH2O double distilled water 
DNA deoxyribonucleic acid 
EC enterochromaffin cells 
EC (Fig. 4) endothelial cell 
ECM extracellular matrix 
ENS enteric nervous system 
Ex[#] exon # (number) 
F1-F2 visceral fat samples 
FB fibroblast 
FC free cholesterol 
FC (Fig. 4) foam cell 
Fig. figure 
FVB/N wild type Friend virus B 
FVB/N/Tph1
-/- Tph1 knockout in FVB/N 
background 
GAPDH glyceraldehyde 3-phosphate 
dehydrogenase (housekeep-
ing gene) 
GCH1 GTP cyclohydrolase 1 
gDNA genomic DNA 
GPCR G-protein coupled seven 
transmembrane receptors 
GTPase guanosine triphosphate hy-
drolase 
HDL high-density liporprotein 
HFD high fat diet 
i.p. intraperitoneal 
IDO 1 indoleamine dioxygenase 1 
IDO 2 indoleamine dioxygenase 2 
IQR interquartile range 
IUPHAR International Union of Basic 
and Clinical Pharmacology 
IVC individually ventilated cage 
KO knockout 
L1-L4 liver samples 
LAGeSo Landesamt für Gesundheit 
und Soziales 
LDL low-density lipoprotein 
LGIC ligand gated ion channel 
LNAA large neutral amino acids 
LNAAT large neutral amino acid 
transporter 
Mac macrophage 
MAO-A monoamine oxidase A 
MAO-B monoamine oxidase B 
MC mast cell 
MM master mix 
Mono monocyte 
MPO myeloperoxidase 
n.a. not applicable 
NEFA not esterified fatty acids 
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NIH National Institutes of Health 
NMR nuclear magnetic resonance 
NO nitric oxide 
NP neutrophil 
ORO Oil red O staining 
ox.LDL oxidized LDL 
PAH phenylalanin hydroxylase 
PCR polymerase chain reaction 
PDGF-B platelet-derived growth fac-
tor B 
PH pulmonary hypertension 
PL platelet 
PND post natal day 
PNS peripheral nervous system 
PTPS 6-pyruvoyl-5,6,7,8-
tetrahydropterin 
qBH2 quinoid dihydrobiopterin 
qPCR real time quantitative PCR 
RH random hexamer 
RhoA Ras homolog gene family, 
member A 
RN raphe nuclei 
RNA ribonucleic acid 
rpm revolutions per minute 
RT room temperature (20-25°C) 
SEM standard error of the mean 
SERT serotonin transporter (also 5-
HTT) 
Sert
-/- Sert knockout 
Slc6a4 solute carrier family 6 mem-
ber 4 (gene name for Sert) 
Slc6a4
-/- see Sert
-/-
 
SMC smooth muscle cell 
SSRI selective serotonin reuptake 
inhibitor 
Tab. table 
TD-NMR time-domain-nuclear-
magnetic-resonance imaging 
TG transglutaminases 
TGF-beta transforming growth factor-
beta 
TH tyrosine hydroxylase 
TPH tryptophan hydroxylase 
TPH1 tryptophan hydroxylase 1 
(periphery) 
Tph1 TPH1 gene 
Tph1
-/- Tph1 knockout 
TPH2 tryptophan hydroxylase 2 
(CNS) 
Tph2 TPH2 gene 
Trp L-Tryptophan 
UCP1 uncoupling protein 1 
UTR untranslated region 
VLDL very low- density lipoprotein 
VMAT vesicular monoamine trans-
porters 
VMAT 1 vesicular monoamine trans-
porter 1 
VMAT 2 vesicular monoamine trans-
porter 2 
VSMC vascular smooth muscle cell 
WD Western type diet 
WHO World Health Organization 
α-SMA alpha smooth muscle actin 
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Fig.I – Aortic Arches of 45 Week old Male Mice (ORO stained) 
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Fig.II – Aortic Arches of 45 Week old Female Mice (ORO stained) 
